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8 part	1
Introduction
As the baby boomers reach seniority and life expectancy increases, the number of elderly is growing, 
and will keep rising in the future. As a consequence of the aging population the prevalence of certain 
diseases, like cardiovascular disease and dementia, increases as well. The number of patients with 
dementia in Europe is estimated to rise over 16 million within 50 years.1 In addition, in the Netherlands - 
comparable to most western countries - both cardiovascular disease and dementia rank in the top five of 
diseases with highest mortality.2 
The adult human brain accounts for only about 2% of the body weight but it receives about 20% of 
the cardiac output.3 It is obvious that heart and brain are related to each other, and that insufficiency 
in blood supply may lead to essential damage of the brain. Therefore, blood flow to, and in the 
brain are securely controlled. On the other hand, vascular disease is highly prevalent in elderly, 
such as atherosclerosis and a diminished heart function, and ultimately these diseases may have 
its consequences on the blood flow in the brain. Pathological brain studies showed that in elderly 
the prevalence of cerebrovascular pathology is extremely high (78%).4 Alzheimer pathology was also 
commonly found (70%), and interestingly, in brains of patients with clinical features of dementia often 
a co-existence of both Alzheimer pathology and cerebrovascular pathology has been demonstrated.4,5 A 
valuable method to visualize and examine the presence of cerebrovascular disease in vivo is with the use 
of magnetic resonance imaging (MRI) of the brain.  
Vascular measures on brain MRI
MRI can be used in different ways to examine cerebrovascular function and disease. Blood flow to the 
brain can be investigated with the use of two-dimensional (2D) phase-contrast MRI. Herewith the blood 
flow in both carotid arteries and the basilar artery can be determined and subsequently, total blood flow 
to the brain can be calculated (see figure 1). The method has proven to be fast and accurate, but it must 
be noted that it is not the same as determination of regional cerebral blood flow which is measured at 
brain tissue level (e.g. as with positron emission tomography).6
Furthermore, structural MRI can be used to demonstrate the presence of large vessel and small vessel 
disease. Large vessel disease includes cortical infarcts in the territory of large blood vessels (figure 2). 
Important expressions of small vessel disease include white matter hyperintensities (WMH), lacunes and 
microbleeds (figure 3). WMH are commonly defined on T2-weighted MRI scans, such as FLAIR images. The 
severity of WMH can be assessed using visual rating scales as the Fazekas scale and the Scheltens scale, 
or using more sophisticated automatic methods to measure volumes of WMH.7-9 Lacunes are identified as 
small cavities surrounded by white matter or subcortical grey matter with a minimum diameter of 3mm. 
The signal intensities are comparable to cerebrospinal fluid on all sequences (on T1-hypointense and T2-
hyperintense). Microbleeds are defined as strongly hypointense, mostly round lesions on the axial FLASH 
2D images with a diameter between 2 and 10mm. 
In line with neuropathological findings, cerebrovascular abnormalities on MRI are commonly found in 
elderly.10 Moreover, the prevalence of vascular disease on brain MRI has been reported to be higher in 
patients with dementia, although the clinical implications are not entirely clear.11-13 
Dementia
Dementia is characterized by an acquired impairment of cognitive function in at least two domains, 
which interferes with normal social or occupational performance (and is not attributable to delirium 
or psychiatric disorders).14 The most common type of dementia is Alzheimer’s disease (AD), followed 
by vascular dementia (VaD). AD, typically presents with severe memory impairment along with other 
cognitive deficits, is currently diagnosed by the criteria of the National Institute on Neurological and 
Communicative Diseases and Stroke-Alzheimer Disease and Related Disorders Association (NINCDS-
ADRDA; table 1).15 The disease is named after the German neuropathologist, Alois Alzheimer, who 
reported already in 1906 on a patient, named as we now know Auguste D (her initials AD foretold the 
future!) who at neuropathology showed the histopathological characteristics of what is nowadays  
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Figure 1;
Total	 cerebral	 blood	 flow	 measurement	 using	 2D	 phase-contrast	 MRI.	 a)	 Sagittal	 2D	 phase	 contrast	 MRI	 an-
giographic	 scout	 image	 for	 localization	 of	 the	 phase-contrast	 imaging	 plane	 (white	 line)	 b)	 anatomical	 view	
of	 transverse	 image	 perpendicular	 to	 the	 carotid	 and	 the	 basilar	 arteries	 c)	 2D	 gradient-echo	 phase	 contrast	






















recognized as AD (amyloid plaques and neurofibrillary tangles).16 Less known is the fact that Alois 
Alzheimer wrote many more papers on VaD, including a detailed description of what was later to 
become Binswanger’s Disease, that Otto Binswanger had only described macroscopically, and recognized 
the importance of cerebrovascular disease in relation to certain neuropsychiatric conditions.17 
Vascular dementia
Traditionally, VaD has been recognized to develop after multiple strokes. The name ‘multi-infarct 
dementia’ became synonymous with all dementias of vascular origin, incorrectly implying that multiple 
brain infarcts are the only cause of VaD, not recognising small vessel disease and strategic small infarcts. 
The experience learns that VaD is difficult to define, leading to several different criteria that are in use 
in different centres over the world. At present, the criteria of the National Institute of Neurological 
Disorders and Stroke Association Internationale pour la Recherche et al’Enseignement en Neurosciences 
(NINDS-AIREN) are the diagnostic criteria which are most often used in VaD studies.18 These criteria 
require the presence of dementia, defined as cognitive decline in memory and 2 other domains, with 
interference in activities of daily living, and evidence of cerebrovascular disease. The latter includes 
both proof on brain imaging and the presence of focal signs on neurological examination (table 2). Most 
likely due to the stringent clinical and radiological definitions the group of VaD patients has hardly been 
examined compared to patients with other dementias, like AD, with regard to risk factor profiles and 
clinical features. 
Mild cognitive impairment
It is thought that dementia develops gradually and in a certain number of patients is preceded by 
cognitive impairment not sufficient for the diagnosis of dementia – a stage usually referred to as 
mild cognitive impairment (MCI).19 It is increasingly recognized that the group of MCI patients is very 
heterogeneous: MCI patients have an increased risk of progression to dementia, mostly AD, but some 
will develop other types of dementia, whereas others will remain stable. Atrophy of the brain, especially 
of the medial temporal lobe has been shown to be a powerful and independent predictor of progression 
to dementia in MCI patients.20-22 In contrast to atrophy, the impact of cerebrovascular disease on 
progression to dementia in this patient group has not been clarified.
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By definition the most prominent clinical feature of dementia is cognitive impairment; especially 
compromised memory, along with other domains like orientation, attention, language, executive 
functions, praxis and visuospatial functions. However, as certain brain functions diminish, also other 
clinical signs may develop. 
There is some literature about a higher prevalence of physical neurological signs, like extrapyramidal 
signs in AD, but the number of reports is limited and often includes small study populations. Current 
criteria of VaD require the presence of focal neurological signs, but in fact which signs are exhibited  
in relation to what kind of cerebrovascular damage has not been established in VaD patients.18 
Moreover, the origin of neurological signs in dementia is unclear. It is not known whether these 
signs reflect age-associated changes, if they are the result of degenerative abnormalities, or if vascular 
pathology plays a role. 
Next to cognitive impairment and neurological signs, behavioural and psychological symptoms are 
important in dementia.23 For example according to Alzheimer’s description of Auguste D., she would 
have suffered next to amnesia and disorientation, from depression, hallucinations and jealousy towards 
her husband.16 Behavioural and psychological symptoms in dementia have been shown to be associated 
with worse prognosis, higher cost of care, earlier institutionalisation and increased caregiver burden.24 
Therefore it is remarkable that literature on the prevalence of these symptoms and their radiological 
underpinnings is scarce. 
part	1 11
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Aims of the thesis
The general objective of this thesis was to explore different vascular MRI measures, like total cerebral 
blood flow, large vessel disease and small vessel disease, in the clinical spectrum from normal aging to 
dementia and to seek relations with possible risk factors. Additionally, we aimed to get a better view of 
the clinical picture of dementia, with regard to the presence of neurological signs and behavioural and 
psychological symptoms, and sought to determine possible associations with MRI measures. 
Thesis outline
Cerebral blood flow in elderly
First, we aimed to get a better view of associations between both cardiovascular risk factors and brain 
characteristics, and total cerebral blood flow at old age. In chapter 2 we describe two studies on total 
blood flow to the brain in a population based cohort elderly. The studies were performed as part of the 
Age, Gene/Environment Susceptibility–Reykjavik Study (AGES-Reykjavik).25 In chapter 2.1 we report 
the results of analyses of a wide spectrum of cardiovascular characteristics assessed both at mid-life 
and late-life in association to total cerebral blood flow in 822 elderly participants. In chapter 2.2 we 
calculated total brain perfusion (total cerebral blood flow per 100mL brain volume) for a sub group, and 
examined the cross-sectional relation between brain volumes and total cerebral blood flow and total 
brain perfusion. Subsequently, we determined annualized measures of grey matter atrophy, whole-brain 
atrophy and progression of WMH and aimed to learn whether these measures were related to a lower 
total cerebral blood flow and lower total brain perfusion at follow-up.
Vascular MRI measures in mild cognitive impairment and dementia
Then, we shifted to a population of patients with cognitive deficits, and examined the role of 
cerebrovascular disease on MRI in patients with cognitive impairment not sufficient for the diagnosis 
of dementia. MCI patients were followed for 2 years and we sought to determine associations between 
presence of baseline atrophy and cerebrovascular disease and progression to dementia (chapter 3.1). 
In chapter 3.2 we investigated the baseline characteristics of a large cohort of patients with VaD who 
participated in a multicenter treatment trial (the VantagE study). To understand more about this type of 
dementia we compared patients with small vessel disease (lacunes and WMH) and large vessel disease 
(large territorial or strategical infarcts) according to their clinical and MRI characteristics and risk factor 
profiles.
 
Neurological signs in dementia and associations with MRI measures
In the last sections of this thesis we took a closer look at the clinical sequelae outside of dementia. 
Chapter 4.1 describes the prevalence of extrapyramidal signs and unilateral signs in a large cohort of 
patients attending a memory clinic, where we expected to find a higher prevalence of signs in patients 
with dementia compared to non-demented subjects. Secondly, we determined presence of WMH in this 
population and studied whether patients with extrapyramidal signs or unilateral signs showed a larger 
volume of WMH, hypothesizing that ischemic vascular damage plays a role in the presence of these 
signs in dementia. Chapter 4.2 focuses on the prevalence of a number of neurological signs in a large 
population of patients with VaD, additionally aiming to determine if the relative frequency of specific 
neurological signs depends on type of cerebrovascular disease on MRI. 
Neuropsychiatric symptoms in Alzheimer’s disease and vascular dementia and 
associations with MRI measures
In chapter 5.1 we describe the prevalence of behavioural and psychological symptoms in patients with 
AD and investigated differences in prevalence of these symptoms according to the presence of medial 
temporal lobe atrophy and WMH on MRI. Subsequently, behavioural and psychological symptoms were 
investigated in VaD. Severity and relative frequency of symptoms was compared between small vessel 
VaD and large vessel VaD (chapter 5.2).
In chapter 6 the main findings of this thesis are summarized, followed by a discussion of the results and 
recommendations for future directions. 
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Bí, bí og blaka
Bí, bí og blaka, 
álftirnar kvaka, 
ég læt sem ég sofi, 
en samt mun ég vaka. 
Bíum bíum bamba, 
börnin litlu ramba 
fram um fjalla kamba 
ao leita sér lamba.
Icelandic	lullaby,	written	by	Sveinbjörn	Egilsson	(1791-1852),	
and	sang	by	my	grandmother	before	we	went	to	sleep
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Abstract
Background
By middle age brain pathology leading to cognitive impairment has already started. One indicator of 
pathology is a decline of total blood flow to the brain (tCBF). Mid- and late-life cardiovascular factors may 
contribute to the reduction in tCBF. We assess the association of mid- and late-life cardiovascular factors  
measured 30 and 5 yrs prior to the measure of tCBF.
Methods
tCBF was measured with two-dimensional phase-contrast MR angiography in 822 men and women 
(58% women, mean age 79 yrs) who participated in the Reykjavik Study (mid-life) and its follow on, the 
AGES-Reykjavik Study I (late-life) and II (measure of tCBF). We used linear regression analysis to study the 
association of tCBF to cardiovascular characteristics measured in mid- and late-life, adjusting for age, sex  
MRI detected infarcts, and brain volume. 
Results
Mean(SD) tCBF was 578(108 ) mL/min, increased with age and did not differ by sex. There were statisti-
cally significant (p<0.05) inverse associations of tCBF to both mid- and late-life measures of hemoglobin, 
hematocrit and diastolic blood pressure, and to late-life indicators of major ECG detected coronary 
abnormalitites.
Interpretation
Hemotologic, hemodynamic and cardiac characteristics affecting cardiac output and amount of blood 
flow to the brain measured at mid-life and at late-life, were associated with lower tCBF in late-life. 
20 part	2
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Introduction
The adult human brain accounts for approximately 2% of  body weight but it receives about 20% of the 
cardiac output.1 Because of the brain’s vital need for a continuous supply of oxygen and glucose, cerebral 
blood flow (CBF) must be tightly regulated. Normally, the brain alters regional blood flow in response to 
changes in brain activity, while maintaining a relatively constant overall CBF.1 However, total cerebral 
blood flow (tCBF) to the brain, determined by summing the flow in both carotid arteries and the basilar 
artery, is known to decline with increasing age.2 TCBF is related to brain size, and a reduction of brain 
volume with ageing (i.e. due to processes such as neurodegeneration) may be the cause of a lower tCBF  
in elderly.3 However, blood oxygenation, rheology, hemodynamics, cardiac function, and other cardio-
vascular factors might also play important roles in this decline with age. 
tCBF can be measured in several ways. At brain tissue level, regional CBF per 100g brain tissue per 
minute can be determined using techniques such as positron emission tomography, single photon 
emission computed tomography, and xenon-computed tomography. However, these measurements are 
complex and invasive and are difficult to implement in studies of the general population. More recently, 
two-dimensional (2D) phase-contrast MR angiography.4 has been shown to be a  non-invasive, fast and 
accurate measure of tCBF. 
The first large studies on tCBF and vascular risk factors using 2D phase-contrast imaging have been 
recently published.3, 5, 6 The results differ slightly, but in general, the studies report inverse relations 
of tCBF to hypertension, diabetes, increasing BMI, and a history of cerebrovascular disease.3, 5, 6 However, 
one study sample consisted of subjects with symptomatic vascular disease and a mean age of 58yrs.5, 6 
The other study was population based and investigated  vascular risk factors in a sample  mean age  
68yrs old.3 
We were interested in tCBF and relations with cardiovascular determinants in an older population since 
this is the group with the greatest prevalence of cognitive dysfunction and brain atrophy. Furthermore, 
because it is increasingly recognized risk factors measured in mid-life are associated with late-life brain 
pathology, we investigated whether tCBF in late-life is related to cardiovascular risk factors earlier in 
life. The AGES-Reykjavik study is a single center population-based follow-up of members of the Reykjavik 
study, a study initiated in 1967 by the Icelandic Heart Association to investigate cardiovascular disease 
and risk factors.7, 8 This provided the unique possibility to examine tCBF in a large population based 
cohort and to determine the associations between tCBF and a wide spectrum of cardiovascular factors 
assessed both at mid-life and late-life.  
Methods
Study population
The design of the Age, Gene/Environment Susceptibility–Reykjavik Study (AGES-Reykjavik) has been  
described previously.7 As noted, AGES-Reykjavik originates from the Reykjavik Study, a community-based 
cohort established in 1967 to prospectively study cardiovascular disease in Iceland. Between 2002 and 
2006, 5764 participants were examined (visit I). In November 2006 follow-up assessments started (and are 
ongoing) (visit II). AGES-Reykjavik was approved by the National Bioethics Committee in Iceland, which 
acts as the institutional review board for the Icelandic Heart Association (approval number VSN-00-
063), and by the institutional review board serving the National Institute on Aging Intramural Research 
Program. All participants gave written informed consent.
MRI measures
MRI of the brain was performed at visits I and II using the same protocols and machine. The visit II 
exam also included a 2D phase-contrast sequence necessary for tCBF determination. In this analysis we 
included all subjects who underwent brain MRI at visit II from May 2006 to September 2008 (n=876).
part	2 21
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MRI protocol
MRI was performed on a 1.5 Tesla machine (General Electric Medical Systems, Waukesha, Wisconsin, 
USA) following a standard protocol, including a PD/T2w FSE sequence (proton density/T2-weighted 
fast spin echo; field of view [FOV] 220mm, matrix 256x256, slice thickness 3.0mm, echo time [TE] 
22ms, TE 90ms, repetition time [TR]: 3220ms, echo train length 8, flip angle 90°) and a FLAIR sequence 
(fluid attenuated inversion recovery; FOV 220mm, matrix 256x256, slice thickness: 3mm, TE: 100ms, 
TR: 8000ms, inversion time [TI] 2200ms, flip angle 90°). Additionally, images were acquired with a 
T1-weighted three-dimensional spoiled gradient echo sequence (FOV 240mm, matrix 256x256, slice 
thickness 1.5mm, TE 8ms, TR 21ms, flip angle 30°). All images were acquired to give full brain coverage. 
Slices were angled parallel to the anterior commisure-posterior comissure line to give reproducibility 
image views in the oblique-axial plane. 
The 2D phase-contrast scan protocol included the following: First, a sagittal 2D phase-contrast MRI 
angiographic scout image was acquired (FOV 220mm, matrix 256x256, TE 6.1ms, TR 33ms, flip angle 30º, 
velocity encoding 80cm/sec, slice thickness 60mm (Figure 1a). On this scout image, an oblique transverse 
imaging plane perpendicular to the ICAs and the BA was chosen for a 2D gradient-echo phase- contrast 
sequence (FOV 220mm, matrix 256x256, TE 6.2ms, TR 20ms, flip angle 9°, velocity encoding 100cm/sec, 
slice thickness 5mm).
 
Analysis of total cerebral blood flow (visit II) 
The images of the cerebral blood flow were analyzed with the software package FLOW (Division of 
Image Processing, Department of Radiology, Leiden University Medical Center).9 This software provides 
automated detection of the vessel lumen boundaries and subsequent quantification of flow and velocities 
(Figure 1b and 1c). The only user-interaction required is the manual placement of a seed point in each 
of the vessels to be analyzed. All determinations were performed by the same person, with an excellent 
agreement between repeated blood flow measurements of 20 scans (coefficient of variation 1.7%). The 
resultant value of the mean signal intensity in each vessel represented the spatial- and time averaged 
flow velocity in that vessel, which is expressed in centimeters per second. By multiplying this average 
velocity by the cross sectional area of the pixels in the vessel, the flow rate (in mL/s) of the carotid arteries 
and basilar artery can be calculated. tCBF is calculated by summing the flow rates of the carotid arteries 
and the basilar artery and multiplied by 60 sec/min. As representation of stationary tissue, ideally the 
velocity measured in background tissue should be zero. However, the flow sequences had some offset 
velocity (likely inherent to the scanner and the methodology). Therefore, a fourth region of interest (ROI) 
was drawn in the pons, and the average velocity in this fourth ROI was subtracted to correct for the 
velocity offset (median [min-max] 1.0 [0.2-1.5] cm/sec). 
Assessmentof covarying brain characteristics
Brain volume, an important determinant of tCBF,3 was determined from visit 1 MRI’s. Volumes of 
grey matter, white matter, white matter hyperintensity (WMH) and cerebrospinal fluid were computed 
automatically with an algorithm based on the Montreal Neurological Institute (MNI) pipeline.10 
The AGES-Reykjavik/MNI pipeline has been modified to accommodate full brain coverage including 
cerebellum and brain stem, multi-spectral analysis using T1-weighted 3D SPGR, FLAIR and PD/T2-
weighted FSE images, high throughput, automatic skull removal and minimal editing. Total brain 
volume was determined by summing the volumes of the grey matter, white matter and WMH; this was  
standardized by total intracranial volume, giving a percent. Cerebral infarcts, which may also influence 
blood flow, were defined as parenchymal defects, areas isointense to cerebral spinal fluid on all pulse 
sequences with a minimum diameter of 4mm. 
Assessment of cardiovascular factors 
Mid-life
Mid-life data on cardiovascular factors were collected as part of the Reykjavik Study.8 Participants 
answered a standardized questionnaire, underwent a clinical exam, had blood drawn and an X-ray 
and electrocardiogram (ECG) made. We examined risk factors, classified into 4 groups: hemotologic, 
hemodynamic, metabolic and cardiac factors. The individual variables were measured as follows:  
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1) Hematologic factors: hemoglobin (mmol/L) and hematocrit (L/L). 2) Hemodynamic factors: diastolic 
and systolic blood pressure (mm/Hg –mean value of two measurements on the right arm in supine 
position), pulse pressure (systolic – diastolic blood pressure), mean arterial pressure (MAP; 1/3 systolic 
+ 2/3 diastolic blood pressure), and hypertension (reported history of hypertension, reported use of 
anti-hypertensive medication, a systolic blood pressure ≥140mmHg or a diastolic blood pressure of 
≥90mmHg, coded as yes/no; 3) Metabolic factors: serum fasting glucose (mmol/L); total cholesterol 
(mmol/L), and triglycerides (mmol/L) and body mass index (BMI)(kg/m2); 4) Coronary factors: current 
smoking (yes/no), a history of cardiac disease (defined by history of angina pectoris, heart disease, heart 
valve disease or coronary thrombosis, coded as yes/no), presence of left ventricular hypertrophy on chest 
X-ray (yes/no); any cardiac disease visible on X-ray (defined by presence of left ventricular hypertrophy, 
right ventricular hypertrophy, mitral valve defect or calcium in the aorta (yes/no)), and minor and major 
abnormalities on a 12 lead ECG,  coded on the basis of the Minnesota coding criteria.11 To obtain groups 
sufficiently large to allow reliable conclusions, ECG findings were further pooled using the criteria of the 
pooling project.12 Minor ECG abnormalities included borderline Q wave (Minnesota code I3), left or right 
axis deviation (codes II1-2), QRS high voltage (codes III1-2), borderline ST segment depression (code IV4) T 
wave flatting (code V3), and QRS low voltage (code IX1). Major ECG abnormalities consisted of ST segment 
depression (codes IV1-2), T wave inversion (codes V1-2), complete or second degree atrioventricular block 
(codes VI1-2), complete left or right bundle branch block (codes VII1-2), frequent premature beats (code 
VIII1) and atrial fibrillation or flutter (code VIII3). 
Late-life 
Participants answered a questionnaire, had their medication registered  based on vials they brought 
to the exam, had clinical measures made, a fasting blood sample drawn, and underwent extensive bio-
imaging. The following variables were included in the analyses, which, when relevant, were defined in 
the same way as the mid-life variables: 1) Hematologic factors: hemoglobin (mmol/L) and hematocrit 
(L/L); Hemodynamic factors: diastolic and systolic blood pressure; pulse pressure; and hypertension; 
3) Metabolic factors: fasting glucose (mmol/L), total cholesterol (mmol/L), triglycerides (mmol/L), BMI 
(kg/m2), and diabetes (defined as history of diabetes, using oral hypoglycemic medication or insulin, 
or if fasting plasma glucose was ≥7.0mmol/L (≥126mg/dL)); 4) Coronary factors: current smoking  (yes/
no), a history of cardiac disease (defined as a history of congestive heart disease, heart valve disorder, 
angina/myocardial infarction or CABG, coded as yes/no); a history of TIA or stroke (yes/no), presence of 
atherosclerosis determined by coronary artery calcium load (quantified with computed tomographic 
images and expressed in Agatston units); minor abnormalities (yes/no) and major abnormalities (yes/no) 
on ECG following the same classification as at mid-life.
Analysis
Analytical sample
TCBF was measured in n=876 subjects. We excluded 14 subjects due to incorrect tCBF measurements,  
7 due to missing mid-life data, and 33 subjects due to missing brain volume data. This resulted 
in a sample of 822 available for this study, with a mean(SD) age of 79(5) yrs at time of blood flow 
determination, 74(5) yrs at assessment of late-life life cardiovascular factors, and a mean(SD) age of 49(6) 
yrs at assessment of mid-life cardiovascular factors. Excluded subjects did not differ in sex, but were 
slightly older compared to the rest of the sample (mean [SD] age 82[6] yrs versus 79[5] yrs).
 
Statistical analysis
Statistical analyses were performed using SPSS 15.0 for Windows (SPSS Inc). We investigated the 
association of tCBF (dependent) to mid- (and late-) life cardiovascular determinants with linear regression 
analyses. Two models were estimated: model 1, adjusted for age and sex, and model 2, adjusted for age, 
sex, presence of infarct on MRI, and brain volume. Coronary artery calcium expressed in Agatston units 
was not normally distributed, therefore we transformed the variable with the natural log and added 1 to 
avoid zeros (ln [1+ coronary artery calcium). 
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Results
The 822 subjects included 479(58%) women. Mean (SD) tCBF was 578(108) mL/min. TCBF decreased as age 
increased (per sd increase of age, difference in tCBF -4.0 [95% CI:-5.4; -2.6]). Mean (SD) tCBF was lower in 
women (574 [105] mL/min) compared to men (584 [112] mL/min), but this difference was not statistically 
significant (p=0.18).  
Cardiovascular characteristics at mid-life and late-life (Table 1)
Subjects had slightly higher levels of hemoglobin and hematocrit in mid-life compared to late-life. Only 
30% of the subjects had hypertension at mid-life (30%), but by late-life 76% fulfilled criteria for hyperten-
sion. Furthermore, compared to late-life, fasting glucose levels were lower at mid-life and diabetes was 
infrequent. In contrast, in late-life 10% of the sample had diabetes and 8% had a fasting glucose of >7.0 
mmol/L. Cardiac disease on ECG was seldom present at mid-life, but at late-life both minor and major ECG 
abnormalities were observed in one out of five (minor abnormalities 21%, major abnormalities 18%). 
Mid-life characteristics and tCBF  (Table 2)
Adjusted for age and sex, we found significant inverse relations of tCBF to mid-life hemoglobin, hemat-
ocrit and diastolic blood pressure levels. These results remained essentially unchanged after additional 
adjustment for presence of infarcts and brain volume. In addition, an increase of MAP was associated 
with a lower tCBF at late-life, independent of age and sex (model 1); but adjustment for brain volume and 
infarcts (model 2), slightly attenuated the relationship. Other hemodynamic variables (systolic BP, pulse 
pressure, and hypertension) were not significantly associated with tCBF. Furthermore, adjusted for age 
and sex, lower tCBF was associated with higher levels of mid-life triglyceride, smoking and the presence 
of left ventricular hypertrophy on X-ray. However, after adjustment for brain volume and infarcts these 
associations lost significance. 
Late-life characteristics and tCBF (Table 3)
As with the mid-life data, there were strong inverse associations of hemoglobin and hematocrit to tCBF, 
in the fully adjusted model 2. Similarly, diastolic BP, MAP, and major ECG abnormalities were associated 
tCBF, independent of age, sex, brain volume and presence of infarcts. Diabetes and increasing levels of 
fasting glucose levels were significantly associated with lower tCBF, but these associations were markedly 
reduced after additional adjustment for brain volume and infarcts. 
To further explore the hemoglobin associations we stratified subjects into low or high hemoglobin level 
by the mean hemoglobin level of the sample (low <8.5 mmol/L, high >8.5mmol/L) and we tested for non-
linear associations [which were not significant]. Stratification suggested hemoglobin was most strongly 
associated to lower tCBF in subjects with high hemoglobin levels, compared to subjects with relatively 
low hemoglobin levels (high hemoglobin: per sd increase of hemoglobin, difference in tCBF -52.6 [95% CI: 
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Table 1; Cardiovascular	factors	at	mid-life	and	late	life:	AGES-Reykjavik	Study
n=822
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Table 2; Linear	regression:	mid-life	cardiovascular	characteristics	
	 and	tCBF	AGES-Reykjavik	Study
n=822 Model 1 Model 2
B (95%CI) B (95%CI)
Hematologic factors
Hemoglobin	 -16.3* -28.5;-4.1 -12.7* -24.2;-1.2
Hematocrit		 -4.0* -6.7;-1.3 -3.0* -5.6;-0.5
Hemodynamic factors
Systolic	BP	 -0.3 -0.7;0.2 -0.05 -0.5;0.4
Diastolic	BP	 -1.1* -1.8;-0.3 -0.7 -1.5;0.0
Pulsepressure 0.4 -0.4;1.2 0.6 -0.2,1.3
Mean	arterial	pressure -0.7* -1.4;-0.0 -0.4 1.1,0.3
Hypertension	 -14.2 -30.2;1.8 -12.3 -28.2;3.9
Metabolic factors
Fasting	glucose	>7.0	mmol/L		 -7.3 -23.6;9.1 -6.3 -21.6;9.0
Cholesterol	 0.4 -6.6;7.3 0.2 -6.2;6.7
Triglyceride		 -17.2* -30.0;-4.0 -10.4 -22.6;1.7
BMI -1.5 3.8;0.8 -1.0 -3.1;1.2
Coronary factors
Current	Smoke	exposure	 -17.9* -33.6;-2.3 -11.1 -25.9;3.6
Self	reported	history	of	CHD 7.9 -39.1;55.0 3.1 -41.0;47.2
Any	cardiac	disease	visible	on	X-ray -16.5 -42.5;9.5 -12.0 -36.3;12.4
Left	ventricular	hypertrophy	on	X-ray -34.9* -69.3;-0.6 -29.6 -61.8;2.6
Minor	abnormalities	on	ECG -21.0 -58.0;16.1 -13.7 -48.4;21.0
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Table 3; Linear	regression:	late-life	cardiovascular	characteristics	
	 and	tCBF	AGES-Reykjavik	Study
n=822 Model 1 Model 2
B (95%CI) B (95%CI)
Hematologic factors
Hemoglobin -47.3* -58.8;-35.8 -48.7* -59.4;-38.1
Hematocrit -10.0* -12.3;-7.7 -10.0* -12.2;-7.8
Hemodynamic factors
Systolic	BP -0.2 -0.5;0.2 -0.1 -0.4;0.3
Diastolic	BP -1.6* -2.4;-0.8 -1.4* -2.1;-0.6
Pulse	pressure 0.3 -0.2;0.7 0.3 -0.1,0.7
Mean	arterial	pressure -0.9* -1.6;-0.3 -0.7* -1.4,-0.1
Hypertension -10.0 -27.5;7.5 -4.1 -20.6;12.3
Metabolic factors
Fasting	glucose	>7.0	mmol/L		 -29.3* -56.6;-2.0 -13.1 -38.9;12.7
Total	cholesterol -1.9 -8.7;4.9 -5.1 -11.5;1.3
Triglycerides -8.1 -19.3;3.1 -4.8 -15.3;5.7
BMI -1.6 -3.4;0.3 -1.2 -3.0;0.5
Diabetes -32.8* -57.1;-8.5 -15.6 -38.7;7.6
Coronary  factors
Current	smoke	exposure -20.9 -44.3;2.5 -20.5 -42.4;1.3
Self	reported	history	of	CHD -5.8 -23.4;11.9 1.7 -15.0;18.4
Self	reported	history	of	stroke/TIA -12.9 -37.8;12.1 -7.4 -31.2;16.5
Coronary	calcification -3.2 -6.5;0.1 -1.9 -5.0;1.3
Minor	ECG	abnormalities -15.2 -33.2;2.7 -5.0 -22.0;12.0
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Discussion
We found tCBF in elderly subjects depends on several different hematologic, hemodynamic, metabolic 
and coronary characteristics. Moreover, based on the mid-life data, these factors begin early to affect 
tCBF. Strengths of this study include the large sample from a population based cohort. Furthermore, 
a wide range of cardiovascular factors was investigated. Combining mid-life and late-life data allowed 
representation of life course associations with tCBF. To determine tCBF, we used 2D phase-contrast 
imaging, which has been shown to be accurate and reliable.4 Additionally, the method to analyze the 
imaging files was automatic and validated.9 
There are some issues need to be taken into account when interpreting the results. We did not have 
tCBF measures at mid-life, so we do not have an estimate of the decline in tCBF associated with the 
factors we investigated. We also do not have a measure of brain volume acquired concurrently with the 
tCBF, so there may be some residual confounding due to brain volume. Finally, subjects with poorer 
health status (and expected lower tCBF) are less likely to participate, and this may underestimate the 
significance of the association of tCBF to the characteristics of interest. 
Independent of age, sex, infarcts and brain volume, both hemotologic factors were strongly inversely 
associated with tCBF, such that tCBF declined with increasing levels of hemoglobin and hematocrit. 
The reduced flow associated  with these hematologic measures has been described before, but never 
in such a large population based study.1, 13-16 The changes in tCBF are thought to be the result of 
cerebral autoregulation, which reacts to both blood viscosity and arterial oxygen.14, 16 It is believed that 
an increase in viscosity (e.g. caused by an increase of hemoglobin and hematocrit) leads to increased 
vascular resistance and a decrease in flow.1, 13 Indeed, we found an inverse association of hemoglobin to 
tCBF in those with higher levels of hemoglobin and not in those with lower levels. However, possibly, 
there is a J shaped relationship of hemoglobin to tCBF that we could not detect. Active vasodilatation 
occurs in reaction to arterial oxygen content,15 ensuring that, for example during anemia, CBF is 
increased. In this present sample, none of the subjects fulfilled criteria for anemia, and the test for 
non-linearity of the associations of hemoglobin to tCBF, was not significant. A larger sample size at 
the lower ends of hemoglobin levels may be needed to detect a non-linear association. However, the 
lack of association in the lower hemoglobin strata may also indicate a diminished capacity in old 
age for cerebral autoregulation to increase tCBF in reaction to low hemoglobin, or an increase in 
dehydration; this needs to be investigated in future studies. Further, earlier studies reported elevated 
hematocrit levels were associated carotid occlusion, and an increased risk for ischemic stroke and 
related mortality.17, 18 Although carotid occlusion will have direct effects on tCBF, the reaction of tCBF to 
high hematocrit may play a crucial role in the development of brain ischemia. This is of interest since 
in ischemic stroke, high hematocrit has been associated with a reduced reperfusion and larger infarct 
size.19  
We found both mid- and late-life levels of diastolic blood pressure, and late-life MAP and major ECG 
abnormalities were associated with tCBF. There was no relation between systolic blood pressure, pulse 
pressure and tCBF. These results suggest the hypothesis that peripheral resistance and cardiac output  
are important initial factors related to total blood flow to the brain later in life. On the other hand, 
diabetes was associated with tCBF when adjusting for age and sex, but not after adjusting for brain 
volume and infarcts. This suggests glycemic or insulin dysregulation may be associated with tCBF 
through its effect on brain perfusion or neurodegeneration. The relation between diabetes and tCBF has 
previously been investigated, but characteristics of the samples vary and results are conflicting. 20 
In summary, we found that multiple factors have to be considered when investigating tCBF in elderly; 
strong inverse relations of tCBF to hemoglobin, hematocrit, diastolic blood pressure, and cardiac 
function were shown. Future research should be aimed at further unraveling the interactions among 
characteristics of blood, heart and blood flow to the heart and brain, and evaluate the significance in 
clinical practice. In this study, mid-life characteristics showed comparable associations with tCBF in 
elderly, which illustrates the importance to recognize cardiovascular disease early in life. 
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Abstract
Objective 
Using magnetic resonance images, we investigated the association of total cerebral blood flow (tCBF) and 
total brain perfusion (tBP) to vascular lesions and a change in measures of brain structure.  
Methods
Baseline (T1) scans were acquired on the population based cohort of men and women (b 1907 – 1935) 
participating in the AGES-RS. A mean (SD) 2.3 (0.1) yrs after T1, a random, non-demented, sub sample 
of the cohort (n=206, age 75±5y, 55% women) was invited for a follow-up scan (T2) that included 
two-dimensional phase contrast imaging to determine tCBF (mL/min) and tBP; (tCBF per 100mL brain 
volume). Blood flow measures were examined in association with baseline presence of infarcts and 
microbleeds, and with annual change in brain tissue volumes estimated with automated computer 
algorithms. The associations were estimated with linear regression adjusted for age and sex.
Results
Mean (SD) tCBF was 577(101mL/min) and mean (SD) tBP was 53.6 (9.4) mL/min per 100mL. Presence of 
vascular lesions at T1 were not associated with tCBF or tBP. Decrements in volumes of whole-brain tissue 
were significantly associated with tCBF (β [95%CI]; -40.9 [-75.7;-4.5]) and tBP (-3.2 [-6.1;-0.1]); grey matter 
with tCBF (-30.3 [-60.3;-0.4]) and(tBP -3.0 [-5.7;-0.4]). Annual progression of white matter hyperintensities 
(WMH) was significantly associated with lower tBP (-12.2 [-21.1;-3.4]).
Conclusion
The association of whole-brain and grey matter tissue loss and progression of WMH to lower tCBF and 
lower total brain perfusion, suggests brain tissue damage leads to a decreased demand for blood, and 
possibly a cycle of reduced demand and cerebral damage.
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Introduction
Increasing age is associated with decline in total cerebral blood flow (tCBF).1-3 This decline is partly de-
termined by brain volume, which may be associated with neurodegeneration, as well as large and small 
vessel disease. However, not clear is the extent to which brain tissue loss (atrophy in the gray and white 
matter) and evidence of cerebrovascular damage contribute to a decline in tCBF. Most likely there is a 
vicious circle, whereby reduced tCBF leads to ischemic changes and atrophy, and these pathologies lead 
to reduced demand for blood. 
Grey matter has a higher demand for perfusion. However, most studies report on changes in the white 
matter. For example, cross-sectional studies have shown an inverse relation between the severity of 
white matter hyperintensities (WMH) and both tCBF and tBP (tCBF per 100mL brain volume).3-5 These 
associations have been reported to be stronger in the presence of subcortical brain atrophy (lower tBP).4 
One previous study reported an inverse association of tCBF to progression of  periventricular and deep 
WMH with a stronger relation  for periventricular lesions.6 
As far as we know, there are no longitudinal studies of the association blood flow measures and of 
progression of brain atrophy and vascular damage. In non-demented elderly, age-related atrophy rates 
ranging from 0.2% to 0.7% per year, and progression rates of WMH of 0.05% of brain volume have been 
reported.7-10 Understanding the temporal association of changes in brain structure and blood flow will 
help to inform us on the trajectory of pathological brain aging and help identify proximal factors leading 
to these pathologic changes. Here we aim to study the association of vascular lesions, brain tissue 
volume, and progression of brain changes to tCBF and tBP. Data are based on a non-demented subsample 




The design of the AGES-Reykjavik has been described previously.11 Briefly, the AGES-Reykjavik cohort 
is based on the Reykjavik Study, a community-based cohort established in 1967 to prospectively study 
cardiovascular disease in Iceland. In 2002 the study was extended to the AGES-Reykjavik Study. Between 
2002 and 2006 5764 men and women participated in detailed evaluations of cardiovascular, musculos-
keletal, metabolic and neurocognitive phenotypes, including MRI scanning of the brain (time point 1; 
T1). AGES-Reykjavik was approved by the National Bioethics Committee in Iceland, which acts as the 
institutional review board for the Icelandic Heart Association (approval number VSN-00-063), and by 
the National Institute on Aging Intramural Institutional Review Board. All participants gave written 
informed consent.
This study includes participants whose T1 MRI was acquired between March 2004 and January 2005 
(figure 1). Between 2006 and 2007 a random sub sample of these participants who were not demented 
at T1 (n=408) were invited for a repeat brain MRI (time point 2; T2). The MRI protocol of half of this 
subgroup (n=206) was the same as in T1, but also included the MRI sequence necessary for tCBF 
determination. The mean (SD) time interval between T1 and T2 was 2.3 (0.1) years (see Figure 1).
MRI protocol
At T1 and T2, MRI was performed on a 1.5 Tesla machine (General Electric Medical Systems, Waukesha, 
Wisconsin, USA) following a standard protocol that included a PD/T2w FSE sequence (proton density/
T2-weighted fast spin echo; field of view [FOV] 220 mm, matrix 256x256, slice thickness 3.0mm, echo 
time [TE] 22ms, TE 90ms, repetition time [TR]: 3220ms, echo train length 8, flip angle 90°), a FLAIR 
sequence (fluid attenuated inversion recovery; FOV 220mm, matrix 256x256, slice thickness: 3mm, TE: 
100ms, TR: 8000ms, inversion time [TI] 2200ms, flip angle 90°) and a T2*-weighted gradient echo based 
echo planar imaging (GRE-EPI) sequence (FOV 220mm, matrix 256x256, slice thickness 3mm, TE 50ms, 
TR 3050ms, flip angle 20°). Additionally, images were acquired with a T1-weighted three-dimensional 
spoiled gradient echo sequence (FOV 240mm, matrix 256x256, slice thickness 1.5mm, TE 8ms, TR 21ms, 
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flip angle 30°). All images were acquired to give full brain coverage. Slices were angled parallel to the 
anterior commissure-posterior commissure line to give reproducible image views in the oblique-axial 
plane. 
Two-dimensional (2D) phase contrast MR angiography is a non-invasive and fast method to measure tCBF 
and has been shown to be accurate and reliable.12 At T2 the 2D phase contrast sequence was added as 
follows. First, a sagittal 2D phase contrast MRI angiographic scout image was acquired (FOV 220mm, 
matrix 256x256, TE 6.1ms, TR 33ms, flip angle 30°, velocity encoding 80cm/sec, slice thickness 60mm). 
On this scout image, an oblique transverse imaging plane perpendicular to the carotid arteries and the 
basilar artery was chosen for a 2D gradient-echo phase contrast sequence (FOV 220mm, matrix 256x256, 













Measurement of total cerebral blood flow 
The images of the cerebral blood flow were analyzed using the software package FLOW (Division 
of Image Processing, Department of Radiology, Leiden University Medical Center).13 This software 
provides automated detection of the vessel lumen boundaries and subsequent quantification of flow 
and velocities. The only user-interaction required is the manual placement of a seed point in each of 
the vessels to be analyzed. All determinations were performed by the same person, with an excellent 
agreement between repeated blood flow measurements of 20 scans (coefficient of variation 1.7%). The 
resultant value of the mean signal intensity in each vessel represented the spatial- and time averaged 
flow velocity in that vessel, which was expressed in cm/sec. By multiplying this average velocity by the 
cross-sectional area of the pixels in the vessel, the flow rate (in mL/s) of the carotid arteries and the 
basilar artery are calculated. Subsequently, the flow rates of the carotid arteries and the basilar artery are 
summed and multiplied by 60sec/min to calculate tCBF (mL/min). As representation of stationary tissue, 
ideally the velocity measured in background tissue should be zero. However, the flow sequences had 
some offset velocity (likely inherent to the scanner and used methodology). Therefore, a fourth region 
of interest (ROI) was drawn in the pons, and the average velocity in this fourth ROI was subtracted to 
correct for the velocity offset (median [min-max] 1.0 [0.2-1.5] cm/sec).
Brain volumes
For T1 and T2 MRIs, volumes of grey and white matter, WMH and cerebrospinal fluid (CSF) were com-
puted automatically with an algorithm based on the Montreal Neurological Institute (MNI) pipeline.14 
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The AGES-Reykjavik/MNI pipeline has been modified to accommodate full brain coverage including cer-
ebellum and brain stem, multi-spectral analysis using T1-weighted 3D SPGR, FLAIR and PD/T2-weighted 
FSE images, high throughput, automatic skull removal and minimal editing. Total brain volume was 
determined by summing the volumes of the grey matter, white matter and WMH. Intracranial volume 
(ICV) was obtained by adding the volumes of CSF to the total brain volume. To correct for inter-individual 
differences in ICV, total brain fraction, was calculated by dividing the brain volume by ICV and expressed 
as percentage. Similarly, grey matter, white matter and WMH fraction were calculated. 
Infarct-like lesions and microbleeds
On MRI at T1, cerebral infarct-like lesions were defined as parenchymal defects, areas isointense to 
cerebral spinal fluid on all pulse sequences with a minimum diameter of 4mm, except for cerebellar 
infarcts, which had no size criteria.  No clinical data was reviewed for these infarct-lesions found on MRI; 
however, for easier reading we; hereafter call these lesions infarcts. The infarcts were classified as corti-
cal, subcortical or cerebellar infarcts. Cortical and cerebellar infarcts were identified by a neuro-radiol-
ogist and radiographically described by three trained radiographers who also identified and described 
subcortical infarcts. Five percent of all scans were re-read without knowledge of the prior reading, at the 
Department of Radiology, LUMC, the Netherlands, to assess inter-rater reliability (weighted kappa = 0.7). 
Average intra-rater reliability based on repeated ratings of 19 cases once every year by each observer over 
the course of the study was 0.9. 
As previously described,15 microbleeds were defined as a focal area of signal void within the brain 
parenchyma that: (1) is visible on T2*-weighted GRE-EPI images and is smaller or invisible on T2-weighted 
FSE images; (2) is not abutting a parenchymal defect; and (3) does not show any other structure in 
the aria of signal void. Areas of symmetric hypointensities of the globus pallidus likely to represent 
calcification or non-hemorrhagic iron deposits were excluded. The presence of microbleeds was assessed 
Covariates
At T1, subjects were administered a questionnaire about medical history; presented currently used 
medication vials; underwent a clinical examination including blood pressure measures and had a fasting 
blood sample drawn. To control for factors that may modulate blood flow to the brain we controlled for 
major cardiovascular risk factors. Hypertension was defined as a self reported doctor’s diagnosis of hy-
pertension, the use of blood pressure lowering drugs, or a systolic blood pressure ≥140mmHg or a diasto-
lic blood pressure of ≥90mmHg. We considered diabetes  present if a history of diabetes was reported, if a 
subject was taking oral hypoglycemic medication or insulin, or if fasting plasma glucose was ≥7.0mmol/l 
(≥126mg/dl). Smoking status was assessed by self report and defined as never, former  
or current smoker. 
Data analysis
Definition of analytical variables.
Per subject, tBP(in mL/min per 100mL) was calculated by dividing total cerebral blood flow (mL/min) by 
brain volume (mL) and multiplying the result by 100. Infarcts and microbleeds were coded as present 
or absent. Brain tissue volumes were normally distributed with the exception of WMH; which was 
transformed with the natural log plus 1 (ln [1+WMH fraction]). To investigate whether the brain volume 
measures significantly changed in the 2 year interval we compared brain tissue measures atT1 and T2 
with paired sample t-tests, and for WMH fraction using the Wilcoxon rank test for non-parametric data. 
Annual change in tissue volume was calculated as the difference in tissue fractions between T1 and T2, 
divided by the time interval in years between the assessments. Annualized measures were expressed as 
change in percent of TICV per year. 
We used linear regression models to assess the relation of blood flow measures to tissue volume (cross-
sectional at T2), presence of vascular lesions measured at T1, and annual change from T1 to T2. All 
regression analyses were adjusted for age and sex (model 1), and additionally adjusted for hypertension, 
diabetes and smoking status (model 2). Statistical analyses were performed using SPSS 14.0 for Windows 
(SPSS Inc). Statistical significance was set at p<0.05. 
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Results
At T2, the sample had a mean±SD age of 78±5 years and 55% were women (table 1). Mean total brain 
volume was 1083±99mL with a total brain fraction of 71.5% Mean tCBF was 577±101mL/min, and  
mean tBP was 53.6±9.4mL/min per 100mL brain volume. 
Cross-sectional associations 
We found no relation of age to tCBF (per SD increase of age, difference in tCBF -2.0 [95%CI = -4.7;0.6]) 
or tBP 0 [95%CI = -0.2;0.3). Men and women had comparable tCBF and comparable flow values in both 
carotid arteries and the basilar artery (tCBF M: 569±109mL/min, F: 584±95mL/min; left carotid artery M: 
227±61mL/min, F:233±55 mL/min; right carotid artery M: 226±54 mL/min,  F: 229±52 mL/min; basilar 
artery M:115±39 mL/min, F: 122±37 mL/min). tBF was higher in women (mean 56.3±8.9mL/min per 
100mL) compared to men (mean 50.3±8.9mL/min per 100mL; independent sample t-test p<0.001).  
Cross-sectionally, tCBF was positively associated with total brain fraction (per SD increase of brain 
fraction, difference in tCBF 8.0 [95%CI = 3.8; 12.2]) (table 2). This was attributable to significant 
associations of tCBF to both grey matter and white matter. Grey matter volume was positively associated 
with tBP. WMH were significantly associated with tBP in model 1, but this was attenuated in model 2. 
Longitudinal associations
At T1, the prevalence of infarcts was 31% and microbleeds were found in 13% of the subjects. Adjusting 
for age and sex, neither infarcts (any, or any infarcts in thesubcortical, cortical or cerebellar regions) or 
microbleeds, were associated with tCBF (p value for all >0.16) or with tBP (p values for all >0.16) (table 3). 
Additional adjustment for hypertension, diabetes and smoking status did not change these results  
(table 4). 
Total brain volume and total brain fraction decreased (respectively from 1099mL to 1083mL; 72.6% to 
71.5%) from T1 to T2, with a mean annual loss of 0.5±0.4% per year of total intracranial volume. The 
mean annual loss of grey matter was 0.4±0.5% , and of WM was 0.2%. Total WMH volume increased from 
a median (interquartile range) volume of 12mL (7-23) to 15mL (7-28) with an annual progression of WMH 
of 0.06% (0.02-0.13). Adjusting for age and sex, all brain volume measures changed significantly (p <0.001) 
over the 2.3 year interval. 
There was a trend between higher annual whole-brain atrophy and lower tCBF, which was strengthened 
after adding to the model smoking status, hypertension and diabetes (table 4). This association mainly 
reflected the changes in the grey matter. Furthermore, there was a significant decrease in tBP as WMH 
increased and grey matter decreased. 
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Table 1;	Characteristics	of	participants:	AGES-Reykjavik	Study
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Table 2; Cross-sectional	association	of	brain	tissue,	tCBF	and	tBP:	AGES-Reykjavik	Study
 
Model Total cerebral blood flow  
(mL/min) Total brain perfusion 
(mL/min per 100mL)
B 95%CI B 95%	CI
Grey matter fraction 1. 7.3 2.4;12.2 0.6 0.1;1.0
2. 6.4 1.5;11.3 0.5 0.1;1.0
White matter fraction 1. 13.0 5.4;20.5 0.3 -0.4;1.0
2. 9.2 1.3;17.1 0.0 -0.7;0.7
WMH fraction 1. -25.7 -57.9;6.6 -3.4 -6.3;-0.6
2. -13.6 -45.8;18.6 -2.5 -5.4;0.3
Total brain fraction 1. 8.	0 3.8;12.2 0.3 -0.04;0.7
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Table 3;	Infarcts	and	microbleeds	in	relation	to	tCBF	and	tBP:	AGES-Reykjavik	Study
 
Model Total cerebral blood flow 
(mL/min)
Total brain perfusion 
(mL/min per 100mL)
B 95%CI B 95%	CI
Any infarct 1. -19.0 -49.8;11.7 -1.3 -4.1;1.5
2. -10.8 -41.1;19.5 -0.6 -0.2;0.3
Cortical infarct 1. -38.0 -94.1;18.0 -3.5 -8.5;1.4
2. -27.6 -83.0;27.7 -2.9 -7.8;2.1
 
Subcortical infarct 1. -21.5 -67.6;24.7 -2.2 -6.3;1.9
 
2. -4.3 -50.4;41.7 -1.0 -5.1;3.2
Cerebellar infarct 1. -24.4 -58.4;9.6 -1.6 -4.7;1.5
2. -19.3 -52.6;13.9 -1.1 -4.2;1.9
Microbleeds 1. -10.6 -53.1;31.8 -1.9 -5.7;2.0







Akkoord_drukker.indd   39 05-11-09   10:49
Table 4; Association	of	annualized	change	in	brain	tissue,		tCBF	and	tBP:	AGES-Reykjavik	Study
Total cerebral blood flow 
(mL/min)
Total brain perfusion 
(mL/min per 100mL)
B 95%CI B 95%	CI
Annual grey matter atrophy 1. -22.9 -53.7;	7.9 -2.6 -5.3;0.2
2. -30.4 -60.3;-0.4 -3.0 -5.7;-0.4
Annual white matter atrophy 1. -39.1 -100.4;22.1 -2.3 -7.7;3.1
2. -25.9 -85.9;34.1 -1.4 -6.7;4.0
Annual WMH progression 1. -97.2 -200.2;5.8 -12.2 -21.2;-3.2
2. -96.2 -196.4;3.9 -12.2 -21.1;-3.4
Annual whole-brain atrophy 1. -34.6 -71.3;2.1 -2.9 -6.2;0.3
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Discussion
Cross-sectionally, adjusting for age and sex, tCBF was associated with total brain tissue, specifically grey 
and white matter volumes. tBP was most strongly positively associated with grey matter volume. We 
report an association of an annual decrease in grey matter, whole-brain tissue volume and lower tCBF. 
Annual progression of WMH and grey matter loss were significantly associated with tBP.
Strengths of the current study include the use of an accurate and reliable measure of tCBF with 2D 
phase-contrast imaging.12 Contrary to most other techniques, it is a non-invasive method which allowed 
us to determine tCBF in a relatively large sample. The study was population based, including only 
non-demented elderly. Furthermore, we used a validated and automatic method to estimate tissue 
volume from the scans. Finally, all analyses with brain tissues were corrected for intracranial volume. 
One limitation of the study is the absence of baseline tCBF values, which would give insight into the 
magnitude of decline in cerebral blood flow and perfusion that follows a change in brain tissue volume. 
Further, although all of the coefficients suggested decline in tCBF with decreasing brain tissue, the 
sample may be too small to find significant differences.
Values for mean tCBF were comparable to some earlier studies in older samples,16,17 but slightly 
higher compared to others.1,3 Recently reported values for total brain perfusion measured with 2D 
phase-contrast imaging were a little lower (respectively 51.2 and 52.2 mL/min per 100mL) compared 
to the mean total brain perfusion we found of 53.6mL/min per 100mL brain volume, likely reflecting 
differences in research population and assessment methodologies.3,4 In this study, delineation of the 
vessel was automatic, while the previous reports used a manual method. Furthermore, we corrected for 
background offset that might have influenced our results. 
Consistent with other cross-sectional studies,3 decreasing brain volumes, including total brain volume, 
grey and white matter volumes, were related to decreasing tCBF. Annual grey matter and whole-brain 
tissue volume loss were significantly associated with lower tCBF after correction for vascular risk factors. 
This likely reflects the normally higher perfusion in grey compared to white matter18; possibly more 
atrophy is needed to detect a significant effect.19 As far as we know, no previous study examined the 
association of annualized change of brain tissue to tCBF.
Our results suggest reduced demand from the atrophying brain leads to lower blood flow to the brain.  
A third time point is needed to determine whether lower blood flow and perfusion leads to more 
atrophy and WMH. 
We found cross-sectionally and longitudinally, WMH reduces brain perfusion, but not tCBF, consistent 
with other.19,20 In the one study that examined the association between progression of WMH and tCBF, 
a stronger association was found with lesions located in the periventricular compared to deep white 
matter.  Interestingly, we did not find a relation between presence of infarcts or microbleeds and tCBF or 
tBP at follow up. By definition brain perfusion is decreased in acute ischemic stroke, but the longitudinal 
effects of infarcts and microbleeds on tCBF and total brain perfusion have to be further elucidated in 
future research.
Together, our findings concerning WMH and atrophy suggest that tissue damage results in a lower 
demand of blood flow and lower total brain perfusion, but we cannot exclude that this was preceded 
by lower tCBF in the first place. Future research is needed to confirm our hypothesis, possibly 
leading eventually to more emphasis on therapeutic strategies directed at the origin of WMH and 
atrophy instead of tCBF. With this study we feel to be one step further in understanding the complex 
equilibrium of total blood flow to the brain, in terms of supply and demand. 
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Abstract
Objective
We sought to determine the predictive value of MRI measures of vascular disease (white matter hyper-
intensities [WMH], lacunes, microbleeds, infarcts) compared to atrophy on progression of mild cognitive 
impairment (MCI) to dementia. 
Methods
We included 152 consecutive patients with MCI. Baseline MRI was used to determine the presence  
of medial temporal lobe atrophy (MTA) and vascular disease (prescence of lacunes, microbleeds and  
infarcts was determined, WMH were rated using a semiquantitative scale). Patients were followed up  
for 2±1 years.
Results
72 (47%) Patients progressed to dementia during follow-up. Of these, 56 (37%) patients were diagnosed 
with Alzheimer’s disease (AD), and 16 (10%) patients were diagnosed with another type of dementia 
(including vascular dementia, frontotemporal lobar degeneration and Parkinson dementia). Converters 
were older, and had a lower mini-mental state examination (MMSE) score at baseline. On baseline MRI, 
patients who progressed to a non-Alzheimer dementia showed more severe WMH and had a higher 
prevalence of lacunes in the basal ganglia and microbleeds compared to non-converters. Cox propor-
tional hazard models showed that adjusted for age and sex , baseline MTA (HR [95%CI] = 2.9 [1.7-5.3]), but 
not vascular disease, was associated with progression to AD. By contrast, deep WMH (HR 5.7 [1.2-26.7]) 
and periventricular hyperintensities (HR 6.5 [1.4-29.8]) predicted progression to non-Alzheimer dementia. 
Furthermore, microbleeds (HR 2.6 [0.9-7.5]) yielded a more than twofold increased, though non-signifi-
cant risk of non-Alzheimer dementia. 
Conclusion
MTA and markers of cerebrovascular disease predict the development of different types of dementia in 
MCI patients. 
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Introduction
Mild cognitive impairment (MCI) is characterized by mild cognitive deficits not sufficient for a diagnosis 
of dementia.1 MCI patients have an increased risk of progression to dementia, mostly Alzheimer’s disease 
(AD) – although the risk of another type of dementia is known to be elevated as well.1-3 Atrophy of the 
medial temporal lobe (MTA), including the hippocampus and entorhinal cortex, is a sensitive marker for 
AD. Visual assessment of MTA has been shown to be a powerful and independent predictor of progression 
to dementia in MCI patients.4-6 Additionally, global cortical atrophy has been demonstrated to be related 
to progression of MCI to dementia.7 In contrast to atrophy, the impact of cerebrovascular disease on 
progression to dementia is less clear. 
Only a small number of longitudinal studies have examined the role of vascular disease in MCI patients, 
and results have been conflicting.7-11 One study found white matter hyperintensities (WMH) to be 
associated with the risk of progression from normal cognitive function to MCI, but not from MCI to 
dementia.7 This is in line with another report that did not find an association between cerebrovascular 
disease (i.e. clinical stroke, extent of WMH or presence of lacunes) and progression of MCI to dementia.9 
In contrast, others did find a relation between WMH and progression to AD in MCI patients.10 
Nonetheless, this study was small (n=27) and used computed tomography instead of magnetic resonance 
imaging (MRI). More recently, a study in a large sample of MCI patients, reported an association between 
WMH and cognitive decline.8 Furthermore, the same group reported WMH to be related to an increased 
risk of vascular or mixed dementia, but not of AD.11 Expression of vascular disease other than WMH, such 
as lacunes and microbleeds, was not taken into account. Little is known about the role of microbleeds 
and cognitive function in MCI or dementia patients, apart from one report that found a relation between 
microbleeds and cognitive impairment in subcortical vascular dementia.12 Another study in non-
demented patients with cerebrovascular disease reported a relation between microbleeds and executive 
dysfunction.13
The aim of this study was to assess the predictive value of MRI measures of both atrophy and  
vascular disease, including infarcts, WMH, lacunes and microbleeds, with respect to progression  
of MCI to dementia. 
Methods
Patients
We consecutively recruited 152 patients with MCI from the outpatient memory clinic of the Alzheimer 
Centre of the VU University Medical Centre (VUmc). Standardized assessment included medical history, 
neurologic examination, laboratory tests, neuropsychological testing including Mini-Mental State 
Examination (MMSE),14 electroencephalogram (EEG) and (MRI of the brain. Diagnoses were made in a 
multidisciplinary consensus meeting according to the Petersen criteria.1 The study was approved by the 
local Medical Ethical Committee. All patients gave written informed consent for their clinical data to be 
used for research purposes.
Clinical follow-up
All patients were annually re-examined for possible alteration in cognitive function with a mean follow-up 
of 2 ± 1 years. Standardized assessment included careful history and cognitive testing. All patients in this 
study were re-evaluated at least once (maximum 5). Patients with stable or improved cognitive function 
at follow-up were regarded as non-converters. Patients who progressed to dementia were regarded as 
converters. Converters were classified in two clusters. One cluster included patients who progressed to AD. 
The other cluster consisted of patients who progressed to a non-Alzheimer dementia including vascular 
dementia (VaD), frontotemporal lobar degeneration (FTLD) and dementia with Lewy Bodies (DLB). To diag-
nose AD we used the criteria of the National Institute on Neurological and Communicative Diseases and 
Stroke-Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA),15 VaD was diagnosed by use 
of the criteria of the National Institute of Neurological Disorders and Stroke-Association Internationale 
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pour la Recherché et l’Enseignement en Neurosciences (NINDS-AIREN),16 FTLD was diagnosed by the Neary 
and Snowden criteria17 and DLB was diagnosed by the Mc Keith criteria.18
MRI protocol
At baseline, MRI was performed on a 1.0 Tesla machine (Magnetom Impact Expert Siemens AG, Erlangen, 
Germany) following a standard protocol, including coronal T1-weighted 3D MPRAGE (magnetization 
prepared rapid acquisition gradient echo; 168 slices, field of view [FOV] 250mm, matrix 256x256, slice 
thickness 1.5 mm, echo time [TE]: 7ms, repetition time [TR]: 15 ms, inversion time [TI] 300 ms, flip angle 
15 degrees), axial FLAIR (fluid attenuated inversion recovery, 17 slices, FOV 250mm, matrix 256x256, 
slice thickness: 5mm, interslice gap: 1.5mm, TE: 105ms, TR: 9000ms, TI 2200 ms, flip angle 180 degrees) 
and axial T2*-weighted gradient echo sequences (19 slices, FOV 250 mm, matrix 256 x 256, slice thickness 
5 mm, interslice gap 1.5 mm, TE 22 milliseconds, TR 800 milliseconds, flip angle 20°).
Image assessment 
Baseline MRI was used to determine presence of atrophy and vascular disease. Visual
rating of MTA was performed on coronal T1-weighted images according to the 5-point (0-4) Scheltens 
scale, using the average score of the left and right side.19 Global cortical atrophy (GCA) was assessed 
visually on axial FLAIR images (possible range of scores 0-3).20 The degree of WMH severity was rated on 
axial FLAIR images using a semiquantitative scale.21 Periventricular and deep white-matter hyperintensi-
ties were rated separately, the rating for each score being based on both size and number of lesions in 
different anatomical regions. Periventricular hyperintensities (PVH) were defined as lesions adjacent 
to the lateral ventricles or the occipital or frontal horns resulting in a score ranging from 0 to 6. Deep 
white-matter hyperintensities (DWMH) were defined as lesions located in the frontal, parietal, occipital, 
and temporal deep white matter with a maximum score of 6 for each region to give a total score ranging 
from 0 to 24. A total WMH score was composed by summing the PVH and the DWMH scores, ranging 
from 0 to 30. Ratings of basal ganglia and infratentorial hyperintensities were not included in the 
present study. Lacunes were defined as T1-hypointense and T2-hyperintense CSF-like lesions surrounded 
by white matter or subcortical grey matter with a minimum diameter of 3mm, not located in areas with 
a high prevalence of widened perivascular spaces (vertex, anterior commisure). Next to an overall count 
of lacunes, the presence of ≥1 lacune in the basal ganglia was determined. Microbleeds were defined as 
strongly hypointense, mostly round lesions on the axial FLASH 2D images with a diameter between  
2 and 10mm. Symmetric hypointensities in the globi pallidi, most likely to be calcification or iron  
deposition, and flow voids artifacts of the pial blood vessels were disregarded. The presence of infarcts 
was determined using the different MRI sequences. 
Statistical analysis
Statistical analysis was performed by means of SPSS 14.0 (SPSS Inc). For analysing purposes MRI measures 
were dichotomised, using for the WMH measurements the median score of the total population. This 
resulted in the following: severe MTA: <1.5 absent, ≥ 1.5 present; severe PVH: <3 absent, score  ≥ 3 present; 
severe DWMH:  <4 absent, ≥ 4 present; severe WMH: <6 absent, ≥ 6 present; presence  
of  ≥ 1 lacune, presence of ≥ 1 microbleed, presence of ≥ 1 infarct. Group comparisons were performed 
using chi-squared tests for dichotomous variables and independent samples t-tests for continuous 
data. Next, Cox proportional hazards models, that account for varying follow-up times, were used to 
investigate the risk of progression to dementia depending on the various dichotomized MRI measures. 
The analysis was performed twice, first using progression to AD as outcome measure with the non-
converters as reference group. Subsequently, progression to a non-Alzheimer dementia was analysed 
as second outcome measure, using again the non-converters as reference group. Data are presented as 
hazard ratio (HR) and accompanying 95% confidence interval (95% CI). The first model shows the crude 
risk estimates. In the second model we adjusted for age and sex. Significance was set at p<0.05.
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Results
Of the total of 152 MCI patients, 72 (47%) patients progressed to dementia during follow-up. Fifty-six 
patients (37%) were diagnosed with AD, and sixteen patients (10%) were diagnosed with a non-Alzheimer 
dementia (VaD n=7, FTLD n=5, DLB n=2, Parkinson dementia n=1, alcohol dementia n=1). Converters had 
a slightly longer follow-up duration and were older, more likely to be female and had a lower MMSE at 
baseline (table 1). 
Baseline MRI measures are presented in table 2. Both patients who progressed to AD and patients 
who progressed to a non-Alzheimer dementia showed more MTA and more cortical atrophy than 
non-converters. Measures of vascular disease were more prevalent among patients who progressed to 
non-Alzheimer dementia compared to non-converters: the severity of WMH (both PVH and DWMH) was 
higher in patients who progressed to another type of dementia compared to non-converters. In addition, 
these patients more often had lacunes in the basal ganglia and microbleeds.
Cox proportional hazard models showed that, adjusted for age and sex, baseline MTA predicted 
progression to AD (HR 2.9 [1.7-5.3]) (table 3). None of the measures of vascular disease predicted 
progression to AD. A different picture emerged looking at progression to non-Alzheimer dementia. 
Adjusted for age and sex, severe WMH (HR 5.8 [1.2-26.6]) was strongly associated with progression to non-
Alzheimer dementia. This association was attributable to both PVH (HR 6.5 [1.4-29.8]; example see figure 
1) and DWMH (HR 5.7 [1.2-26.7]), with the highest risk for PVH. Furthermore, the presence of microbleeds 
inferred almost threefold, though non-significant, increased risk of progression to non-Alzheimer 
dementia (HR 2.6 [0.9-7.5]). The same was seen for the presence of lacunes in the basal ganglia, which 
showed a more than twofold, though non-significant, predictive value on progression to non-Alzheimer 
dementia (HR 2.4 [0.8-7.5]. These results remained essentially unchanged after additional adjustment for 
MTA or MMSE (data not shown). Moreover, MTA showed a twofold, though non-significant increased risk 






Number	of	patients	n(%) 80	(53%) 72	(47%) 56	(37%) 16	(10%)
Follow-up	duration 1.8	(1.1) 2.2	(1.3)* 2.2	(1.3) 2.2	(1.4)
Age	(years) 68	(9) 72	(7)** 72	(7)* 75	(6)**
Sex	,	women	n(%) 31	(39%) 40	(56%)* 33	(59%)* 7	(44%)
MMSE	–	baseline 27	(2) 26	(2)** 26	(2)** 27	(2)
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Table 2; Baseline	MRI	characteristics
Non-converters Converters AD Non-Alzheimer
dementia
MTA	 0.7	(0.8) 1.4	(0.9)*** 1.4	(1.0)*** 1.2	(0.8)**
Cortical	atrophy 0.6	(0.7) 1.0	(0.8)	** 1.0	(0.7)** 1.2	(0.9)**	
PVH 2.3	(1.7) 2.9	(1.6) 2.6	(1.5) 3.8	(1.5)**
DWMH 4.9	(5.4) 5.4	(5.2) 4.4	(4.6) 8.9	(5.6)**
Total	WMH 7.1	(6.9) 8.3	(6.5) 6.9	(5.9) 12.7	(6.9)**
Presence	≥1	lacune	n(%) 15	(19%) 15	(21%) 10	(18%) 5	(31%)
Presence	of		≥1	lacune	BG	n(%) 9	(11%) 13	(18%) 8	(14%) 5	(31%)*
Presence	of		≥1	MB	n(%)	# 11	(15%)	 10	(16%) 4	(9%) 6	(38%)*









Model 1 Model 2   Model 1 Model 2   
MTA 2.9	(1.7-5.0) 2.9	(1.7-5.3) 2.9	(1.1-7.9) 2.5	(0.8-7.2)
GCA 1.6	(0.8-3.1) 1.4	(0.7-2.7) 2.4	(0.8-7.0) 2.2	(0.7-7.0)
PVH 1.3	(0.7-2.2) 1.1	(0.7-2.0) 7.3	(1.7-32.4) 6.5	(1.4-29.8)	
DWMH 1.4	(0.8-2.4) 1.3	(0.8-2.3) 5.7	(1.3-25.5) 5.7	(1.2-26.7)
Total	WMH 1.3	(0.8-2.2) 1.2	(0.7-2.2) 6.0	(1.3-26.8) 5.8	(1.2-26.6)
Lacunes 1.2	(0.6-2.4) 1.1	(0.5-2.2) 2.3	(0.8-6.8) 2.1	(0.7-6.4)
Lacunes	basal	ganglia 1.4	(0.7-3.0) 1.2	(0.6-2.6) 2.7	(0.9-8.1) 2.4	(0.8-7.5)
Microbleeds 0.7	(0.3-2.0) 0.8	(0.2-2.2) 2.5	(0.9-7.2) 2.6	(0.9-7.5)
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Discussion
We showed that in MCI patients, MTA and markers of cerebrovascular disease predicted progression 
to different types of dementia. MTA was a risk factor for progression from MCI to AD, while conversely 
the presence of cerebrovascular disease was independently associated with progression of MCI to a non-
Alzheimer dementia, mostly VaD. 
The role of atrophy in progression to dementia has been shown before. Earlier reports already noted 
visual assessment of MTA as good predictor of progression of MCI to dementia.4-6 MTA has been shown 
to be present not only in patients with AD but also in other dementias (like VaD and DLB).22-24 This is in 
line with our, although nonsignificant, more than twofold increased risk of MTA for progression to a 
non-Alzheimer dementia. 
There has been a growing interest lately in the possible influence of vascular factors in the development 
of AD. Vascular risk factors, like hypertension and diabetes,  have been associated with an elevated risk of 
AD, and AD patients have been reported to show more vascular abnormalities on MRI than controls.25-29 
Contrary to our expectation, we did not find any relation between presence of cerebrovascular disease 
on baseline MRI and progression to AD. With respect to WMH, this is in line with some9, 11 but not all10 
previous reports. However, the latter study was small and used CT instead of MRI.10 Although we found 
no influence of WMH on progression from MCI to AD, progression to non-Alzheimer dementia was 
strongly associated with both PVH and DWMH, with the highest risk attributable to PVH. These findings 
confirm the recently reported predictive value of DWMH and especially PVH for vascular or mixed 
dementia.11 Others did not find a predictive value of WMH for progression to non-Alzheimer dementia.7,9 
Nonetheless, in both last mentioned studies the number of patients was small (respectively 3 patients 
and 7 patients). We had a sample of 16 patients who progressed to a non-Alzheimer dementia. Of these, 
the largest subgroup consisted of VaD. Still, the effect did not seem attributable to this group alone, since 
especially in patients with Parkinson dementia, DLB and alcohol dementia, we observed vascular disease 
as well. We are not sure how to interpret this finding. It is known that cerebrovascular disease can cause 
parkinsonism.30 Alternatively, it must be noted that diagnosis was based on clinical criteria, leaving the 
possibility of mixed disease. Unfortunately, the sample size did not allow examination of  progression to 
specific dementia types other than AD. 
We demonstrated that the prevalence of lacunes in the basal ganglia was higher in patients who 
progressed to non-Alzheimer dementia compared to non-converters. A population based study showed 
that silent, mostly lacunar brain infarcts were a risk factor for dementia.29 Other reports in MCI patients 
did not find an association between lacunes and progression to dementia.9, 31 In this study, Cox analysis 
of lacunes in the basal ganglia was, although borderline significant; suggestive of a more than twofold 
elevated risk of progression to a non-Alzheimer dementia. We did not find a predictive value of large 
vessel infarcts on progression of MCI to dementia. Although having a (large vessel) stroke is known to 
double the risk of dementia,32 in MCI patients the absence of progression related to infarcts has been 
reported before.9 A study in patients with VaD found that patients with multi-infarct or strategic infarct 
dementia were predominantly diagnosed directly from a cognitive normal status, whereas patients with 
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Our study showed that the prevalence of microbleeds was higher in patients who progressed to a non-
Alzheimer dementia compared to non-converters. Furthermore, the presence of microbleeds showed 
an almost threefold, borderline significant risk for progression to a non-Alzheimer dementia. Little 
research has been performed on the role of microbleeds in MCI patients, and on microbleeds in relation 
to cognitive dysfunction. A study in 86 patients with subcortical VaD found microbleeds to be related 
to all cognitive domains with the exception of language function.12 Another study in non-demented 
patients with cerebrovascular disease found a relation between microbleeds and executive dysfunction.13 
Microbleeds are presumed to reflect cerebral amyloid angiopathy (CAA), a type of cerebrovascular 
pathology found with an incidence of 80-98% in AD.34, 35 In the current study, we did not find a higher 
prevalence of microbleeds and patients who progressed to AD compared to non-converters. Nonetheless, 
our results suggest that microbleeds are a risk factor for progression to a non-Alzheimer dementia. 
Among the limitations of this study is the use of visual rating scales of MRI markers. Volumetric 
measures of MTA and WMH could lead to different effect sizes, at the cost of being less generalizable to 
clinical practice. A complex issue is the role of MRI in the follow-up diagnosis, even though the diagnosis 
of dementia basically is a clinical diagnosis. At baseline none of the patients fulfilled the clinical criteria 
of dementia and progression to dementia itself will not have been influenced by the MRI scan. In 
assessing the specific dementia types, MRI may have been used as a supportive element and therefore 
may have induced some circularity. This is especially the case for vascular dementia, as current criteria 
of require evidence of cerebrovascular disease on imaging (NINDS-AIREN).16 Any study assessing the risk 
of progression to at least vascular dementia might consequently suffer from some degree of circularity. 
However, we feel that the influence of this circularity is limited, as the clinical diagnosis of the specific 
dementia types was fundamentally based on the clinical picture and not on MRI. Unfortunately, we have 
no neuropathological confirmation of our diagnoses and it must be noted that patients with dementia 
frequently have shown multiple brain pathologies.36 We demonstrated in this study that patients with 
vascular abnormalities on baseline MRI were more likely to develop non-Alzheimer dementia, mostly 
VaD. Still, it is conceivable that a large proportion of patients in fact suffered from mixed disease. Future 
research incorporating neuropathological confirmation is needed to answer this question. Another 
limitation is the absence of clinical characterization of the MCI cases into subgroups (amnestic/non-
amnestic, single domain/multiple domain).37 The clinical subtype may be related to the type of dementia 
(AD versus non-Alzheimer dementia) a MCI patient is most likely to progress to. Future research should 
be aimed to find out if the MRI determinations (of atrophy and cerebrovascular disease) add predictive 
value over this clinical MCI characterization. Compared to the conversion rate of 12% per year reported 
by Petersen et al, the conversion rate of almost 25% in our group of MCI patients seems rather high. 
However, our results are comparable to the conversion rate of other memory clinics,38, 39 while the 
conversion rate reported by Petersen et al was found in a general community setting. 
A strong element is the exploration of the influence of a broad range of vascular abnormalities on 
MRI, including infarcts, WMH, lacunes and microbleeds. We adjusted analyses for age and sex, and 
additionally for MMSE and MTA without essential change of the results. Furthermore, we included 
more MCI patients than most previous reports, including a considerable number of patients who 
progressed to non-Alzheimer dementia. However, the group of sixteen patients was not large enough 
to allow examination of  progression to specific dementia types other than AD. To conclude, in the 
clinical setting of a memory clinic, one should be aware of cerebrovascular disease as it appears to be an 
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Abstract
Objective
The aim of this study was a cross-sectional comparison of clinical and MRI characteristics and risk factor 
profiles between patients with small vessel disease (lacunes and white matter hyperintensities) and large 
vessel disease (large territorial or strategical infarcts) in a large cohort of VaD patients.
Methods
Patients with VaD (NINDS-AIREN) were included in a large multicenter treatment trial (the VantagE 
study). All patients were examined by a neurologist and interviewed about their medical history. Based 
on MRI, patients were classified as having large vessel VaD, small vessel VaD, or a combination. Other 
MRI characteristics included white matter hyperintensities (WMH), medial temporal lobe atrophy (MTA) 
and general cortical atrophy.
Results
Of the 706 patients, 522 (74%) had small vessel disease, 126 (18%) had large vessel disease and 58 (8%) 
had both. Patients with small vessel disease were older and less educated,  and showed more cortical 
and medial temporal lobe atrophy than patients with large vessel disease. The most prevalent vascular 
risk factors (hypertension, diabetes and smoking) were equally distributed between the different types of 
VaD. However, patients with large vessel disease had more hypercholesterolemia and cardiac risk factors 
compared to patients with small vessel disease.
Conclusion
Cerebrovascular disease underlying VaD consists in the majority of small vessel disease and in about 
one fifth of large vessel disease. This study demonstrates heterogeneity between these two groups with 
regard to risk factor profile and atrophy scores on MRI. 
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Introduction
Vascular dementia (VaD) is caused by cerebrovascular disease. Traditionally, VaD has been recognized 
to develop after multiple strokes. The name ‘multi-infarct dementia’ became synonymous with all 
dementias of vascular origin,1 incorrectly implying that multiple brain infarcts are the only cause of 
VaD. Currently, the criteria of the National Institute of Neurological Disorders and Stroke Association 
Internationale pour la Recherche et al’Enseignement en Neurosciences (NINDS-AIREN) are the diagnostic 
criteria which are most often used in VaD studies.2 According to those criteria, neuroimaging is required 
to demonstrate cerebrovascular disease. The radiological standards define both topographic and severity 
criteria. Evidence for cerebrovascular disease sufficient for the diagnosis of VaD includes large vessel and 
small vessel disease. Large vessel disease includes large territorial or strategic infarcts, while small vessel 
disease consists of lacunes, white matter changes or bilateral thalamic lesions. 
At present, both small vessel and large vessel disease may be sufficient for the diagnosis of VaD. However, 
little is known about the relative prevalence of small vessel and large vessel disease in VaD and their 
specific underlying cerebrovascular disease, or about their relation with neurodegenerative changes as 
observed on MRI. Medial temporal lobe atrophy (MTA) is a widely used marker of neurodegeneration, 
specifically in Alzheimer’s disease (AD),3, 4 but it is also observed in other dementias, including VaD.5-7 
Several studies have investigated determinants of VaD, and a number of risk factors have been identified. 
In addition to age,8, 9 vascular risk factors such as history of stroke,8, 10, 11 hypertension,11-13 diabetes,11, 
14 hyperlipidaemia,15 smoking 16 and cardiac risk factors 8, 9 have been reported. We hypothesized that 
heterogeneity in cerebrovascular damage underlying VaD would be related to heterogeneity in risk factor 
profile.  
The aim of this study was to determine the relative frequency of small vessel and large vessel disease 
in a large cohort of VaD patients enrolled into a multicenter randomized trial, and to compare MRI 
characteristics and  risk factor profile dependent on type of vascular damage.   
Methods
Study design and patients
Baseline data of 706 patients aged 50-85 years, included in the VantagE study, were used. The VantagE 
study was a large multicenter, phase III, prospective, randomized, double-blind clinical trial on the ef-
fects of rivastigmine in patients with VaD (Novartis International AG, Basel, Switzerland). Trial inclusion 
criteria included both fulfilment of the DSM-IV diagnostic criteria for VaD and fulfilment of the NINDS-
AIREN criteria for probable VaD.2 The NINDS-AIREN criteria for probable VaD were slightly modified: If 
neuroimaging criteria for subcortical VaD were met as assessed by the central neuroradiologist, patients 
were not required to have evidence of a temporal relationship between the dementia syndrome and the 
evidence of cerebrovascular disease (i.e. these patients were permitted to enter the study with a clinical 
diagnosis of possible VaD by NINDS-AIREN criteria).2, 17 Excluded from entry into the study were patients 
with a history of stroke within the 3 months prior to baseline unless the patient was considered to have 
fully stabilized in function; a current diagnosis of any primary neurodegenerative disorder; and a current 
diagnosis of major depression. As well patients with space-occupying lesions or lobar haemorrhages were 
excluded. All patients gave written informed consent. The study was approved by local Ethics Commit-
tees.
Baseline clinical assessment
Diagnostic evaluation included complete medical history (including family history and medication 
intake), physical and neurological examination, laboratory tests, extensive  neuropsychological testing 
including Mini-Mental State Examination (MMSE)18 and MRI of the brain. Patients had to have a MMSE 
score of 10-24 to be included in the study.
Vascular risk factors were determined by history taking as well as physical examination. The following 
variables were included in the analyses: a history of hypertension (yes/no), diabetes mellitus (yes/no), 
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hypercholesterolemia (yes/no), current smoking status (yes/no), and a history of one of the following 
angina/myocardial infarct (yes/no), atrial fibrillation (yes/no), congestive heart disease (yes/no), heart valve 
disorder (yes/no), carotid stenosis (yes/no), or peripheral vascular disease (yes/no). Patients were asked 
about their medication use concerning anti-hypernsive medication, diabetic medication and cholesterol 
lowering drugs. Blood pressure was measured and the mean value of two measurements on the right 
arm in supine position at two different occasions was used in the analysis. Blood samples were taken to 
determine (among others) mean random glucose (mmol/L) and cholesterol (mmol/L) levels. In addition, 
family history was taken concerning dementia, strokes, cardiac vascular disease and peripheral vascular 
disease.
MRI protocol
All patients underwent MRI examination before randomization. MRI scanners operating between 0.5 and 
1.5 Tesla were used. Axial spin-echo T2-weighted images (T2-WI; echo time [TE]: 80 to 120 ms; repetition 
time [TR]: 3000 to 4000 ms; slice thickness=5 mm); axial fluid-attenuated inversion recovery (FLAIR) im-
ages (TE: 110 to 150 ms; TR: 9000 to 10000 ms; inversion time: 2000 to 2200 ms; slice thickness=5 mm); 
and axial, sagittal, and coronal spin-echo T1-weighted images (T1-WI; TE: 11 to 20 ms; TR: 500 to 700 ms; 
slice thickness=5 mm) were acquired. 
Image assessment
Image assessment was performed centrally at the Image Analysis Center (VU Medical Center, Amster-
dam, the Netherlands) by agreement of two experienced readers blinded to clinical information, with the 
use of digital image files. The assessment of vascular abnormalities included the items of the radiological 
NINDS-AIREN criteria for VaD, according to operational definitions earlier proposed (see table 1).19 Based 
on these criteria, patients were classified as having large vessel VaD, small vessel VaD, or a combina-
tion. For the fulfilment of large vessel disease both a topography and a severity criterion for large vessel 
disease had to be met. In case of small vessel disease, for white matter hyperintensities (WMH) both to-
pography and severity criteria had to be met, for multiple lacunes and bilateral thalamic lesions only the 
topography criterion was sufficient. The degree of WMH severity was rated visually on axial FLAIR images 
using the Age Related White Matter Changes (ARWMC) scale.20 In short, WMH are ill-defined hyperinten-
sities of >5mm, rated on a 4-point scale ranging from 0 (no lesions) to 3 (diffuse involvement of the entire 
region), within 5 regions of the brain bilaterally. Here, we used the total degree of WMH (range 0-30) by 
summing the region-specific scores of both hemispheres. With respect to the WMH criteria for small 
vessel disease, we used the ARWMC scale to define involvement of 25% of the total white matter (at least 
twice a score of 2 and twice a score of 3 in the frontal and parieto-occipital regions). A lacune was defined 
as a lesion with a diameter of ≥ 3mm, with CSF like intensity on all sequences on MRI surrounded by 
white matter or subcortical  gray matter. A paramedian thalamic infarction was defined as: an infarct 
extending into the paramedian part (defined as extending to the third ventricle) of the thalamus; the ex-
tension may be limited to the gliotic rim of the infarct that surrounds the parenchymal defect. All other 
thalamic lesions with a diameter of ≥3mm were considered as ‘thalamic lesions’. Lesions in the thalamus 
do not always have the same intensity as CSF on all sequences (for example not always on the T1), there-
fore it was decided to use the term ‘lesions’, to include both thalamic lacunes and thalamic non-lacunar 
lesions. All ‘thalamic lesions’ were regarded as small vessel disease, in contrast to paramedian thalamic 
infarcts which were regarded as large vessel disease of the posterior cerebral artery. In addition, care was 
taken to review thalamic lesions and infarcts on T2 weighted images as they can easily been missed on 
the FLAIR.21 Further MRI evaluation included MTA on coronal T1-weighted images using the Scheltens 
scale (possible range of scores: 0 to 4),3 and global cortical atrophy (GCA) on axial FLAIR images (possible 
range of scores: 0 to 3).22
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Statistical analysis
Statistical analysis was performed by means of SPSS 12.0 (SPSS Inc). For comparison of data between the 
different types of VaD (small vessel disease, large vessel disease or a combination) chi-square tests were 
used for dichotomous outcome variables. For continuous data we used analysis of variance (ANOVA) with 
post hoc Bonferroni tests, with age and sex as covariates. Associations between the MRI measures were 
assessed using partial correlations, controlling for age and sex. Basic associations between the types of 
VaD and risk factors were assessed in unadjusted analyses using chi-square tests. Subsequently, we used 
logistic regression models with the risk factors as dependent variables, and the different types of VaD as 
categorical covariate, controlling for age and sex. 
Table 1; Classification	of	large	vessel	disease	and	small	vessel	disease,	based	on	NINDS-AIREN	criteria	for	VaD2
Large vessel disease 
1.  Topography—radiological lesions associated with dementia  









2.  Severity—in addition to the above, relevant radiological  
lesions associated with dementia include:
				Large	vessel	lesions	of	the	dominant	hemisphere
				Bilateral	large	vessel	hemispheric	strokes









The total study population involved 706 patients with VaD, with a mean age of 73 years (SD 8), and an 
overrepresentation of men (63%) (table 2). The patients were mildly-to-moderately demented with a mean 
MMSE score of 19 (SD 4). Of the 706 patients, 522 (74%) had small vessel disease, 126 (18%) had large 
vessel disease and 58 (8%) had both. Patients with small vessel disease were older and less educated than 
patients with large vessel disease. The MMSE was comparable in patients with small and large vessel 
disease; however, patients with a combination of small and large vessel disease had a lower MMSE.
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Inspection of specific MRI abnormalities in patients with small vessel disease (n=522) revealed that small 
vessel disease was for the largest part attributable to extensive WMH (the diagnosis of VaD was based 
solely on WMH in 40% of the patients) (figure 1). Small vessel disease based on either lacunes (6%) or 
thalamic lesions (9%) without additional occurrence of WMH was rare. A combination of different forms 
of small vessel disease was observed in 45% of the patients. The majority of patients with large vessel 
disease (n=126) showed just one type of infarct (71%). Two types of infarcts were shown in a quarter 
of the patients (27%), and the presence of three types of infarcts was rare (2%). The majority of infarcts 
were shown in an association area of the medial cerebral artery (MCA) (n=64) or in a watershed area of 
the carotid territories (n=56) (figure 2). Infarcts in the territories of the posterior cerebral artery (PCA) 
were demonstrated less frequently (n=40). Bilateral infarcts of the anterior cerebral artery (ACA) were 
uncommon (n=4), and never occurred without an additional large vessel infarct. Examination of patients 
with a combination of small and large vessel disease (n=58) showed more or less the same distribution 
of types of infarct as patients with only large vessel disease. However, inspection of the different forms 
of small vessel disease in this combination group showed more bilateral thalamic lesions compared to 
patients with only small vessel disease. 
Examination of other MRI abnormalities showed, as expected, that patients with small vessel disease had 
more WMH than the large vessel group, with the combination group in between. Patients with small 
vessel disease showed in 8% of cases a cerebral infarct on MRI (note that a larger proportion of patients 
had infarcts, as infarcts in the non-dominant hemisphere do not lead to a diagnosis of large vessel VaD). 
Both cortical atrophy and MTA were more severe among patients with small vessel disease compared to 
patients with large vessel disease (table 2). Adjusted for age and sex, the presence of a cerebral infarct 
was marginally negatively correlated to cortical atrophy (partial r= - 0.16, p<0.001), whereas the presence 
of multiple lacunes  and severity of WMH were both positively correlated to cortical atrophy (partial 
r=0.18, p<0.001 and r=0.12, p =0.001). Correlations between vascular MRI abnormalities and MTA were 




Lacunae and thalamic lesions 7%
WHM and lacunae and thalamic lesions 15%
WHM and thalamic lesions 14%







multiple	basal	ganglia	and	 frontal	white	matter	 lacunes	 (lacunes),	or	a	combination	 thereof.	Data	presented	as	
percentage	of	patients	with	small	vessel	disease	demonstrating	these	different	forms	of	small	vessel	disease.	
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In the total group, hypertension was the most prevalent risk factor (80%), followed by 
hypercholesterolemia (39%), diabetes (26%) and smoking (20%) (table 3). Hypercholesterolemia was more 
often present in patients with large vessel disease compared to patients with small vessel disease, with 
the combination group in between. The presence of the other three most prevalent risk factors was 
equally distributed between the different types of VaD. Patients with large vessel disease used more often 
cholesterol lowering drugs compared to patients with small vessel disease. Mean random glucose and 
cholesterol levels, as well as blood pressure measurements, were not different between the types of VaD. 
Cardiac risk factors (history of angina/myocardial infarct, atrial fibrillation, congestive heart disease, 
heart valve disorder) and carotid stenosis were more frequently present in patients with large vessel 
disease compared to patients with small vessel disease. The presence of peripheral vascular disorder did 
not differ between the subgroups. Patients with large vessel disease or a combination of small and large 
vessel disease had a higher prevalence of family history of cardiac disease compared to patients with small 
vessel disease. A family history of dementia was infrequently reported by patients in the combination 








Small & large  
vessel disease
Number	of	patients 522 126 58
Demographics 	 	 	
Age	(years) 73	(8) 71	(8)a 72	(8) p<0.05
Sex		n	(%men) 314	(60%) 84	(67%) 42	(72%) ns
Education	(years) 9.0	(4.0) 10.7	(3.7)a 9.4	(3.8) p<0.001
MMSE	 19.2	(3.8) 18.6	(4.1) 17.5	(4.0)a p<0.01
MRI
ARWMC1 16.5	(4.9) 6.5	(4.3)a,	c 13.6	(5.5)a p<0.001
Cortical	atrophy	 1.5	(0.8) 1.2	(0.8)a 1.4	(0.8) p<0.001
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Table 3; Risk	factors	















Medical history 	 	 	 	
Smoking	(current)	 144	(20) 105	(20) 27	(21) 12	(21) ns
Hypertension 562	(80) 410	(79) 105	(83) 47	(81) ns
Diabetes 184	(26) 129	(25) 37	(29) 18	(31) ns
Hypercholesterolemia 270	(39) 176	(34)b,c 68	(54) 26	(45) p<0.001
Angina/myocardial	infarct 125	(18) 72	(14) 39	(31)a 14	(24) p<0.001
Atrial	fibrillation	 75	(11) 41	(8) 29	(23)a,	c 5	(9) p<0.001
Congestive	heart	disease	 36	(5) 22	(4) 13	(10)a 1	(2) p<0.01
Heart	valve	disorder	 28	(4) 14	(3) 11	(9)a 3	(5) p<0.01
Carotid	stenosis	 68	(10) 39	(8) 25	(21)a,	c 4	(7) p<0.001
Peripheral	vascular	disease	 59	(8) 38	(7) 14	(11) 7	(11) ns
Medication use              
Hypertension	 490	(70) 354	(67) 95	(76) 41	(72) ns
Diabetes		 144	(21) 100	(19) 29	(23) 15	(26) ns
Hypercholesterolemia		 168	(24) 101	(20)b 50	(40) 17	(30) p<0.001
Blood pressure     
Systolic	BP	(mm/Hg)	mean	(SD) 139	(15) 140	(15) 137	(15) 137	(15) ns
Diastolic	BP	(mm/Hg)	mean	(SD) 79	(9) 80	(9) 78	(9) 79	(10) ns
BP	>140/90	mm/Hg			 298	(44) 225	(44) 51	(43) 22	(39) ns
Blood samples
Random	glucose	(mmol/L)	mean(SD) 6.6	(2.7) 6.6	(2.7) 6.6	(2.7) 6.5	(2.6) ns
Cholesterol	(mmol/L)	mean	(SD) 5.3	(1.1) 5.4	(1.1) 5.2	(1.2) 5.3	(1.0) ns
Family history
Dementia	 164	(24) 124	(25)c 34	(28)c 6	(11) p<0.01
Strokes	 226	(34) 160	(33) 46	(38) 20	(35) ns
Cardiovascular	disease 201	(30)	 129	(26) 50	(42)a	 22	(38)	 p<0.01	
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Discussion
In this large cohort of VaD patients we demonstrated that the diagnosis of VaD was in three-quarter of 
the patients (74%) based on small vessel disease, compared to almost one fifth of the patients (18%) who 
fulfilled the criteria for large vessel VaD and one out of ten patients (8%) who fulfilled criteria for both 
types of VaD. Patients with small vessel disease showed more cerebral atrophy, as shown by higher scores 
of MTA and cortical atrophy. By contrast, large vessel disease seemed to be associated with hypercholeste-
rolemia and cardiac disease. 
Few other studies have examined the relative prevalence of small vessel and large vessel disease in VaD.23, 24 
A study performed in patients with vascular dementia and patients with Alzheimer’s disease combined 
with cerebrovascular disease, reported a relative prevalence of 64% of extensive WMH, 40-47% of lacunes, 
and 39-46% of infarcts, percentages comparable to our results.25 A cohort of 68 Asian, male VaD patients 
demonstrated a relatively high frequency of small vessel disease that was similar to the current study.24 
However, in contrast to findings in the current study where the majority of small vessel disease consisted 
of WMH, the high prevalence of small vessel disease in this Asian cohort was due to a large amount of 
lacunes, possibly related to genetic factors. In agreement with our results, a previous neuropathological 
study supports the view that small vessel disease is the main substrate relevant in VaD, after comparing 
brains with vascular disease of demented and non-demented patients.26 
The prevalence of WMH only was remarkably high in the present study. In the whole cohort, 58% of the 
patients showed WMH sufficient for the criteria of small vessel disease.2 WMH are not specific for VaD, 
but also commonly present in non-demented individuals and in AD patients.27-30 However, compared 
to healthy elderly or other types of dementia, the pattern of WMH in VaD by definition is extensive.28 
Involvement of at least 25% of the total white matter is considered sufficient for a diagnosis of VaD 
related,31, 32 although this percentage was set purely arbitrarily. Moreover, application of this threshold 
is also debatable. In the present study the threshold was defined using the ARWMC score,19 however, for 
example volumetric assessment of WMH might have yielded more accurate measures. 
In our sample VaD patients had moderate to severe MTA and cortical atrophy on MRI. Although more 
severe among patients with small vessel disease, both MTA and cortical atrophy were also observed 
in patients with large vessel VaD. This is in accordance with earlier studies which demonstrated more 
severe MTA in VaD patients compared to controls.5-7 There are several possible explanations for the 
relation between cerebrovascular disease and neurodegenerative changes. First, MTA and cortical atrophy 
as observed in VaD may be due to coexisting AD or even to misdiagnosis, patients actually suffering 
AD.33, 34 Although with lack of neuropathological confirmation we cannot exclude this possibility, all 
our patients were carefully diagnosed by the clinical and radiological NINDS-AIREN criteria for VaD.2 To 
fulfil the NINDS-AIREN criteria, cerebrovascular disease has to be shown on neuroimaging (other criteria 
like DSM-III, ICD-10 and DSM-IV do not require neuroimaging). Furthermore, a neuropathological study 
showed for the NINDS-AIREN criteria a low sensitivity, but a high specificity excluding 91% of patients 
with Alzheimer’s disease.35  Second, a synergistic interaction between degenerative and vascular lesions 
has been suggested.33, 36, 37 Third, neurodegenerative changes may be secondary to vascular disease, due 
to e.g. ischemia or Wallerian degeneration. However, the design of our study prevented us from drawing 
conclusions on causality of the associations we found. Future research projects using more sophisticated 
and modern measures can help to identify possible concomitant AD in VaD patient groups. Additionally, 
further research in this field is necessary to determine the underlying relation between atrophy and 
cerebrovascular disease.
Hypertension was the most prevalent risk factor, with a prevalence of 80 percent in the whole cohort. 
Previously the presence of hypertension has been found to triple the risk of VaD,38 reflecting the 
importance of this risk factor. The prevalence of hypertension was similar in patients with small vessel 
and large vessel disease, as were other highly prevalent risk factors such as diabetes and smoking. In 
contrast, hypercholesterolemia, although of high prevalence in small vessel disease (one third of the 
patients), was even almost twice as prevalent in patients with large vessel disease. Additionally, cardiac 
risk factors and a history of carotid stenosis were more often present in patients with large vessel disease 
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compared to patients with small vessel disease. This combination of large vessel VaD and cardiac risk 
factors and carotid stenosis is in line with the associations between these risk factors and large vessel 
stroke without dementia.39, 40 A study comparing the risk factor profile in patients with small vessel 
and large vessel disease without dementia, found in accordance with our results a higher prevalence 
of hypercholesterolemia and myocardial infarct in patients with large vessel disease. However, in 
contrast to the comparable prevalence of hypertension we found in both patient groups, they reported 
a higher prevalence of hypertension in patients with small vessel disease.41 Although several studies 
have examined risk factors in patients with VaD,8-16 the difference in risk factor profile according to 
type of cerebrovascular disease in VaD has seldom been demonstrated. To our knowledge, only one 
neuropathological study investigated cardiovascular disease in small vessel and large vessel VaD. In 
agreement with our results, they found cardiovascular features consistently more often in the large 
vessel compared to the small vessel group.42 
Strengths of the present study include the large study population, as it is one of the largest clinical series 
of patients affected by VaD to date. A limitation results from the study design (a treatment trial), which 
could have had an effect on the inclusion of patients and limits the  possibility to generalize the results 
to the VaD patient group as a whole. Patients had to be able to undergo extra examinations, probably 
resulting in the exclusion of patients with severe vascular disease. However, this would have held for 
participation in any study, not only clinical trials. Furthermore, we cannot exclude the possibility of 
misdiagnosis. However, all patients were carefully screened for fulfilment of the clinical and radiological 
NINDS-AIREN criteria for VaD,2 generally considered accurate criteria. Nonetheless, this could also imply 
a limitation, since the NINDS-AIREN criteria have been shown not to be interchangeable with other 
diagnostic methods for VaD,43 which requires caution when comparing these results to other studies. 
Another limitation is the definition of risk factors. In some countries all patients with stroke regardless 
of their cholesterol level are put on statin therapy, therefore the data about use of cholesterol lowering 
medication should be interpret with care. Furthermore, although all patients underwent the same 
diagnostic evaluation, there was no extensive cardiovascular work-up and therefore probably a certain 
amount of not yet known cardiovascular disease was missed. In stroke studies small and large vessel 
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disease is often classified according to the TOAST criteria.44 It can be useful in future studies of vascular 
dementia to use these classification, especially to be able to make a differentiation between large vessel 
disease caused by large vessel atherosclerosis and cardioembolism.  
In conclusion, we found that the majority of cerebrovascular damage in VaD consists of small vessel 
disease, and that this small vessel disease is mostly WMH. In addition, we showed that patients with 
VaD show moderate MTA and cortical atrophy, the severity of the atrophy being higher in patients with 
small vessel disease compared to patients with large vessel disease. In contrast, patients with large vessel 
disease have more cardiac risk factors compared to patients with small vessel disease. 
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Abstract
Purpose
To determine the frequency of neurological signs in a memory clinic population and to explore  
their associations with white matter hyperintensity (WMH). 
Methods
We included patients with Alzheimer disease (AD; n=210), vascular dementia (VaD; n=34), mild cognitive 
impairment (MCI; n=86) and subjective complaints (n=153). Presence of extrapyramidal and unilateral 
signs was assessed from medical charts. On MRI, WMH volumes were extracted automatically.
Results
Extrapyramidal signs were found in 10% and unilateral signs in 12% of the patients. Age and sex adjust-
ed, extrapyramidal signs occurred more often in VaD compared to patients with subjective complaints. 
Unilateral signs were more prevalent in all groups compared to patients with subjective complaints. 
Two-way ANOVA with WMH as dependent variable showed a main effect of diagnosis (p<0.001), but not 
of extrapyramidal signs (p=0.62). In contrast, two-way ANOVA showed main effects of diagnosis (p<0.001) 
and unilateral signs (p=0.001). Furthermore, there was an interaction between these factors (p=0.04); if 
unilateral signs were present, patients with subjective complaints and VaD showed more WMH, whereas 
there was no relation in AD and MCI. 
Conclusion
Extrapyramidal and unilateral signs are common in memory clinic patients, but are only modestly 
related to WMH. 
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Introduction
Neurological signs have been related to dementia.1-3 In patients with dementia the presence of 
neurological signs has been associated with a worse prognosis.2, 4, 5 Little is known, however, about the 
relative frequency of neurological signs in different dementia stages and types, or about their underlying 
neuropathological substrate.
Alzheimer’s disease (AD) is the most common form of dementia. AD patients have shown a high 
frequency of primitive reflexes (41%),4 cranial nerve signs (23%),2 and extrapyramidal signs (12%-30%).2, 4, 6, 7 
Furthermore, neurological signs and especially extrapyramidal signs showed rapid progression over 
time and were more prevalent in more severe AD cases.2, 7 Although current criteria of vascular dementia 
(VaD) require the presence of neurological signs,8 little is known  about their frequency. Research 
showed that VaD patients in general demonstrate a number of signs, including both unilateral signs (e.g. 
reflex asymmetry, hemimotor dysfunction) and extrapyramidal signs (e.g. rigidity, hypokinesia).2, 9 The 
term mild cognitive impairment (MCI) is used to characterize patients with mild cognitive deficits not 
sufficient for the diagnosis of dementia.10 It is known that a substantial proportion of MCI patients will 
ultimately develop dementia. Research on neurological signs in MCI is scarce. Three studies, of which 
two were only directed at extrapyramidal signs, found the frequency of most neurological signs in MCI to 
be higher than in subjects without cognitive impairment but lower than in dementia.11,12, 13 In addition, 
extrapyramidal signs were related to the severity of cognitive impairment and an increased risk of 
progression to AD.  Comparative studies into neurological signs in the various diagnostic groups of AD, 
VaD and MCI are few and due to methodological differences the studies are often difficult to compare. 
Furthermore, most research has focussed on extrapyramidal signs, and other neurological signs, like 
hemimotor dysfunction, reflex asymmetry or hemianopia were often not taken into account. 
The origin of neurological signs in dementia is not entirely clear. It is not known whether these signs 
for example reflect age-associated changes or if they are the result of degenerative abnormalities. 
Associations between extrapyramidal signs and substantia nigra pathology have been suggested in 
AD.14, 15Others hypothesize that vascular pathology may play a role.16 On brain MRI, white matter 
hyperintensities (WMH) are regarded as suggestive of vascular pathology and considered to reflect 
ischemic damage to the brain.17 WMH have been related to decreased gait performance,18 and 
associations with extrapyramidal signs in elderly have been suggested.19-21 In VaD patients, WMH 
appeared to be related to rigidity, parkinsonian type gait disorder, dysarthria and dysphagia.9 
Additionally, at least one unilateral sign was found in three-quarter of the more than 500 patients with 
small vessel VaD.9 The role of WMH in relation to neurological signs in MCI or AD patients has not been 
studied.
Considering the expected frequency and consistency of assessments we decided to focus on 
extrapyramidal signs and unilateral signs, leaving out some other neurological signs such as primitive 
reflexes. The primary aim of our study was to determine the frequency of extrapyramidal signs and 
unilateral signs in a large cohort of patients attending a memory clinic, expecting to find a higher 
frequency of signs in patients with dementia compared to non-demented subjects. Secondly, we 
determined presence of WMH in this population and studied whether patients with extrapyramidal signs 
or unilateral signs showed a larger volume of global WMH, hypothesizing that ischemic vascular damage 
plays a role in the presence of these signs in dementia.    
Methods
Patients
We consecutively included patients (n=519) who attended our outpatient memory clinic between April 
2004 and September 2007 and who were subsequently diagnosed with AD, VaD or MCI or if clinical 
investigations showed no abnormalities. All patients visiting our memory clinic are investigated by 
a standardized diagnostic work-up. Standardized assessment included medical history, physical and 
neurological examination, laboratory tests, neuropsychological testing including Mini-Mental State 
Examination (MMSE), electroencephalogram (EEG) and magnetic resonance imaging (MRI) of the brain. 
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Subsequently, diagnoses are made in a multidisciplinary consensus meeting according to widely used 
clinical criteria. For the diagnosis of AD the criteria of the National Institute on Neurological and 
Communicative Diseases and Stroke-Alzheimer Disease and Related Disorders Association (NINCDS-
ADRDA)22 were used, and VaD was diagnosed by use of criteria of the National Institute of Neurological 
Disorders and Stroke-Association Internationale pour la Recherché et l’Enseignement en Neurosciences 
(NINDS-AIREN).8 MCI was diagnosed according to the Petersen-criteria.10 When all clinical investigations 
were normal (ie, MCI criteria were not fulfilled), patients were considered to have subjective complaints. 
The study was approved by the local Medical Ethical Committee. All patients gave written informed 
consent for their clinical data to be used for research purposes.
Neurological signs 
The medical notes of the first neurological examination were reviewed retrospectively to assess the 
presence of neurological signs. In this study we used only the data concerning unilateral signs and 
extrapyramidal signs. Unilateral signs were regarded to be present, if one or more of the following 
signs were found at neurological examination: (1) hemimotor dysfunction, defined as any asymmetry 
in muscle tone or strength of extremities, (2) hemisensory dysfunction, not scored if there was an overt 
peripheral neuropathy or when a sensory deficit was caused by a former surgery, (3) hemianopsia, 
(4) reflex asymmetry, scored only if there was clear asymmetry of more than one deep tendon reflex, 
(5) Babinski sign, and (6) hemiplegic gait. Extrapyramidal signs were regarded to be present if one or 
more of the following signs were found at neurological examination: (1) rigidity, scored when the notes 
mentioned rigidity, cogwheel phenomenon or increased muscle tone without indications of increased 
reflexes, (2) hypokinesia, scored when the notes mentioned hypokinesia, bradykinesia, decreased arm 
swing or facial rigidity, (3) Parkinsonian resting tremor and (4) Parkinsonian gait, defined as a slow gait 
with shuffling steps, decreased arm swing, stooped posture and difficulty turning. All signs were rated as 
‘absent’ or ‘present’, and as such used in the data analyses. 
APOE
APOE genotype was determined, isolating DNA from 10 ml EDTA blood by the QIAamp DNA blood 
isolation kit from Qiagen. The genotype was determined with the Light Cycler APOE mutation detection 
kit (Roche Diagnostics GmbH, Mannheim, Germany). Subjects were classified as APOE e4 non-carriers or 
carriers of at least one APOE e4 allele.
MRI protocol
All patients underwent MRI of the brain. The scan had to be performed at the same day (n=442) or within 
one year after baseline neurological examination (n=77; median time difference[interquartile range] = 
1.7[1.0-2.9] months) to be included in the study. MRI was performed on a 1.0 Tesla machine (Magnetom 
Impact Expert Siemens AG, Erlangen, Germany) following a standard protocol, including coronal T1-
weighted 3D MPRAGE (magnetization prepared rapid acquisition gradient echo; 168 slices, field of view 
[FOV] 250mm, matrix 256x256, slice thickness 1.5mm, echo time [TE]: 7ms, repetition time [TR]: 15ms, 
inversion time [TI] 300ms, flip angle 15°) and axial FLAIR (fluid attenuated inversion recovery, 17 slices, 
FOV 250mm, matrix 256x256, slice thickness: 5mm, interslice gap: 1.5mm, TE: 105ms, TR: 9000ms, TI 
2200ms, flip angle 180°) and axial spin-echoT2-weighted images (21 slices, FOV 250mm, matrix 512x512, 
slice thickness 5mm, interslice gap 1.5mm, TE 119ms, TR 5775ms, flip angle 180°).
WMH volumes
First, image quality was assessed using visual inspection to exclude images with movement artefacts 
(n=3). Furthermore, we excluded images with intracerebral pathology (tumor; n=1). Then, WMH volumes 
were determined on the remaining scans (n=515). WMH volumes were automatically extracted following 
the method previously described in.23, 24 Briefly, an intracranial mask is created based on the automatic 
template based segmentation of the T2 images. The white matter (WM), grey matter, and cerebrospinal 
fluid (CSF) templates are automatically mapped on the T2 image. Next, the T2 and FLAIR images are 
automatically co-registered, and the CSF segmentation is finalized (taking into account both the FLAIR 
and the T2 signal intensities).25 Intracranial (IC) volumes and parenchyma volumes (= IC – CSF volume) 
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were automatically extracted. As described before,25 the automatic WMH segmentation is based on a 
Fuzzy interference system, which uses linguistic variables to classify a voxel. Using the Fuzzy C-Means 
algorithm,26 each voxel of the FLAIR image was classified according to the voxel signal intensity (DARK, 
MEDIUM_BRIGHT and BRIGHT) and according to the voxel position (guided by the mapped templates; IC, 
WM). Unlike in the original method where both T2 and FLAIR signal intensities were considered, in this 
study the lesions were extracted based on the FLAIR signal intensity only using the following rule: 
If voxel_position is WM and flair_intensity is BRIGHT then segmented_voxel is WMH. 
To optimize the automatic segmentation outcome for our data set, we first created a “gold standard” 
by manually outlining the WMH in 20 patients. The agreement between the gold standard and the 
automatic segmentation was maximized by varying the minimum membership degrees of the FLAIR 
signal intensity to BRIGHT and the voxel position in WM, in a grid search way. The exact volumes 
of WMH were computed automatically. Infratentorial hyperintensities were not taken into account. 
Finally, all segmentations were visually inspected to determine if the quality of the segmentation was 
satisfactory. To do so, mosaic views of all individual segmentation results were generated as overlays 
on the input images, and side by side with “clean” input images. Errors in the segmentation included 
misregistration of the maps (n=11) and failure of the WMH segmentation (n=21). After exclusion of these 
scans, we had WMH volumes of n=483 images available for this study (AD n=210, VaD n=34, MCI n=86, 
subjective complaints n=153).
Lacunes and infarcts
The presence of lacunes was visually assessed and defined as T1-hypointense and T2-hyperintense CSF-
like lesions surrounded by white matter or subcortical grey matter with a minimum diameter of 3mm, 
not located in areas with a high prevalence of widened perivascular spaces (vertex, anterior commisure). 
The presence of infarcts was determined using the different MRI sequences. 
Statistics
Statistical analyses were performed using SPSS 14.0 for Windows (SPSS Inc). Differences in baseline 
characteristics between the diagnostic groups were analysed using chi-squared test for dichotomous 
outcome variables and one-way analysis of variance (ANOVA) for continuous data. For comparison of 
frequency of neurological signs between diagnostic groups we used logistic regression models, adjusting 
for age and sex, with the patients with subjective complaints as reference group.
WMH volumes were not normally distributed, therefore WMH volumes were log-transformed 
(ln[1+WMH volume]). Comparison of WMH volumes between the diagnostic groups was performed using 
one-way ANOVA with post hoc Bonferroni tests, adjusted for age, sex and intracranial volume. Finally, to 
examine the relation between diagnosis, presence of neurological signs and WMH volumes we used two-
way ANOVA’s using WMH volumes as the dependent variable, diagnosis and presence of neurological 
signs as independent variable and age, sex and intracranial volumes, and additionally lacunes and 
infarcts, as covariates. 
Results
Baseline clinical characteristics are presented in table 1. The mean age at the time of MRI was 67±11 
years with 226(47%) women. The mean MMSE was 24±6, with the highest score for patients with 
subjective complaints and the lowest score for patients with AD and VaD. Of the AD patients 70% 
showed to have at least 1 APOE e4 allel, in contrast to patients with subjective complaints (31%) and 
VaD (35%), with the MCI patients in between (54% with at least 1 APOE e4 allel). Of the total population 
of 483 patients, 50 patients (10%) showed extrapyramidal signs and 60 patients (12%) showed unilateral 
signs at neurological examination. The most frequently observed extrapyramidal signs included rigidity 
and Parkinsonian gait disorder. Hemimotor dysfunction and reflex asymmetry were the most frequently 
observed unilateral signs. 
Logistic regression showed that extrapyramidal signs occurred more often in all diagnostic groups 
compared to patients with subjective complaints (OR’s [95% CI] varying from 2.8 [1.0-8.2] for MCI to 12.1 
[4.1-36.0] for VaD; table 2). In MCI and AD these effects disappeared after adjustment for age and sex, 
while the relative frequency of extrapyramidal signs remained high in VaD patients (OR [95% CI]: 5.4 
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[1.7-17.3]). Unilateral signs were more prevalent in all diagnostic subgroups compared to patients with 
subjective complaints (OR’s [95% CI] varying from 4.7 [1.6-13.9] for MCI to 18.1 [5.8-55.9] for VaD). These 
estimates were only slightly attenuated after adjustment for age and sex.
Adjusted for age and sex, total brain fraction was lower in MCI, AD and VaD patients than in patients 
with subjective complaints. In addition, the brain fraction of AD patients was lower compared to MCI 
patients. Lacunes and infarcts were most frequently demonstrated by VaD patients, without differences 
in frequency between AD, MCI and patients with subjective complaints. Total WMH volumes were larger 
in both AD (p<0.05) and VaD (p<0.001) compared to patients with subjective complaints and MCI, and 
VaD patients showed higher WMH volumes compared to AD (p <0.001). After additional adjustment for 




MCI AD VaD p value 
Number	of	patients	 153 86 210	 34
Demographics
Age	(years) 59	(10) 69	(8) 70	(10) 71	(9) <0.001
Sex		n	(%women) 79	(52%) 23	(27%) 113	(54%) 11	(31%) <0.001
MMSE	 29	(1) 27	(2) 20	(5) 21	(6) <0.001
APOE	e4	(≥1	allel)	n(%) 44	(31%) 38	(54%) 124	(70%) 7	(35%) <0.001
Neurological signs
Extrapyramidal.signs 6	(4%) 9	(11%) 24	(12%) 11	(33%) <0.001
Rigidity 4	(3%) 7	(8%) 14	(7%) 9	(27%) <0.001
Brady/hypokinesia 2	(1%) 5	(6%) 10	(5%) 3	(10%) 0.10
Tremor 2	(1%) 3	(4%) 9	(5%) 4	(12%) 0.03
Parkinsonian	gait 0 1	(1%) 9	(5%) 5	(16%) <0.001
Unilateral.signs 5	(3%) 12	(14%) 30	(15%) 13	(38%) <0.001
Hemimotor	dysfunction 4	(2%) 5	(6%) 9	(4%) 6	(18%) <0.01
Hemisensory	dysfunction 1	(1%) 1	(1%) 3	(2%) 1	(3%) 0.71
Hemianopsia 1	(1%) 1	(1%) 5	(3%) 3	(9%) 0.02
Reflex	asymmetry 1	(1%) 7	(8%) 12	(6%) 11	(32%) <0.001
Babinski	sign 2	(1%) 5	(6%) 8	(4%) 4	(13%) 0.02
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Subsequently, we investigated the association between WMH volumes and presence of extrapyramidal 
signs. Two-way ANOVA with diagnosis and extrapyramidal signs as independent variables and WMH 
volume as dependent variable showed a main effect of diagnosis (p<0.001), but not of extrapyramidal 
signs (p=0.62). Furthermore, there was no interaction between diagnosis and extrapyramidal signs 
(p=0.45), indicating that the difference of WMH volumes in the diagnostic groups was not related 
to the presence of extrapyramidal signs (figure 1). A different picture emerged looking at unilateral 
signs. Two-way ANOVA showed a main effect of diagnosis (p<0.001) and of unilateral signs (p=0.001). 
In addition, there was an interaction between diagnosis and unilateral signs (p=0.04; figure 2). Patients 
with subjective complaints and VaD patients showed higher WMH volumes if unilateral signs were 
present compared to patients without unilateral signs, whereas unilateral signs were not related to 
WMH volumes in AD and MCI patients. These results remained essentially unchanged after additional 




complaints MCI AD VaD
Extrapyramidal signs
Model	1 1	(ref) 2.8	(1.0-8.2) 3.2	(1.2-8.1) 12.1	(4.1-36.0)
Model	2 1	(ref) 1.3	(0.4-4.1) 1.6	(0.6-4.3) 5.4	(1.7-17.3)
Unilateral signs
Model	1 1	(ref) 4.7	(1.6-13.9) 5.0	(1.9-13.2) 18.1	(5.8-55.9)















Brain	fraction	(parenchyma/IC) 0.84	(0.03) 0.81	(0.03)a 0.79	(0.03)a,b 0.79	(0.04)a
Lacunes	present	n(%) 22	(14%) 16	(19%) 27	(13%) 27	(79%)a,b,c
Infarct	present	n(%) 5	(3%) 5	(6%) 6	(3%) 12	(43%)a,b,c
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Discussion
We found that neurological signs are common in a memory clinic population and differed in frequency 
according to diagnosis. A comparable number of MCI and AD patients showed unilateral (14% and 15%) 
and extrapyramidal signs (11% and 12%). The frequency of extrapyramidal signs in AD in our study is 
comparable to most earlier reports.2, 4, 5 Others found higher frequencies,6, 7 probably associated with 
differences in disease severity and assessment methodologies. Concerning MCI patients, our results 
are comparable to a previous report.11 A few studies found more signs in MCI compared to cognitively 
normal people, but contrary to our results, less than in demented individuals.11-13 A possible explanation 
is the population based origin of the former studies, while we examined a memory clinic cohort which 
might have influenced the severity of both MCI and AD. 
Strengths of the current study include the large population and the simultaneous examination of 
different diagnostic groups. Since the presence of neurological signs is known to be influenced by age, 
all analyses were age-adjusted.27 Furthermore, we used a validated, fully automatic method to determine 
WMH volumes. All analyses with WMH were corrected for intracranial volume. An important limitation 
is the lack of WMH volumes of separate hemispheres or information about possible asymmetric 
distribution of WMH. On the other hand, WMH is often found bilaterally on MRI. Furthermore, the 
neuropathology of WMH is known to be heterogeneous and more sophisticated imaging techniques are 
needed to determine when WMH relates to actual damage (associated with neurological signs).28 Another 
important limitation was the use of the clinical neurological examination instead of a standardized 
rating scale, which may have resulted in an underestimation or overestimation of the frequency of 
neurological signs.6 However, this was random over patient groups and probably did not influence 
robustness of group comparisons. We hope that our study will draw more attention to the presence of 
neurological signs in memory clinic patients and make the use of standardized neurological examination 
more common to facilitate comparison between different centers and diseases. Furthermore, we did 
not have neuropathological confirmation of our diagnosis and cannot exclude mixed-disease or even 
misdiagnosis (like concomitant Lewy-body or Parkinson’s disease). However, all our patients were 
carefully screened and diagnosed according current criteria.8, 10, 22. Finally, the retrospective cross-
sectional study design makes it impossible to draw conclusions on causality. 
 
Unilateral signs were more prevalent in all diagnostic subgroups compared to patients with subjective 
complaints. Furthermore, we found unilateral signs to be related to WMH in patients with subjective 
complaints and VaD. A vascular origin of unilateral signs caused by an asymmetric disruption of motor 
pathways seems plausible. Although mainly related to large vessel disease, the association between 
unilateral signs and small vessel disease has been shown before in VaD.9 In MCI and AD, the absence 
of a relation between WMH and unilateral signs suggests that next to vascular abnormalities other 
pathological changes might attribute to unilateral signs. Although cortical asymmetry has been found in 
AD, a possible association with unilateral signs has never been examined.29, 30 In general, a combination 
of prominent unilateral signs and focal cortical signs are considered indicative of corticobasal 
degeneration (CBD) instead of AD.31 However, a number of case-reports has described patients with 
unilateral motor signs suspected of CBD, who turned out to have AD at post mortem examination, 
associated with asymmetric cortical tau burden.32-35 
Although the concept of vascular parkinsonism is controversial, there seems no doubt that 
cerebrovascular disease can cause elements of parkinsonism.36 In non-demented elderly a relation 
between WMH and extrapyramidal signs has been found.21 The main hypothesis is that WMH can cause 
disruption of neural connections between the frontal cortex, thalamus and the striatum resulting in 
extrapyramidal signs. Remarkably, we found no relation between WMH and extrapyramidal signs in 
any of the diagnostic groups. However, after adjustment for age and sex only VaD patients showed more 
extrapyramidal signs compared to patients with subjective complaints, which still seems to imply a 
vascular etiology. We showed that neurological signs are common in a memory clinic population; the 
clinical implication of specific neurological signs has to be explored in future studies. Further studies are 
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needed to examine the relation between neurological signs and specific atrophy markers. Additionally, 
with the use of more sophisticated techniques such as diffusion tensor imaging, white matter 
connectivity of the brain which may be impaired by vascular pathology can be explored. And most 
important, future research should be aimed at finding the meaning of neurological signs in the different 
forms of dementia, in terms of prognosis and outcome.
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Figure 2; Estimated	 marginal	 means	 of	




agnosis	 and	 presence	 of	 unilateral	 signs	
as	 independent	 variables,	 and	 age,	 sex	
and	 intracranial	 volume	 as	 covariates,	
demonstrated	 main	 effects	 of	 diagno-
sis	 (p<0.001)	 and	 of	 unilateral	 signs	
(p=0.001).	 Additionally,	 there	 was	 an	
interaction	between	diagnosis	and	unilat-
eral	signs	(p=0.04).
Figure 1; Estimated	 marginal	 means	
of	 total	 WMH	 volumes	 in	 the	 diagnos-
tic	 groups,	 categorized	 by	 presence	 of	
extrapyramidal	 signs.	 Two-way	 ANOVA	
using	 total	 WMH	 volume	 as	 depend-
ent	 variable,	 diagnosis	 and	 presence	 of	
extrapyramidal	 signs	 as	 independent	
variables,	 and	 age,	 sex	 and	 intracranial	
volume	as	covariates,	showed	a	main	ef-
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Abstract
Purpose
The aim of this study was to describe the prevalence of a number of neurological signs in a large popula-
tion of patients with vascular dementia (VaD) and to compare the relative frequency of specific neurologi-
cal signs dependent on type of cerebrovascular disease. 
Methods
706 Patients with VaD (NINDS-AIREN) were included from a large multicenter clinical trial (registration 
number NCT00099216). At baseline neurological examination, the presence of sixteen neurological signs 
was assessed. Based on MRI, patients were classified as having large vessel VaD (18%; large territorial 
or strategical infarcts on MRI), small vessel VaD (74%; white matter hyperintensities (WMH), multiple 
lacunes, bilateral thalamic lesions on MRI), or a combination of both (8%).
Results
A median number of 4.5 signs per patient was presented (maximum 16). Reflex asymmetry was the most 
prevalent symptom (49%), hemianopia was most seldom presented (10%). Measures of small vessel dis-
ease were associated with an increased prevalence of dysarthria, dysphagia, parkinsonian gait disorder, 
rigidity and hypokinesia and as well to hemimotor dysfunction. By contrast, in the presence of a cerebral 
infarct, aphasia, hemianopia, hemimotor dysfunction, hemisensory dysfunction, reflex asymmetry and 
hemiplegic gait disorder were more often observed. 
Conclusion
The specific neurological signs demonstrated by patients with VaD differ according to type of imaged 
cerebrovascular disease. Even in people who meet restrictive VaD criteria, small vessel disease is often 
seen with more subtle signs, including extrapyramidal signs, whereas large vessel disease is more often 
related to lateralized sensorimotor changes and aphasia.
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Introduction
Vascular dementia (VaD) is the second most common type of dementia worldwide.1 At present, the 
criteria of the National Institute of Neurological Disorders and Stroke Association Internationale pour 
la Recherche et al’Enseignement en Neurosciences (NINDS-AIREN) are most often used to diagnose 
VaD.2 These criteria require the presence of dementia, defined as cognitive decline with interference in 
activities of daily living, and evidence of cerebrovascular disease. The latter includes both proof on brain 
imaging and the presence of focal signs on neurological examination. However, little is known about the 
relative prevalence of specific neurological signs in VaD. The NINDS-AIREN criteria suggest signs such as 
hemiparesis, lower facial weakness, Babinski sign, sensory deficit, hemianopia and dysarthria.2 Other cri-
teria for VaD requiring focal signs on neurological examination are the Diagnostic and Statistical Manual 
of Mental Disorders third and fourth edition (DSM III/IV)  and the criteria of the International Statistical 
Classification of Diseases, tenth revision (ICD-10).3-5 The DSM III and IV mention neurological signs such 
as exaggeration of deep tendon reflexes, extensor plantar response, pseudobulbar palsy, gait abnormali-
ties or weakness of an extremity. The ICD-10 includes signs such as unilateral increased tendon reflexes, 
an extensor plantar response or pseudobulbar palsy. Nonetheless, the prevalence of specific neurological 
signs in VaD patients is not known.
Cerebrovascular disease can be caused by large vessel disease, including large territorial or strategic 
infarcts, and small vessel disease, consisting of multiple lacunes, white matter hyperintensities (WMH) or 
bilateral thalamic lesions.6 It would be plausible that neurological signs differ according to the types of 
underlying vascular disease. The aim of this study was to investigate the relative prevalence of a number 
of specific neurological signs in a large population of patients with VaD according to the NINDS-AIREN 
criteria included in a clinical trial, and to compare neurological signs by type of underlying cerebrovascu-
lar disease. 
Methods
Study design and patients
Baseline data of 706 patients aged 50-85 years, included in the VantagE study, were used. The VantagE 
study was a large multicenter, phase III, prospective, randomized, double-blind clinical trial on the ef-
fects of rivastigmine in patients with VaD (registration number NCT00099216, Novartis International AG, 
Basel, Switzerland). Trial inclusion criteria included both fulfilment of the DSM-IV diagnostic criteria for 
VaD and fulfilment of the NINDS-AIREN criteria for probable VaD, with central assessment of the neu-
roimaging criteria at the Image Analysis Center (VU Medical Center, Amsterdam, the Netherlands).2, 4 The 
NINDS-AIREN criteria for probable VaD were slightly modified:7 if neuroimaging criteria for subcortical 
VaD were met as assessed by the central neuroradiologist, patients were not required to have evidence 
of a temporal relationship between the dementia syndrome and the evidence of cerebrovascular disease. 
Accordingly, patients with cortical VaD entered the study with a clinical diagnosis of probable VaD, but 
patients with subcortical VaD were permitted to enter the study with a clinical diagnosis of possible VaD 
by NINDS-AIREN criteria. Furthermore, focal signs, as evidence of cerebrovascular disease, were expanded 
to allow presence or history of any findings on neurological examination indicating cerebrovascular 
disease. Patients had to have a MMSE score of 10-24 to be included in the study. Excluded from entry into 
the study were patients with a history of stroke within the 3 months prior to baseline unless the patient 
was considered to have fully stabilized in function; a current diagnosis of any primary neurodegenera-
tive disorder; and a current diagnosis of major depression. Patients with space-occupying lesions or lobar 
haemorrhages were excluded. All patients gave written informed consent. The study was approved by 
local Ethics Committees. 
Baseline clinical assessment
Diagnostic evaluation included complete medical history, physical and neurological examination, 
laboratory tests, neuropsychological testing including Mini-Mental State Examination (MMSE)8 and MRI 
of the brain. For all patients, a standard neurological exam was performed, during which the presence 
of sixteen specific neurological signs was assessed: aphasia, dysarthria, dysphagia, pseudobulbar signs 
(palmomental and snout reflexes), field cut/hemianopia, hemimotor dysfunction indicating upper motor 
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neuron lesions, hemisensory dysfunction, reflex asymmetry, babinsky sign, bilateral increased deep 
tendon reflexes, hemiplegic gait disorder, atactic gait disorder (atactic gait defined as a broad based gait 
pattern indicative of cerebellar involvement) and parkinsonian type gait disorder, extrapyramidal signs 
shown by resting or postural tremor, non-spastic rigidity or hypokinesia. All neurological signs were 
assessed as ‘none/absent’, ‘mild’, ‘moderate’, ‘severe’ or ‘very severe’ and as such included, except for the 
signs hemianopia and reflex abnormalities which were graded as ‘none/absent’ and ‘present’. For this 
study, all signs were dichotomised as ‘none/absent’ = 0 and ‘present’ = 1, and as such used in the data 
analysis. The following six signs were regarded as ‘unilateral signs’: aphasia, hemianopia, hemimotor 
dysfunction, hemisensory dysfunction, reflex asymmetry, hemiplegic gait. Furthermore, we considered 
‘presence of extrapyramidal signs’, determined as presence of one or more of the following: tremor, non-
spastic rigidity, hypokinesia or parkinsonian type gait disorder.
MRI protocol
All patients underwent MRI examination before randomization. MRI scanners operating between 0.5 and 
1.5 Tesla were used. Axial spin-echo T2-weighted images (T2-WI; echo time [TE]: 80 to 120 ms; repetition 
time [TR]: 3000 to 4000 ms; slice thickness=5 mm); axial fluid-attenuated inversion recovery (FLAIR) im-
ages (TE: 110 to 150 ms; TR: 9000 to 10000 ms; inversion time: 2000 to 2200 ms; slice thickness=5 mm); 
and axial, sagittal, and coronal spin-echo T1-weighted images (T1-WI; TE: 11 to 20 ms; TR: 500 to 700 ms; 
slice thickness=5 mm) were acquired.
Image assessment 
Vascular abnormalities were evaluated by agreement of two experienced readers blinded to clinical in-
formation, with the use of digital image files. The items of the radiological NINDS-AIREN criteria for VaD 
were determined, according to operational definitions earlier proposed.6 Based on these criteria, patients 
were classified as having large vessel VaD, small vessel VaD, or a combination of both. For the fulfilment 
of large vessel disease both a topography and a severity criterion (= lesion of the dominant hemisphere or 
bilateral hemispheric strokes) has to be met. In case of small vessel disease, for white matter hyperinten-
sities (WMH) both topography and severity criteria have to be met, for multiple lacunae and bilateral tha-
lamic lesions only the topography criterion is sufficient. The degree of WMH severity was rated visually 
on axial FLAIR and T2-WI images using the Age Related White Matter Changes (ARWMC) scale.9 In short, 
WMH are ill-defined hyperintensities of >5mm, rated on a 4-point scale ranging from 0 (no lesions) to 3 
(diffuse involvement of the entire region), within 5 regions in each hemisphere. Here, we used the total 
degree of WMH (range 0-30) by summing the region-specific scores of both hemispheres. Lacunes were 
rated as presence or absence of multiple lacunes, defined as at least 2 lacunes in the basal ganglia and 
at least 2 lacunes in the frontal white matter. The presence of bilateral thalamic lesions was assessed, 
to meet the criterion, at least one lesion in each thalamus had to be present. In addition to assessment 
of large vessel VaD according to radiological NINDS-AIREN criteria, the presence of a cerebral infarct (of 
the anterior cerebral artery, in the territory of the posterior cerebral artery, in an association area of the 
medial cerebral artery or in the watershed area of the carotid territory) was also determined. 
Statistical analysis
All statistical analyses were performed using SPSS 14.0 (SPSS Inc). Associations between the number 
of neurological signs and MMSE score were assessed using partial correlations, controlling for age and 
sex. For comparison of neurological signs between the different types of VaD (small vessel VaD, large 
vessel VaD or a combination) chi-square tests were used. Subsequently, to adjust for age and sex, we 
used logistic regression models with the individual neurological signs as dependent variables, and the 
different types of VaD as categorical covariate. In addition, associations between neurological signs 
and specific MRI measures of cerebrovascular disease were assessed using logistic regression analysis, 
adjusting for age and sex. We used the individual neurological signs as dependent variables. Independ-
ent variables were dichotomized as follows: extensive WMH absent (ARWMC < 15) or present (ARWMC 
≥ 15) (determined using the median score of the whole population, ARWMC = 15), multiple lacunes and 
bilateral thalamic lesions absent or present, large vessel infarct - independent of fulfilment of the criteria 
of large vessel VaD - absent or present. The associations between neurological signs and MRI measures of 
cerebrovascular disease were tested in separate models. 
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Table 1; Patient	demographics	and	characteristics





















The total study population of 706 VaD patients had a mean (±SD) age of 73±8 years (table 1). On average, 
patients were mildly-to-moderately demented with a mean MMSE score of 19±4. On the basis of the op-
erational definitions for the radiological part of the NINDS-AIREN criteria, 522 (74%)  patients had small 
vessel VaD, 126 (18%) had large vessel VaD, and 58 (8%) had both small and large vessel VaD. The mean 
ARWMC score was 14.5±6.2 (median 15). There were 203 (29%) patients who showed multiple lacunes, 
269 (38%) patients had bilateral thalamic lesions, and the presence of a cerebral infarct was demonstrat-
ed by 226 (32%) patients (n=4 anterior cerebral artery, n=52 posterior cerebral artery, n=57 association 
area of the medial cerebral artery, n=57 watershed area of the carotid territory, n=56 >1 cerebral infarct).
A median (range) number of 4.5 (0-16) signs per patient were presented (see figure 1; number of pre-
sented signs per patient). There were 19 patients who did not present any of the aforementioned selected 
neurological signs, however, all had shown other neurological signs (e.g. lower facial weakness), or symp-
toms not otherwise specified. We found a small negative correlation between the number of presented 
neurological signs and the MMSE (adjusted for age and sex, partial r=-0.14, p<0.001). Prevalence of the 
sixteen evaluated neurological signs in the total population is shown in figure 2. Reflex asymmetry was 
the sign which was shown most often (49%), followed by hemimotor dysfunction (44%), dysarthria (43%) 
and aphasia (41%). The symptom which was most seldom presented was hemianopia (10%). 
The relative prevalence of specific neurological signs appeared to be different between patients with 
small vessel and large vessel VaD (table 2). Dysarthria, dysphagia, parkinsonian type gait disorder and hy-
pokinesia were more prevalent in patients with small vessel VaD compared to patients with large vessel 
VaD. Patients with large vessel VaD more frequently showed aphasia, hemianopia, hemisensory dysfunc-
tion and reflex asymmetry. The results did not change after adjustment for age and sex. Other signs, 
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including the babinski sign, atactic gait disorder and tremor, were equally distributed between patients 
with small vessel or large vessel VaD. In addition, the number of signs presented per patient did not dif-
fer between patients with small vessel VaD, large vessel VaD or a combination (p>0.30). In an additional 
analysis, we compared the presence of at least one unilateral sign (presence of aphasia, hemianopia, 
hemimotor dysfunction, hemisensory dysfunction, reflex asymmetry or hemiplegic gait) and presence 
of an extrapyramidal signs (parkinsonian gait, tremor, rigidity or hypokinesia) according to type of cer-
ebrovascular disease. The majority of patients with small vessel VaD (76%) showed at least one unilateral 
sign, but to a lesser extent (p<0.001) than patients with large vessel VaD, who almost invariably showed 
unilateral signs (large vessel VaD: 93%; large+small vessel VaD: 90%). Conversely, presence of at least one 
extrapyramidal sign was highest in patients with small vessel disease (54%), but they were also shown by 
















Aphasia	 183	(35) 78	(62)a 28	(48) <0.001
Dysarthria 240	(46)b,c 43	(34) 20	(34) 0.02
Dysphagia 114	(22)b 16	(13) 8	(14) 0.04
Pseudobulbar	signs 155	(30) 37	(29) 14	(24) 0.68
Hemianopia 26	(5) 36	(29)a 10	(17)a <0.001	
Hemimotor	dysfunction 217	(42) 62	(49) 31	(53) 0.09
Hemisensory	dysfunction 95	(18) 36	(29)a 111	(19) 0.03
Reflexes
Reflex	asymmetry 239	(46) 71	(56)a 39	(67)a 0.002
Babinski	sign 196	(38) 51	(41) 24	(41) 0.74
Bilateral	increased	
deep	tendon	reflexes
207	(40) 44	(35) 19	(33) 0.41
Gait
Hemiplegic 118	(23) 34	(27) 21	(36)a 0.06
Atactic 150	(29) 39	(31) 14	(24) 0.64
Parkinsonian	type 169	(32)b 20	(16) 12	(21) <0.001
Extrapyramidal
Tremor 74	(14) 16	(13) 4	(7) 0.29
Rigidity 112	(21) 20	(16) 10	(17) 0.32


















Aphasia 0.62	(0.46-0.84) 0.53	(0.37-0.76) 0.56	(0.41-0.77) 1.86	(1.35-2.58)
Dysarthria 1.45	(1.05-1.98) 1.60	(1.13-2.27) 1.28	(0.93-1.76) 0.55	(0.39-0.77)
Dysphagia 1.69	(1.14-2.51) 2.71	(1.81-4.05) 1.56	(1.07-2.89) 0.52	(0.34-0.81)
Pseudobulbar	signs 1.28	(0.91-1.79) 1.30	(0.90-1.87) 0.94	(0.67-1.33) 0.83	(0.58-1.18)
Hemianopia 0.34	(0.20-0.57) 0.33	(0.17-0.66) 0.47	(0.27-0.83) 6.63	(3.83-11.48)
Hemimotor	dysfunction 0.95	(0.70-1.28) 1.49	(1.06-2.09) 0.94	(0.69-1.29) 1.73	(1.25-2.39)
Hemisensory	dysfunction 0.92	(0.63-1.34) 0.84	(0.54-1.29) 0.75	(0.51-1.11) 1.66	(1.13-2.44)
Reflex	asymmetry 0.91	(0.67-1.23) 0.85	(0.61-1.20) 0.84	(0.61-1.14) 1.89	(1.37-2.61)
Babinski	sign 0.79	(0.58-1.07) 1.12	(0.79-1.58) 1.23	(0.90-1.68) 1.16	(0.84-1.61)
Bilateral	increased	deep	
tendon	reflexes
1.07	(0.78-1.45) 0.97	(0.68-1.38) 1.22	(0.89-1.67) 0.76	(0.55-1.07)
Hemiplegic	gait 1.14	(0.80-1.63) 1.22	(0.83-1.80) 1.38	(0.97-1.96) 1.68	(1.17-2.41)
Atactic	gait 1.08	(0.78-1.51) 0.82	(0.56-1.19) 1.04	(0.74-1.45) 0.88	(0.62-1.26)
Parkinsonian	type	gait 1.45	(1.03-2.03) 2.10	(1.45-3.03) 1.42	(1.01-1.98) 0.44	(0.30-0.66)
Tremor 0.83	(0.53-1.29) 0.99	(0.60-1.63) 0.73	(0.45-1.16) 0.61	(0.37-1.02)
Rigidity 1.53	(1.04-2.25) 1.63	(1.09-2.43) 1.27	(0.87-1.86) 0.68	(0.45-1.04)







Subsequently we related the various MRI measures of cerebrovascular disease (extensive WMH, multiple 
lacunes, bilateral thalamic lesions, presence of a cerebral infarct) to the presence of neurological signs 
(table 3). Extensive WMH was associated with an increased risk of dysarthria, dysphagia, parkinsonian 
type gait disorder and rigidity. The presence of multiple lacunes additionally showed an increased risk of 
hemimotor dysfunction. Bilateral thalamic lesions were associated with an increased risk of dysphagia, 
parkinsonian type gait disorder and hypokinesia. Furthermore, these measures of small vessel disease 
were associated with a lower risk of aphasia and hemianopia. In contrast, the presence of a cerebral 
infarct was associated with a higher risk of hemimotor dysfunction, aphasia, hemianopia, hemimotor 
dysfunction, hemisensory dysfunction, reflex asymmetry and hemiplegic gait disorder, while the risk of 
dysarthria, dysphagia and extrapyramidal signs was lower in patients with a cerebral infarct. 
Discussion
In this large cohort of VaD patients we found that neurological signs of reflex asymmetry (49%), 
hemimotor dysfunction (44%) and dysarthria (43%) were most prevalent, while hemianopia was 
rarely observed (10%). Although the number of signs did not differ according to type of underlying 
cerebrovascular disease, the specific neurological signs differed by type of vascular abnormality. 
Overall, little has been reported previously about the relative prevalence of specific neurological signs in 
VaD.10-12 Different criteria for VaD suggest different signs (DSM/ICD-10/NINDS-AIREN), and some criteria 
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don’t require the presence of neurological signs at all (Alzheimer’s Disease Diagnostic and Treatment 
Centers (ADDTC)).2-5, 13 However, the criterion of presence of focal neurological signs is nowhere clearly 
specified, neither in the NINDS-AIREN criteria, nor in other criteria of VaD. The NINDS-AIREN criteria 
only give a suggestion of symptoms that might be encountered. We examined sixteen signs, but there 
are many other possible signs we did not assess, like the presence of lower facial weakness. On the other 
hand, our study shows that in addition to signs of lateralization, non-focal signs such as extrapyramidal 
signs are also often observed in patients with VaD, suggesting that a broad definition of neurological 
signs should be made. Alternatively, it could be argued that the criterion of neurological signs should 
be left out of the diagnostic criteria altogether, as with the widespread availability of neuroimaging 
nowadays, the presence of cerebrovascular disease can be established in a more direct way. In 
conclusion, these results add to the growing awareness that refinement of the current criteria of VaD 
may be necessary.
The presence of a cerebral infarct was related to lateralized sensorimotor changes and aphasia, a result 
one would expect according to the localisation of the infarcts. These signs are the focal signs which 
are most often mentioned in criteria for VaD, in addition to other signs such as the babinski sign and 
pseudobulbar signs, which were equally prevalent among patients with cerebral infarcts and small vessel 
disease. In contrast to large vessel infarcts which are likely to produce acute signs, the onset of small 
vessel VaD is often insidious and more subtle neurological signs would be expected. The associations 
we found between small vessel disease and subtle signs of dysphasia and dysarthria are in agreement 
with previous findings.11, 14 Furthermore, we found associations between small vessel disease, including 
WMH, lacunes and bilateral thalamic lesions, and extrapyramidal signs such as rigidity, hypokinesia 
and parkinsonian gait disturbance. In literature the concept of vascular parkinsonism is controversial, 
but associations between small vessel disease and extrapyramidal signs have been reported before.15, 16 
Nonetheless, none of the criteria for VaD suggests the presence of extrapyramidal signs as a qualifying 
neurological sign. Gait disorders are common in VaD, and in the NINDS-AIREN criteria specified as 
clinical feature consistent with the diagnosis.2 In small vessel disease, gait disturbances have traditionally 
been classified as ‘marche à petit pas’, an apraxic-atactic or Parkinsonian gait.14 We demonstrated a 
difference in gait pattern between small vessel and large vessel VaD patients, with a hemiplegic type gait 
disturbance in large vessel disease and parkinsonian type gait disturbance in small vessel disease. 
Strengths of the present study include the large study population, as it is one of the largest clinical series 
of patients affected by VaD to date. Additionally, the screening for fulfilment of radiological criteria for 
probable VaD was performed carefully by central assessment. To diagnose patients with VaD the NINDS-
AIREN criteria were used, widely used and generally considered accurate criteria, although the criteria 
have been shown not to be interchangeable with other diagnostic methods for VaD.10 A limitation 
includes the study design of a cross-sectional cohort study, which precludes the assessment of causality 
or the evolution of symptomatalogy. Another limitation is possible inter-rater variability due to the 
performance of neurological examination in several centres by several assessors. Ideally, reliability data 
should have been provided, but for the present study, these were not available. Furthermore, setting, 
entry criteria and other design features of a randomized clinical trial may have introduced a selection 
bias on the inclusion of patients. 
Finally, the unavoidable circularity of studying neurological signs in VaD patients – that by definition are 
required to have neurological signs – is a complex issue. However, we feel that the description of the 
relative frequency of a large number of specific neurological signs indeed adds to the field. Moreover, 
we showed that specific signs were related to specific types of imaged vascular damage. Further studies 
should endeavour to avoid this inherent circularity, for example by studying presence of neurological 
signs in relation to MRI abnormalities in a broader group of patients with dementia, irrespective of the 
specific nosological diagnosis. 
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Figure 2; Prevalence of neurological signs.
Percentage	of	patients	of	the	total	population	presenting	individual	neurological	signs.	All	neurological	
signs	were	rated	in	n=706	patients,	except	for	hemianopia	which	had	2	missing	values	(n=704).
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Abstract
Background
The neuropathology of behavioural and psychological symptoms is much less understood than xthe 
neuropathology of cognitive impairment in AD. On MRI, medial temporal lobe atrophy (MTA) is 
presumed to reflect Alzheimer-type pathology. White matter hyperintensities (WMH) are considered 
markers of vascular pathology. 
Aim: We investigated differences in prevalence of behavioural and psychological symptoms in AD 
according to the presence of MTA and WMH on MRI.
Methods
Behavioural and psychological symptoms of 111 consecutive AD patients were assessed using the 
Neuropsychatric Inventory (NPI). Symptoms were considered present when the score was ≥1. On MRI, 
MTA was rated using the 5-point Scheltens-scale and WMH using the 4-point Fazekas-scale. Both MRI 
measures were dichotomised (MTA: absent 0/1, present 2-4; WMH absent 0/1, present 2/3). 
Results
Of the 111 AD patients, 60(55%) had MTA, and 32(29%) had WMH. The presence of MTA was  
associated with the presence of WMH (β2=11.8, p<0.001). The prevalence of behavioural and  
psychological symptoms – defined as a NPI score of ≥1 on at least one symptom – was 74%.  
The median NPI score of the total study population was 6(0-41). There was no difference in  
prevalence according to MTA (p=0.53) or WMH (p=0.18). On inspection of individual NPI items,  
neither MTA, nor WMH was related to any of the symptoms. 
Conclusions
There were no differences in prevalence of behavioural and psychological symptoms  
according to MTA or WMH, as rated on MRI. This suggests that the occurrence of those  
symptoms depends on other determinants, such as coping style or genetic make-up.  
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia, characterized by gradually increasing 
cognitive impairment.1 In addition to cognitive impairment, behavioural and psychological symptoms 
in AD are considered to be equally important.2 These symptoms have been shown to be associated with 
worse prognosis, higher cost of care, earlier institutionalisation and increased caregiver burden.3, 4 
However, little is known about the radiological underpinnings of these behavioural and psychological 
symptoms.
On MRI, medial temporal lobe atrophy (MTA) and white matter hyperintensities (WMH) are both 
commonly observed in AD. MTA is presumed to reflect disease severity as it has been related to the 
burden of Alzheimer-type pathology.5, 6 WMH are regarded as suggestive of vascular pathology and 
considered to reflect ischemic damage to the brain.7 MTA and WMH are both associated with cognitive 
problems in AD.8, 9 Moreover, both MRI abnormalities have been shown to be involved in the earliest 
stages of cognitive decline, even before dementia.10 In AD, MTA especially has been related to memory 
impairment, whereas WMH has been reported to affect frontal lobe function resulting in executive 
dysfunction.11, 12 Still, it is unclear whether MTA and WMH are also associated with other symptoms 
in dementia such as behavioural and psychological symptoms. Hypothetically these may be caused by 
disruption of the connections between the anterior cingulated gyrus and other cortical and subcortical 
area’s or by affecting structures relevant to emotion and social behaviour including the amygdala and 
anterior temporal cortex.   
Few studies have focused on behavioural and psychological symptoms and MRI abnormalities in AD. 
Only one previous study examined involvement of the medial temporal lobe and showed an association 
with delusions in a small group of AD patients.13 Reports about the role of WMH and behavioural 
and psychological symptoms in AD have been conflicting. Associations between WMH and apathy,14 
depression,15 suicidal ideation,16 delusional misidentification 17 and aberrant motor behaviour 18 have 
been described. However, the studies were relatively small, and none of the studies could confirm the 
results of the previous reports. Moreover, other studies did not find any relation between WMH and 
psychiatric symptoms.19-21 We hypothesized that, since MTA is known to progress along with dementia 
severity, the presence of MTA would be related to the occurrence of behavioural and psychological 
symptoms. Furthermore we expected vascular involvement as illustrated by WMH to express with a 
different behavioural and psychological profile compared to patients without vascular involvement. 
WMH in non-demented older subjects have been associated with depressive symptoms,22 and we 
hypothesized that likewise, affective symptoms would be promoted by WMH in AD patients as well.
To our knowledge, no previous report has examined both MRI markers in relation to behavioural and 
psychological symptoms in dementia. We have therefore assessed the associations between these 
symptoms and MTA and WMH in a relatively large sample of AD patients attending a memory clinic.
Methods
We consecutively recruited 111 patients with probable AD from the outpatient memory clinic of the 
Alzheimer Centre of the VU University Medical Centre (VUmc). Standardized dementia assessment 
included medical history, neurological exam, laboratory tests, neuropsychological testing including Mini-
Mental State Examination (MMSE),23 electroencephalogram (EEG) and magnetic resonance imaging (MRI) 
of the brain. Diagnoses were made in a multidisciplinary consensus meeting according to the National 
Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease 
and Related Disorders Association (ADRDA) diagnostic criteria.1 The study was approved by the local 
Medical Ethical Committee. All patients gave written informed consent.
Behavioural and psychological assessment
To evaluate behavioural and psychological symptoms (including delusions, hallucinations, agitation/
aggression, depression/dysphoria, anxiety, elation/euphoria, apathy, disinhibition, irritability, 
and aberrant motor behaviour), the Neuropsychiatric Inventory (NPI 10-item), an informant rated 
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instrument, was used.24 For each neuropsychiatric domain, frequency (range 0 – 4) and severity (range 
0 – 3) are rated. Subsequently, the domain score is calculated as the product of the frequency and 
severity. The sum of the 10 domain scores provides the total NPI score (maximum score =120). Presence 
of behavioural and psychological symptoms was defined as a score of 1. The abbreviated Geriatric 
Depression Scale (GDS-15) was used to additionally assess depressive symptoms.25 
MRI
MRI was performed on a 1.0 Tesla machine (Magnetom Impact Expert Siemens AG, Erlangen, Germany) 
following a standard protocol, including coronal T1-weighted 3D MPRAGE (magnetization prepared 
rapid acquisition gradient echo; 168 slices, FOV 250mm, matrix 256x256, slice thickness 1.5 mm, TE: 
7ms, TR: 15 ms, TI 300 ms, flip angle 15 degrees) and axial FLAIR (fluid attenuated inversion recovery, 
17 slices, FOV 250mm, matrix 256x256, slice thickness: 5mm, interslice gap: 1.5mm, TE: 105ms, TR: 
9000ms, TI 2200 ms, flip angle 180 degrees). Visual rating of MTA was performed on coronal T1-weighted 
images according to the 5-point (0-4) Scheltens scale.8 The degree of WMH severity was rated visually on 
axial FLAIR images using the 4-point (0-3) Fazekas scale.26 Both MRI measures were dichotomised (MTA 
average score 0/1 = no atrophy, MTA score 2–4 = atrophy; WMH grade 0/1 = no WMH, grade 2/3  = WMH 
present). 
Statistical analysis
Statistical analysis was performed by means of SPSS 12.0 (SPSS Inc). Group comparisons were performed 
using chi-squared tests for dichotomous outcome variables and independent samples t-tests for 
continuous data. Subsequently, we used logistic regression models with the individual NPI symptoms 
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Results
Demographic, clinical and MRI variables are shown in table 1. More than half of the patients had MTA, 
while one third of patients showed moderate or severe WMH. The combination of both MTA and WMH 
was observed in 26 (23%) of the patients. The presence of MTA was associated with the presence of WMH 
(χ2=11.8, p=0.001). Both MTA and WMH were associated with a higher age (MTA t=4.3, p=0.03; 
WMH t=4.3, p<0.001). Patients with MTA tended to have a lower MMSE ( t=2.1, p=0.057), but there was 
no relation between WMH and MMSE ( t=0.2, p=0.22). There were no differences in sex or depressive 
symptoms as measured using the GDS according to MTA or WMH. 
 
In the total cohort of 111 patients, the prevalence of any behavioural or psychological symptom was 
74%, with a median NPI score of 6 (range 0 – 41). Apathy and irritability were the most common 
symptoms in the whole group, euphoria was the rarest symptom (affecting 60%, 26% and 0% patients, 
respectively). The presence of any symptom was related to a higher GDS score (t=4.2,  p<0.001), and 
related to a lower MMSE (t=2.5, p=0.01). There was no difference in prevalence of any behavioural or 
psychological symptom according to MTA (χ2=0.4, p=0.53) or WMH (χ2=1.8, p=0.18). Also the combination 
of MTA and WMH showed no difference in presence of symptoms compared to patients without MTA or 
WMH (χ2=0.2, p=0.64). Figures 1 and 2 show the prevalence of individual behavioural and psychological 
symptoms according to the presence of MTA and WMH, respectively. We did not find a relation between 
MTA or WMH and any of the individual symptoms (all p>0.12). These results remained unchanged after 
adjustment for age, sex and MMSE. 
Discussion
The main finding of this study is the absence of any association between the behavioural and 
psychological profile and MTA or WMH, two widely used MRI markers in AD. On examination of 
individual NPI items, neither MTA nor WMH was related to any of the symptoms. These findings suggest 
that the presence of behavioural and psychological symptoms depends on other determinants.
We hypothesized that MTA would be related to the prevalence of symptoms. However, we did not find an 
association between any behavioural or psychological symptom and MTA. Our findings are in agreement 
with the observation that – unlike cognition that gradually declines in the course of the disease – 
behavioural and psychological symptoms may have a more fluctuating manifestation.27 Apparently 
behavioural and psychological symptoms are not directly related to disease progression as measured 
using MTA, but depend on other factors. A previous report examined AD patients with delusions, and 
showed asymmetric involvement of the medial temporal lobe.13 However, a different study method was 
used; only delusional symptoms were examined, while we evaluated the whole spectrum of behavioural 
and psychological symptoms, and CT-scans were used instead of MRI. To our knowledge, other 
behavioural or psychological symptoms have never been explored in relation to MTA in AD patients. In 
non-demented patients, smaller hippocampal volume has been related to depression.28, 29 As possible 
cause of this decline in volume in depressed patients, repeated stress and associated glucocorticoid 
excess have been suggested.28 On the contrary, decrease of hippocampal volume in AD has been related 
to the extent of Alzheimer-type neuropathology.5 Probably, primary depression should be considered as 
a psychiatric illness which develops following a different mechanism than behavioural and psychological 
symptoms in AD. 
We hypothesized that vascular involvement as indicated by WMH would express with a different 
clinical presentation of behavioural and psychological symptoms compared to patients without 
vascular involvement, but we could not objectify such dissimilarity. The concept of ‘vascular depression’ 
assumes that a disruption of fronto-striatal circuits, due to vascular lesions such as WMH, predisposes, 
perpetuates or exacerbates depressive symptoms.30 We were not able to show any difference in 
prevalence of neuropsychological or behavioural symptoms in AD patients with or without vascular 
involvement, measured as WMH. However, others did find a relation in AD patients. Associations 
between WMH and apathy,14 depression,15 suicidal ideation,16 delusional misidentification17 and aberrant 
motor behaviour18 have been described. Nevertheless, none of the studies could confirm the results of the 
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previous reports and other reports were negative.19-21 Moreover, a recent study showed that patients with 
AD and with vascular dementia have similar neuropsychiatric profiles.31 This provides further support for 
our results, that within a group of AD patients, additional vascular involvement does not influence the 
behavioural and psychological profile. 
Among the strengths of our study is the relatively large study population, compared to previous 
reports. In addition, we simultaneously examined both MTA and WMH, two widely used MRI markers of 
pathology in AD, in relation to a wide spectrum of psychiatric domains using the NPI. The use of the NPI 
may also imply a limitation of the study. Information of the caregiver is used to grade the occurrence and 
severity of neuropsychiatric symptoms in patients. The results therefore may partially reflect coping style 
of the caregiver. To measure MTA and WMH we used rather crude measurements, which on the other 
hand are widely used and easily applicable in clinical practice. Possibly, however, more sophisticated 
and quantitative measures may reveal correlations that we were not able to detect. Some authors have 
proposed regional associations between brain changes an behavioural and psychological symptoms.14, 
32 In further study work it would be interesting to explore whether there was a relationship between  
behavioural and psychological symptoms and regional WMH or atrophy of specific brain regions, such as 
the amygdala or certain cortical (e.g. frontal) areas. Furthermore, the general burden of neuropsychiatric 
symptoms (median NPI score 6) in our cohort was quite low. It would be important in future studies also 
to investigate subjects with higher burden of symptoms, as it is possible that associations may then be 
seen. Nonetheless, we feel that our results suggest that the occurrence of behavioural and psychological 
symptoms in AD patients is at least partly dependent on other determinants, such as caregiver 
characteristics or genetic factors.33, 34
In conclusion, we showed that behavioural and psychological symptoms do have a high prevalence 
among AD patients, which emphasizes the importance to recognize these symptoms, especially with 
regard to care and prognosis. However, we were not able to identify a relation between behavioural and 
psychological symptoms and visual rating of MTA and WMH on MRI. Further research in this field, using 
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Abstract
Aim
We investigated the prevalence of behavioural and psychological symptoms in vascular dementia (VaD) 
from baseline data of the VantagE study and compared the severity and relative frequency of symptoms 
between small vessel VaD and large vessel VaD. 
Methods
Behavioural and psychological symptoms of 484 VaD patients included in a large multicenter clinical 
trial (registration number NCT00099216) were determined using the 12-item Neuropsychiatric Inventory 
(NPI). Symptoms were considered present when the score was ≥1. Based on MRI, patients were classified 
as having small vessel VaD (83%) or large vessel VaD (17%).
Results
Behavioural and psychological symptoms were reported in 92% of the VaD patients. The median NPI 
score of the total study population was 9 (0-76), with a median number of 3 symptoms per patient. 
Apathy (65%) was most prevalent, followed by depressive symptoms (45%), irritability (42%) and agitation/
aggression (40%). Patients with small vessel VaD reported more apathy, aberrant motor behaviour and 
hallucinations than patients with large vessel VaD (p<0.05). In contrast, patients with large vessel VaD 
reported a higher severity of agitation/aggression and euphoria (p<0.05).
Conclusion
Behavioural and psychological symptoms are common in VaD. Patients with small vessel and large vessel 
VaD demonstrate different profiles of symptoms, with especially more apathy in small vessel VaD and 
more agitation/agression in large vessel VaD. 
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Introduction
Behavioural and psychological symptoms are increasingly recognized as important clinical features 
of the dementia syndrome. These symptoms impact on the quality of life of patients with dementia, 
and have been associated with increased caregiver burden, more rapid progression of cognitive and 
functional decline, earlier institutionalization and mortality.1 In Alzheimer’s disease (AD), a prevalence 
of about 90% for behavioural and psychological symptoms has been reported.2, 3 Vascular dementia (VaD) 
is the second most common type of dementia worldwide, but in contrast to AD, only a couple of small 
studies on behavioural and psychological symptoms have been conducted in VaD patients. 
In spite of the modest body of literature, diagnostic criteria for VaD such as the criteria of the National 
Institute of Neurological Disorders and Stroke Association Internationale pour la Recherche et 
al’Enseignement en Neurosciences (NINDS-AIREN), specify that clinical features consistent with the 
diagnosis include personality and mood changes, abulia, depression and emotional incontinence.4 
Results of studies on behavioural and psychological symptoms in VaD differ slightly, but apathy, 
depressive symptoms and agitation/aggression have been reported as symptoms of highest prevalence 
and severity.5-10 These former studies are hampered by methodological shortcomings, as VaD was mostly 
not the main diagnosis under study as studies investigated a large sample of AD patients with a small 
additional group of VaD patients. Furthermore, due to differences in research populations, diagnostic 
criteria, and methods to assess presence of symptoms, results are difficult to compare.
According to the NINDS-AIREN criteria for VaD, neuroimaging is required to demonstrate 
cerebrovascular disease. VaD can be based on small vessel disease (lacunes, white matter hyperintensities 
or bilateral thalamic lesions) or large vessel disease (large territorial or strategic infarcts). We 
hypothesized that the behavioural and psychological profile of VaD patients differs according to type 
of underlying vascular disease. In small vessel VaD symptoms such as apathy would be expected due to 
disruption of corticosubcortical circuits, while in large vessel VaD a wide range of symptoms would be 
plausible, related to size, location and cortical involvement of the large vessel infarct. For example after 
ischemic stroke a broad variety of psychological and behavioural symptoms has been demonstrated with 
depressive symptoms and irritability being of highest frequency.11 In VaD, only two previous reports 
made the differentiation between small vessel and large vessel disease.6, 9 Both studies used computed 
tomography with different criteria to define small vessel and large vessel VaD, and inconsistent results 
were reported. 
The aim of this study was to determine the presence of behavioural and psychological symptoms in a 
large cohort of 484 VaD patients enrolled in a clinical trial, and to compare the severity and prevalence 
of symptoms according to type of underlying vascular disease (small vessel or large vessel) as assessed on 
magnetic resonance imaging (MRI) using well-defined radiological criteria.12 
Methods
Study design and patients
We examined the baseline data of patients enrolled into the VantagE study (registration number 
NCT00099216). The VantagE study was a multicenter, phase III, prospective, randomized, double-blind, 
placebo-controlled clinical trial of the effects of rivastigmine in patients with mild to moderate VaD.13 
Trial inclusion criteria included both fulfilment of the DSM-IV diagnostic criteria for VaD and fulfilment 
of the NINDS-AIREN criteria for VaD according to central assessment of the neuroimaging criteria.4 The 
NINDS-AIREN criteria for probable VaD were slightly modified: if neuroimaging criteria for subcortical 
VaD were met as assessed by the central neuroradiologist, patients were not required to have evidence 
of a temporal relationship between the dementia syndrome and the evidence of cerebrovascular disease. 
Accordingly, patients with cortical VaD entered the study with a clinical diagnosis of probable VaD, but 
patients with subcortical VaD were permitted to enter the study with a clinical diagnosis of possible 
VaD by NINDS-AIREN criteria. Excluded from entry in the study were patients with a current diagnosis 
of any primary neurodegenerative disorder, a current diagnosis of major depression, or a history of 
stroke within the 3 months before baseline unless the patient was considered to have fully stabilized in 
function. Patients with space occupying lesions or lobar hemorrhages were excluded. For the current 
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study, patients were required to have data on psychological and behavioural symptoms and MRI data 
(n=525). Furthermore, MRI data had to be classifiable as either fulfilment of criteria of small vessel VaD 
or fulfilment of criteria of large vessel VaD (see below; n=484). Patients who fulfilled criteria for both 
small vessel and large vessel disease were excluded (n=39). All patients gave written informed consent. 
The study was approved by the local Ethics Committees. 
Baseline clinical assessment
Diagnostic evaluation included complete medical history, physical and neurological examination, 
laboratory tests, neuropsychological testing including Mini-Mental State Examination (MMSE), and 
MRI of the brain. The use of sleep medication (yes/no), antidepressants (yes/no) and other behavioural 
regulating medication (including antipsychotics and anxiolytics; yes/no) was recorded. Global staging 
of dementia severity was performed with the Global Deterioration Scale (GDS). To evaluate behavioural 
and psychological symptoms (including delusions, hallucinations, agitation/aggression, depression/
dysphoria, anxiety, elation/euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, night 
time behaviour disturbances and appetite changes), the Neuropsychiatric Inventory (NPI, 12-item), an 
informant rated instrument, was used.14 Using the NPI, the twelve behavioural domains are evaluated 
by sample questions such as: delusions (Does the patient believe that others are stealing from him?); 
hallucinations (Does the patient talk to people who are not there?); agitation/aggression (Is the patient 
uncooperative, resistive to help from others?); depression/dysphoria (Does the patient say or act that he 
is sad or in low spirits?) anxiety (Does the patient say that he is worried about planned events?); euphoria 
(Does the patient find humour in and laugh at things that others do not find funny?); apathy (Does the 
patient seem less spontaneous and less active than usual?); disinhibition (Does the patient say crude 
things or make sexual remarks that he would not usually say?); irritability (Does the patient have sudden 
flashes of anger?); aberrant motor behaviour (Does the patient pace around the house without apparent 
purpose?); night time behaviour disturbances (Does the patient have problems with sleeping and is he 
often awake during the night?); appetite changes (Has the patient changed in appetite, eating habits 
or in physical weight?). For each neuropsychiatric domain, severity (0=absent, 1=mild, 2=moderate, 
3=severe) and frequency (0=absent, 1=occasionally, less than once per week, 2=often, about once per 
week, 3=frequently, several times per week but less than every day, 4=very frequently, once or more 
per day or continuously) are rated. Subsequently, the domain score is calculated as the product of the 
frequency and severity. The sum of the 12 domain scores provides the total NPI score (maximum score = 
144). Presence of behavioural and psychological symptoms was defined as a score of ≥ 1. 
MRI protocol
All patients underwent MRI examination before randomization. Scanners operating between 0.5 and 1.5 
Tesla were used. Axial spin-echo T2-weighted images (T2-WI; echo time [TE]: 80 to 120 ms; repetition time 
[TR]: 3000 to 4000 ms; slice thickness=5 mm); axial fluid-attenuated inversion recovery (FLAIR) images 
(TE: 110 to 150 ms; TR: 9000 to 10000 ms; inversion time: 2000 to 2200 ms; slice thickness=5 mm); and 
axial, sagittal, and coronal spin-echo T1-weighted images (T1-WI; TE: 11 to 20 ms; TR: 500 to 700 ms; slice 
thickness=5 mm) were acquired. 
Image assessment
Image assessment was performed centrally at the Image Analysis Center (VU Medical Center, 
Amsterdam, the Netherlands) by agreement of two experienced readers blinded to clinical information, 
with the use of digital image files. The assessment of vascular abnormalities included the items of the 
radiological NINDS-AIREN criteria for VaD, according to operational definitions earlier proposed.12 
Based on these criteria, patients were classified as having large vessel VaD (strategic large vessel infarct 
of the dominant hemisphere or bilateral hemispheric strokes) or small vessel VaD (white matter 
hyperintensities involving at least β of the white matter, multiple lacunes or bilateral thalamic lesions). 
Statistics
Statistical analysis was performed by means of SPSS 14.0 (SPSS Inc). To compare baseline characteristics 
between small vessel and large vessel VaD chi-squared tests were used for dichotomous variables, 
Mann-Whitney U tests for non-parametric data and independent sample t-tests for continuous data. 
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Comparison of the total NPI score, the total number of symptoms and the NPI score per symptom 
between small vessel VaD and large vessel VaD was performed using Mann-Whitney U tests. The 
prevalence of symptoms (present/not present) was compared between large vessel and small vessel VaD 
using chi-squared test. Subsequently, to control for age, sex, MMSE, dementia duration and the use of 
psychotropic medication, logistic regression analysis was performed with the individual NPI symptoms 
as dependent variable, and the different types of VaD (small vessel or large vessel) as independent 
variable.
Table 1; Patient	demographics	and	characteristics








Age	(years) 73	(8) 71	(9) <0.05
Sex		n	(%women) 154	(38%) 28	(34%) ns
Education	(years) 9	(4) 11	(4) <0.05
Duration	of	dementia	(years) 2(2) 3	(3) <0.05
Medication	–	sleep	disorder	n(%) 47	(12%) 7	(9%) ns
Medication	–	antidepressant	n(%) 94	(24%) 19	(23%) ns
Medication	–	behavioural	disorder	n(%) 47	(12%) 5	(6%) ns
MMSE	 19	(4) 19	(4) ns
GDS 4	(2-6) 4	(2-5) ns
Neuropsychiatric	Inventory	%	≥1 372	(93%) 75	(90%) ns
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Results
Baseline demographics are shown in table 1. The total population included n=484 VaD patients with a 
mean(SD) age of 72(8) yrs and included 182(38%) women. On average, patients were mildly-to-moderately 
demented with a mean MMSE score of 19(4) and a median(range) GDS score of 4(2-6). Based on the 
operational definitions for the radiological part of the NINDS-AIREN criteria, n=401(83%) had small vessel 
VaD and n=83(17%) had large vessel VaD. Patients with small vessel VaD were slightly older but had a 
shorter duration of dementia compared to patients with large vessel VaD. The percentage of patients 
using psychotropic medication was comparable in both groups. 
In the total cohort, the prevalence of any behavioural or psychological symptom was 92%, with a median 
NPI score of 9(0-76). A median number of 3(0-11) symptoms per patient was reported. Thirty-seven 
patients did not report any symptom, and two patients reported 11 of the 12 NPI symptoms. Apathy 
was the symptom that was reported most often (65% of the total population), followed by depressive 
symptoms (45%), irritability (42%) and agitation/aggression (40%). Hallucinations (6%) and euphoria (6%) 
were the symptoms that were reported most infrequently. 
No differences were found between small and large vessel VaD comparing the total NPI score and the 
total number of reported symptoms per patient. However, there appeared to be differences in the 
individual NPI symptoms between small vessel VaD and large vessel VaD (figure 1). Patients with small 
vessel VaD had a higher severity of apathy, aberrant motor behaviour and hallucinations than patients 
with large vessel VaD. In contrast, symptoms of agitation/aggression and euphoria were more severe 
in large vessel VaD compared to small vessel VaD. The prevalence of individual NPI symptoms in small 
vessel and large vessel VaD was comparable (figure 2). Patients with small vessel VaD had a numerically 
higher prevalence of apathy, aberrant motor behaviour and hallucinations than patients with large 
vessel VaD. Patients with large vessel VaD were reported as having more frequent euphoria compared 
to patients with small vessel VaD. Furthermore, the prevalence of agitation/aggression (48% compared 
to 38%) and irritability (49% compared to 41%) was higher in large vessel than small vessel VaD, but 
these differences did not reach significance. Logistic regression analysis with adjustment for age, sex, 
MMSE, dementia duration and the use of sleep-, antidepressant- and behavioural-medication, yielded 
comparable results, with a significantly higher risk of apathy and aberrant motor behaviour for small 
vessel VaD than large vessel VaD, and more euphoria in large vessel VaD (all p<0.05).  
Discussion
The main finding of the present study is that the profile of neuropsychiatric symptoms differs between 
small vessel and large vessel VaD. Apathy, aberrant motor behaviour and hallucinations are more 
severe and more prevalent in patients with small vessel VaD compared to large vessel VaD. Conversely, 
agitation/aggression and euphoria are more severe in patients with large vessel VaD.
The observed prevalence of 92% of any behavioural and psychological symptom in the total study 
population is in agreement with earlier reports.5, 8, 10, 15 Furthermore, the highest prevalence for apathy, 
followed by depressive symptoms, irritability and agitation/aggression confirms previous findings 
in populations of VaD patients.5, 6 Other studies have demonstrated a slightly different order of these 
symptoms, for example with the highest frequency of depressive symptoms, followed by agitation/
aggression and apathy.8, 10 In our study, apathy had the greatest severity and prevalence in both small 
vessel and large vessel VaD. Both severity and prevalence were even significantly higher in small vessel 
VaD than in large vessel VaD. Apathy may be induced by changes in the neural networks that generate 
and control goal directed actions, that are mostly represented within the prefrontal cortex connections 
to basal ganglia, thalamus, and limbic system structures.16 It seems plausible that disruption of the 
white matter tracts between frontal cortex and basal ganglia by severe WMH may result in apathy. 
Furthermore, other vascular damage according to the definition of small vessel disease include multiple 
lacunes (at least 2 lacunes in the frontal lobe and 2 lacunes in the basal ganglia) or bilateral thalamic 
lesions, also structures that are thought to play a role in the origin of apathy.12, 16 In line with our results, 
a recent study in patients with cerebral autosomal dominant arteriopathy with subcortical  
infarcts and leukoencephalopathy (CADASIL) demonstrated that CADASIL patients with apathy had a 
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higher WMH burden and more lacunes compared to patients without apathy.17 Furthermore, apathy 
has been recognized as important clinical feature in many neurodegenerative diseases, like Alzheimer’s 
disease, Parkinson’s disease and supranuclear palsy.18-20 We have no neuropathological confirmation 
of the diagnosis of VaD and the possibility of concomitant pathology or even misdiagnoses cannot be 
excluded. However, all our patients were carefully diagnosed by the clinical and radiological NINDS-
AIREN criteria, which are known to have a high specificity.21
Patients with large vessel VaD showed a different profile of neuropsychiatric symptoms, with a higher 
severity of agitation/aggression and euphoria compared to small vessel VaD. We expected a wide 
variety of symptoms in large vessel VaD, but the total NPI score and the total number of symptoms was 
comparable to small vessel VaD. In contrast to our results, a previous study in patients with VaD found 
a higher score for each symptom in large vessel compared to small vessel VaD, but without significant 
differences between both groups.6 However, to differentiate between small vessel and large vessel 
disease computed tomography was used instead of MRI, which may have influenced the subdivision 
of VaD patients.  A high severity of agitation/aggression in VaD and specifically to large vessel VaD has 
been previously described.6, 8, 10 Moreover, aggressive behaviour has been described as a possible - and if 
present - important  clinical feature after hemispheric infarction in territories of the anterior, middle or 
posterior cerebral arteries.22, 23 
Other symptoms were equally distributed between small vessel and large vessel VaD, like depressive 
symptoms. In accordance to the ‘vascular depression hypothesis’, subcortical vascular lesions frequently 
have been related to depression at late life, and also after ischemic stroke the risk of depression has been 
estimated at 33%.24-26 In line, we found a high prevalence of depressive symptoms in both small vessel 
(43%) and large vessel VaD (45% of the patients).
Strengths of the current study include the large study population, as it is one of the largest clinical 
series of patients affected by VaD to date. Additionally, a wide spectrum of psychiatric domains was 
investigated using the NPI. All patients were carefully screened for fulfilment of the clinical and 
radiological NINDS-AIREN criteria for VaD, generally considered accurate and specific criteria. We chose 
to use a quite low cut-off for symptoms being classed as present/absent comparable to most other 
studies in the field. However, some other reports used a NPI score >4 per symptom as cut-off to define 
‘clinically relevant symptoms’, what makes results of different studies not always interchangeable. 
Limitations include setting, entry criteria and other design features of a randomized clinical trial, which 
may have introduced a selection bias on the inclusion of patients. Although this might have led to an 
underestimation of symptoms, we do not believe it has played a role in the differences between small 
vessel and large vessel disease. Another limitation includes the study design of a cross-sectional cohort 
study, which precludes the assessment of causality or the evolution of symptomatology. Furthermore, 
the informant based structure of the NPI, which uses information of the caregiver to grade the 
occurrence and severity of neuropsychiatric symptoms in patients, may partially reflect coping style of 
the caregiver. 
In conclusion, our study shows a high prevalence of behavioural and psychological symptoms amongst 
VaD patients, both in small and large vessel VaD. Furthermore, our results demonstrate that small 
vessel VaD demonstrates a different profile of behavioural and psychological symptoms compared 
to large vessel VaD. In particular, apathy, aberrant motor behaviour and hallucinations were more 
severe and more common in small vessel than large vessel VaD, possibly reflecting disruption of white 
matter tracts between frontal cortex and basal ganglia, while euphoria and agitation/aggression were 
more severe among patients with large vessel VaD. The treatment and prognostic implications of the 
different neuropsychiatric profiles between patients with small vessel and large vessel VaD remains to 
be elucidated in further research. However, recognition of these symptoms may be of importance with 
regard to optimizing care and determining prognosis. 
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The importance of vascular factors in the aging brain and dementia is increasingly being recognized. 
In this thesis we explored different vascular MRI measures, like total cerebral blood flow, large vessel 
disease and small vessel disease, in the clinical spectrum from normal aging to dementia, and we 
assessed relations between these MRI measures and several cardiovascular characteristics and risk 
factors. In addition, we aimed to get a better view of the clinical picture of dementia, determining the 
presence of neurological signs and neuropsychiatric symptoms in memory clinic patients and specifically 
in VaD, and additionally we assessed the relation between these signs and symptoms, and different MRI 
measures.
Summary
Cerebral blood flow in elderly
We examined the total blood flow to the brain in an elderly population in Iceland. Using 2D phase-
contrast MR angiography, blood flow was measured in the basilar artery and the carotid arteries, 
and summed to calculate tCBF. In line with  literature, increasing age was associated with a decrease 
in tCBF (chapter 2.1).1 Additionally, tCBF in elderly showed to be dependent on several different 
cardiovascular characteristics, including factors related to hematology, hemodynamics, and metabolic 
and cardiac disease. Moreover, some of these inverse associations with tCBF could already be found 
with cardiovascular characteristics assessed at mid-life, highlighting the importance to recognize 
cardiovascular disease early in life. Next to cardiovascular factors, it seems obvious that characteristics of 
the brain itself can influence blood flow due to a change of demand. TCBF is known to depend on brain 
volume, and with aging, brain volume decreases (i.e. due to processes such as neurodegeneration), while 
for example ischemic vascular lesions may progress.2-4 We extended on previous cross-sectional studies 
on associations between brain volume and tCBF, by focussing in the next study on the relation between 
longitudinal measures of brain volume, including gray and white matter volume, WMH volume, and 
tCBF (chapter 2.2). Relations were shown between higher annual grey matter and whole-brain atrophy 
and both lower tCBF and brain perfusion. Furthermore, annual progression of WMH was inversely 
associated with total brain perfusion, independent of age, sex and vascular risk factors. Collectively, the 
results suggest that brain tissue damage leads to a decreased demand for constituents of blood, implying 
a cycle of reduced demand and cerebral damage.
Vascular measures on MRI in mild cognitive impairment and dementia
Subsequent to aging of the general population as described above, we were interested cerebrovascular 
MRI changes in elderly with cognitive deficits. Although previous studies showed that both MTA and 
global cortical atrophy are independent predictors of progression to dementia in MCI patients, the 
impact of vascular disease on progression to dementia is less clear.5-7 We examined patients with MCI 
and sought to determine the predictive value of cerebrovascular disease on MRI on progression to 
dementia (chapter 3.1). Consecutive MCI patients of our outpatient memory clinic were included in 
the study and followed for 2 years. The presence of MTA and vascular disease (prescence of lacunes, 
microbleeds, infarcts, severity of WMH) was determined on baseline MRIs. In MCI patients, MTA and 
markers of cerebrovascular disease predicted progression to different types of dementia. MTA was a risk 
factor for progression from MCI to AD, while conversely the presence of cerebrovascular disease was 
independently associated with progression of MCI to a non-Alzheimer dementia, mostly VaD. 
VaD has been reported to be the second most common type of dementia.8 However, hardly any large 
studies in this patient group, e.g. on clinical or MRI characteristics, have been executed. To fill this gap 
of knowledge, we examined baseline characteristics of a large population VaD patients (n=706) included 
in a multi-center clinical trial on the effects of rivastigmine in VaD (chapter 3.2). Based on MRI, patients 
were classified as having large vessel VaD, small vessel VaD, or a combination of both. We demonstrated 
that the diagnosis of VaD was in three-quarter of the patients based on small vessel disease, compared 
to just one fifth of the patients who fulfilled the criteria for large vessel VaD and one out of ten patients 
who fulfilled criteria for both types of VaD. Patients with small vessel disease were older and less 
educated, and showed more cortical atrophy and MTA than patients with large vessel disease. In contrast, 
patients with large vessel disease had more hypercholesterolemia and cardiac risk factors compared to 
patients with small vessel disease, illustrating heterogeneity between small vessel and large vessel VaD.
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Neurological signs in dementia in relation to MRI measures 
Next, we examined clinical features, other than cognition, in dementia, and sought to determine 
relations between clinical symptoms and MRI measures. To start with, we assessed the presence of 
extrapyramidal and unilateral signs in memory clinic patients, with AD, VaD, MCI and subjective 
complaints (chapter 4.1). Furthermore, WMH volumes on MRI were extracted automatically with a 
method based on a Fuzzy interference system. We found extrapyramidal signs in 10% and unilateral 
signs in 12% of the patients. Adjusted for age and sex, extrapyramidal signs occurred more often in 
VaD compared to patients with subjective complaints. Unilateral signs were more prevalent in all 
groups compared to patients with subjective complaints. Moreover, we found that if unilateral signs 
were present, patients with subjective complaints and VaD showed more WMH, whereas there was no 
relation in AD and MCI. 
Subsequently, we examined the presence of neurological signs more extensively in VaD (chapter 4.2), 
determining the presence of a wide range of neurological signs in a large group of VaD patients and 
comparing the relative frequency of specific neurological signs dependent on type of cerebrovascular 
disease. Literature on this interesting topic is scarce, although presence of neurological signs is 
required according to current diagnostic criteria of VaD.9 We found a median number of 4.5 signs per 
patient, with reflex asymmetry as most prevalent symptom. Measures of small vessel disease were 
associated with an increased prevalence of dysarthria, dysphagia, parkinsonian gait disorder, rigidity 
and hypokinesia and as well to hemimotor dysfunction. By contrast, in the presence of a cerebral 
infarct, aphasia, hemianopia, hemimotor dysfunction, hemisensory dysfunction, reflex asymmetry and 
hemiplegic gait disorder were more often observed.  
Neuropsychiatric symptoms in Alzheimer’s disease and vascular dementia
In the final part, we determined the prevalence of behavioural and psychological symptoms, first 
in AD (chapter 5.1) and second in VaD (chapter 5.2). The prevalence of symptoms was high in both 
populations. Additionally, both in AD and VaD, apathy was the most prevalent symptom. In AD, we 
found no differences in prevalence of symptoms according to MTA or WMH, as rated on MRI, suggesting 
that the occurrence of symptoms in AD depends on other determinants, such as coping style or genetic 
make-up. Relations between specific distributions of WMH or atrophy and neuropsychiatric symptoms 
have also been suggested, as for example more sophisticated MRI measures found neuroanatomical 
correlates with the prevalence of symptoms in AD, such as apathy and grey matter density loss in 
the anterior cingulate and frontal cortex bilaterally.10 Future studies are needed to confirm these 
hypotheses. In VaD, we found that patients with small vessel and large vessel VaD demonstrated 
different profiles of symptoms. Especially more apathy was reported in small vessel VaD and more 
agitation/agression in large vessel VaD, further underlining the heterogeneity between these two 
groups.   
Discussion
Interest in vascular factors in relation to brain aging and dementia exists since long ago, for example 
as described by Alois Alzheimer who published several articles on ‘mental disturbances’ of vascular 
origin between 1895-1913.11 Alzheimer was a respected neuropathologist (as well as neurologist and 
psychiatrist), and tried to link clinical features with vascular pathologies of the brain. Then, with the 
introduction of MR imaging in the mid-eighties, the research field changed enormously. Visualization of 
vascular abnormalities in the brain during life helps us to learn more about the origin of these changes 
and their clinical consequences. Due to the relatively novelty of the technique, MR imaging itself and 
methods to analyze imaging files underwent rapid developments and became more and more available, 
making examination of large populations possible. 
Striking elements of this thesis are the investigation of several vascular MR measures like total cerebral 
blood flow, WMH and microbleeds. Furthermore, we examined the whole spectrum of normal aging 
to MCI and dementia, and explored both risk factors and clinical features. First, we showed relations 
between cardiovascular characteristics and longitudinal brain measures and tCBF in elderly. 
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Second, we demonstrated relations between vascular MRI measures and progression of MCI to dementia, 
and described different risk factor profiles for small vessel and large vessel VaD. Thirdly, we reported 
the prevalence of neurological signs and neuropsychiatric symptoms in memory clinic patients and 
specifically in VaD and determined relations between presence of signs and symptoms and different 
MRI measures. In our opinion, with these different aspects described in this thesis we contribute to the 
understanding of vascular changes on brain MRI and their clinical sequelae. 
Methodological considerations
Selection of study population
A strong aspect of this thesis is the use of different research populations and study designs, including 
a population based cohort study, the study of memory clinic patients and analyses of baseline data of 
a large clinical trial. However, every study design has its own advantages and disadvantages. Strengths 
of population based studies, as applied in the first two studies of this thesis, are that besides survival 
bias, selection bias hardly plays a role. Furthermore, data are uniformly and prospectively collected. 
This allowed not only the examination of multiple cardiovascular characteristics of a large population, 
but additionally, with the combination of mid-life and late-life data, life course associations with tCBF 
could be examined. However, to gain more statistical power, for the study of diseases it is easier to 
examine cohorts of patients in a clinical setting. Patients visiting our outpatient memory clinic were 
studied to learn more about MCI and AD, and the presence of neurological signs was examined in the 
whole spectrum of patients with subjective complaints, MCI, AD and VaD. Prevalence of symptoms was 
compared between patients with subjective complaints and MCI or dementia. It must be noted that 
patients with subjective complaints have been shown to have a higher risk on progression to dementia 
compared to controls, and therefore might not be comparable to healthy aging.12 VaD has been reported 
as second most prevalent type of dementia, however, the number of patients analyzed in our memory 
clinic was relatively small.8 To be able to examine VaD patients more extensively, baseline data of a large 
multicenter clinical trial in VaD were examined, including one of the largest clinical series of patients 
affected by VaD to date. Nevertheless, the study design of a clinical trial may have had an effect on the 
inclusion of patients and perhaps has limited the possibility to generalize the results to the VaD patient 
group as a whole. Common to all three studies on VaD described in this thesis we found differences 
between patients with small vessel VaD and large vessel VaD, including differences in risk factor profiles, 
prevalence of neurological signs and severity of behavioural and psychological symptoms. Caution must 
be taken in interpretation of these results since all three studies covered the same study population, 
which might have had its influence on the consistency of the heterogeneity. 
Diagnosis
The inevitable circularity of some studies might be a concern. In the study of MCI patients, it might 
not be surprising that patients with extensive vascular abnormalities on brain MRI are later diagnosed 
with VaD instead of AD. At baseline, none of the patients fulfilled the clinical criteria of dementia, and 
progression to dementia itself will not have been influenced by the MRI scan. Nonetheless, in assessing 
the different dementia types, MRI may have been used as a supportive element and therefore may have 
induced some circularity. Comparable circularity is conceivable for the study of neurological signs in 
VaD patients – that by definition are required to have neurological signs. However, we feel that the 
description of the relative frequency of a large number of neurological signs and their relations to 
specific types of imaged vascular damage, indeed adds to the field. Care should be taken though, that the 
NINDS-AIREN criteria, although generally considered accurate and specific, have been shown not to be 
interchangeable with other criteria for VaD.13 Another potential limitation in the patient-related studies 
is misdiagnosis. Then again, all patients were carefully screened for fulfilment of current diagnostic 
criteria. 
MRI techniques and assessments
Finally, different techniques were used to analyze the MR images. The technique we chose to measure 
cerebral blood flow has been shown to be non-invasive, fast and accurate.14 On the other hand, it 
is a rather rough method to determine the total amount of blood flowing to the brain. To measure 
blood flow at brain tissue level, regional CBF per 100g brain tissue per minute can be assessed using 
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techniques such as positron emission tomography or dynamic contrast-enhanced MRI. However, these 
techniques are invasive and complex, and difficult to use in large study populations (- an exception may 
be arterial spin labelling [ASL], a novel MRI technique).15 
Structural MRI measures were assessed sometimes visually, such as counting the number of lacunes or 
microbleeds or using visual rating scales, and sometimes we used fully-automatic volumetric methods 
for example to measure WMH volumes. Although an equal validity between visual ratings scales and 
volumetric methods has been reported, others suggested that volumetry is more sensitive to detect small 
group differences.16, 17 Finally, we used operational definitions for the NINDS-AIREN criteria for VaD, 
which were carefully applied by central assessment. However, the radiological criteria to diagnose VaD 
are known to be complex, especially for inexperienced raters.18 A low reliability in inexperienced raters 
has been described, and due to these problems with applicability, comparison of our findings to other 
studies may be difficult. 
Clinical implications 
Vascular risk factors
In our study on cardiovascular characteristics, we found associations between mid-life characteristics 
and tCBF at late-life. Accordingly, careful control of cardiovascular risk factors early in life to prevent 
cerebrovascular disease appears to be an important goal for clinical practice. Additionally, strong 
relations between late-life cardiovascular characteristics and late-life tCBF were shown, including 
characteristics related to hematology, hemodynamics and cardiac function. These results underline the 
significance to be aware of vascular determinants in the older population and keep them in optimal 
condition. Ultimately, vascular risk factors may lead to such low blood flow to the brain that ischemic 
small vessel disease or stroke will be the consequence. Additionally, risk factors such as high blood 
pressure and diabetes have been associated with brain atrophy on MRI.19, 20 Moreover, vascular disease 
has been shown to increase the risk of both VaD and AD.21 For example hypertension has been reported 
to triple the risk of VaD, in line with our finding in VaD patients, where hypertension appeared to be 
the most prevalent risk factor with a prevalence of 80% in the whole cohort.21 In patients with dementia 
therapeutic options are relatively scarce, and risk factor related therapy in patients who already have 
dementia seems a logical step to prevent further vascular damage to the brain. Effects could also be 
expected in AD, as vascular factors were reported to be related to disease progression.22, 23 Nonetheless, 
the role of cardiovascular medications in dementia has not been firmly established yet, and results 
can be confusing. The use of statins and beta-blockers has been reported to slow the rate of functional 
decline in AD.24 In VaD patients, the use of antiplatelet or anticoagulant medication was related to a 
longer life expectancy than those without.25, 26 On the contrary, AD patients using antiplatelet therapy 
had no benefit, but instead the use increased the risk of serious bleedings.27 Furthermore, anticoagulant 
medication has been associated to a greater risk of intracerebral heamorrhages in the presence of 
microbleeds on MRI, which can be of high prevalence in dementia.28 Future research to the effects of 
cardiovascular medication in dementia is needed. 
Clinical features
Subsequent to the relation between cerebrovascular MRI measures and cardiovascular factors, we were 
interested in the relation between cerebrovascular measures and clinical features in dementia. Our 
results indicate that next to cognitive impairment, also neurological signs, such as extrapyramidal and 
unilateral signs, as well as behavioural and psychological symptoms are highly prevalent in dementia. 
In patients with dementia, both the presence of neurological signs and neuropsychiatric symptoms 
have been related to a worse prognosis, higher cost of care and earlier institutionalisation.29-31 The 
high prevalence of symptoms in our studies highlight the importance to recognize these symptoms in 
clinical practice. In VaD, we found associations between WMH and other cerebrovascular disease, and 
the prevalence of neurological signs and neuropsychiatric symptoms, what seems to implicate that 
prevention of cerebrovascular damage may lead to prevention of these signs and symptoms. In AD it 
seems to be more complex. We did not find a relation in AD between severity of WMH and the prevalence 
of neurological signs or neuropsychiatric symptoms, suggesting that in AD these signs and symptoms 
depend on other characteristics. Future research is needed to unravel the structural underpinnings of 
both neurological signs and neuropsychiatric symptoms in AD.  
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Future perspectives
We examined cerebrovascular disease in the aging brain, using MRI to measure vascular changes. 
However, the research field is broad and there were several aspects we could not assess. For example 
more longitudinal research is needed to examine changes in cerebral blood flow overtime, to compare 
baseline and follow up blood flow and analyse intracerebral and clinical consequences of flow 
alterations. Furthermore, with the use of other techniques it is possible to examine brain perfusion; 
blood flow irrigating the brain expressed in milliliters per 100 gram of tissue per minute, corresponding 
to microcirculatory tissue perfusion rather than the flow of the main vascular axes. Techniques, like PET 
and dynamic susceptibility weighted MRI, are often complex and invasive, but hopefully will be available 
and applicable to large study populations one day. The same holds for novel MRI techniques, where for 
example diffusion tensor imaging has shown promising results to determine true white matter damage 
in cerebral small vessel disease, but availability of this technique needs to increase.32 
Vascular measures
Although the radiological NINDS-AIREN criteria include important vascular disease such as infarcts, 
lacunes and WMH, some other measures are not incorporated. For example cortical microinfarcts seem 
also to contribute significantly to the progression of cognitive deficits in brain aging.33 Additionally, 
microbleeds are not mentioned in the criteria, while in subcortical VaD the presence of microbleeds has 
been related to cognitive functioning.34 Moreover, in our study in MCI patients, the baseline prevalence 
of microbleeds appeared to be higher in patients who progressed to a non-Alzheimer dementia (mostly 
VaD) than in patients who remained stable, which also seems to imply a relation between microbleeds 
and cognitive functioning. A fascinating fact regarding microbleeds is their relation to both to vascular 
disease and cerebral amyloid angiopathy. Cerebral amyoloid angiopathy is a cerebrovascular pathology 
which is found with an incidence of 80-98% in AD patients.35 Therefore, microbleeds can potentially 
be regarded as the missing link between vascular disease and AD pathology. However, the origin of 
microbleeds in terms of risk factors and pathogenesis, as well as clinical consequences in both VaD 
and AD have to be elucidated in future research. Another issue include the radiological NINDS-AIREN 
criteria itself. The NINDS-AIREN criteria were designed in 1993, with recognition of the added value 
of neuroimaging.9 At this moment, more than sixteen years later, the availability and the knowledge 
of brain imaging have remarkably improved. Now seems the time for a critical reappraisal of the 
criteria. For example involvement of at least 25% of the total white matter is considered sufficient for a 
diagnosis of VaD, but this percentage was set purely arbitrarily.9 Moreover, application of this threshold 
is also debatable. Further work is needed to improve the quality of the radiological criteria for VaD and 
simultaneously increase their interobserver agreement. 
Diagnosis of VaD
Proceeding with the above, the NINDS-AIREN criteria (which we used to diagnose VaD) are the diagnostic 
criteria that are currently most often used in VaD studies.9 However, also other criteria such as the 
criteria of the International Statistical Classification of Diseases, tenth revision (ICD-10) and the 
Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM IV) are in use. 31, 32 Since 
different criteria have been shown not to be interchangeable, comparison of different studies can be 
difficult.13, 36, 37 In this day and age of globalisation, we plead for the application of only one and the same 
set of criteria, enabling everybody speak the same “clinical language”. In addition, we believe that, next 
to a reappraisal of the radiological criteria, further work is needed to refine the general criteria. We 
showed that cerebrovascular disease underlying VaD consisted in the majority of small vessel disease. 
Although small vessel disease is considered to develop gradually, the NINDS-AIREN criteria require a 
temporal relation between evidence of vascular disease and dementia.9, 38 In our opinion, the temporal 
criterion can be omitted in the criteria for small vessel VaD. Furthermore, we demonstrated several 
differences in risk factor and clinical profiles between patients with small vessel VaD and large vessel 
VaD. The difference between these two types of VaD should at least be included in a more pronounced 
way in new VaD criteria. Finally, currently evidence of cerebrovascular disease includes next to imaging 
criteria the presence of neurological signs. However, with the widespread availability of imaging 
nowadays to establish the presence of vascular in a more direct way, it could be argued that the criterion 
of neurological signs should not be required.
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VaD – AD
AD pathology and cerebrovascular disease are both very common, and as a result they inevitably occur 
together in many cases.39 However, the association seems to be more complex than a mere coincidence, 
as there is now evidence for a significant AD – VaD overlap in terms of risk factors and clinical features. 
It has been suggested that AD and cerebrovascular disease may work synergistically to cause cognitive 
decline, but until now, it remains to be elucidated how the two interact. For example in the study of 
MCI patients, we found no predictive value of progression to AD of any of the vascular measures. On 
the other hand, in our sample VaD patients, moderate to severe MTA and cortical atrophy were shown, 
suggesting a relation between vascular disease and atrophy. Future research is needed to confirm our 
findings and further elucidate the interactions between vascular disease and AD pathology. 
Clinical features
More research is necessary to the origin of clinical features in dementia. As earlier described, we did not 
find a relation between WMH and the presence of neurological signs or neuropsychiatric symptoms in 
AD patients. Possibly, in AD these signs and symptoms depend on other determinants, such as caregiver 
characteristics or genetic make-up. Additionally, it would be interesting to examine clinical features of 
AD in relation to more specific brain regions, looking at vascular disease, atrophy or regional cerebral 
blood flow. Recently, with the use of voxel-based-morphometry, certain foci of grey matter loss have 
been related to different neuropsychiatric symptoms.10 Future studies of this kind may help to clarify the 
mechanisms and brain circuits involved in certain clinical features in dementia.  
In conclusion, we hope that this thesis will result in further study on the significance of vascular disease 
in aging and dementia, emphasizing the combination of state of art novel brain imaging techniques with 
rigorous clinical evaluation and etiological and treatment studies. 
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Conclusions
The following conclusions can be drawn from the studies presented in this thesis:
1.  Total blood flow to the brain in elderly is dependent on several cardiovascular  
characteristics of which hemoglobin and hematocrit levels, diastolic blood  
pressure and cardiac disease are the most important. Additionally the associations  
with tCBF can be traced back to cardiovascular characteristics at mid-life.
2.  Longitudinal MRI measures, as whole-brain and grey matter atrophy, and progression  
of WMH per year, predict total blood flow to the brain in elderly.
3.  In patients with MCI, MTA and markers of cerebrovascular disease predict progression  
to different types of dementia. MTA is a risk factor for progression from MCI to AD,  
while conversely the presence of cerebrovascular disease is associated with progression  
of MCI to a non-Alzheimer dementia, mostly VaD. 
4.  Cerebrovascular disease underlying VaD consists in the majority of small vessel  
disease and in about one fifth of large vessel disease. Heterogeneity exist between  
these two groups with regard to risk factor profile and atrophy scores on MRI, the  
severity of the atrophy being higher in patients with small vessel disease compared  
to patients with large vessel disease. In contrast, patients with large vessel disease  
have more cardiac risk factors compared to patients with small vessel disease. 
5.  Neurological signs are common in a memory clinic population,  
but are only modestly related to WMH.
6.   In VaD patients, specific neurological signs differ according to type of imaged  
cerebrovascular disease, with small vessel disease being often seen with more  
subtle signs, including extrapyramidal signs, whereas large vessel disease is  
more often related to lateralized sensorimotor changes and aphasia.
7.  Behavioural and psychological symptoms have a high prevalence among AD patients,  
but there is no difference in prevalence of these symptoms according to MTA or WMH  
as rated on MRI.
8.  In VaD, behavioural and psychological symptoms are commonly reported. Small  
vessel VaD and large vessel VaD show different profiles of symptoms, with especially  
more apathy in small vessel VaD and more agitation/aggression and euphoria  
in large vessel VaD. 
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Nederlandse samenvatting
Van normale veroudering tot dementie;
Risicofactoren en klinische verschijnselen in relatie tot vasculaire veranderingen op MRI van de hersenen
Het aantal ouderen in de westerse wereld neemt met de vergrijzing snel toe. Als gevolg van deze 
vergrijzing stijgt ook de prevalentie van bepaalde ziekten, zoals bijvoorbeeld cardiovasculaire ziekte 
(=hart- en vaatziekte) en dementie. Het is duidelijk dat het hart en de hersenen aan elkaar gerelateerd 
zijn, en dat een tekort aan bloedtoevoer zal leiden tot schade in de hersenen. Een belangrijke manier  
om de aanwezigheid van cerebrovasculaire ziekte gedurende het leven te visualiseren en te onderzoeken, 
is met behulp van magnetic resonance imaging (MRI).
MRI onderzoek kan op verschillende manieren toegepast worden. Zo kan met behulp van een 2D phase-
contrast MRI de bloed flow (volume van het bloed dat per tijdseenheid stroomt [eenheid = mL/min]) in 
de twee arteriae carotes (hals slagaderen) en de arteria basilaris (derde slagader die naar het achterste 
deel van de hersenen gaat) bepaald worden. Door de flow uit deze slagaderen op te tellen kan men de 
totale bloed flow naar de hersenen berekenen. Daarnaast kan structurele MRI gebruikt worden om de 
aanwezigheid van large vessel disease (schade aan de grote bloedvaten) en small vessel disease (schade 
aan de kleine bloedvaten) aan te tonen. Bij large vessel disease is er sprake van een (corticaal) infarct 
in het stroomgebied van een groot bloedvat. Belangrijke maten van small vessel disease zijn lacunaire 
infarcten (kleine infarcten met een maximale grootte van 1cm), microbloedingen en ischemische 
(ischemie=onvoldoende doorbloeding) witte stof afwijkingen (oplichtende vlekjes op de MRI scan waarvan 
de gedachte is dat zij veroorzaakt worden door het minder goed functioneren van de kleine bloedvaatjes 
in de witte stof van de hersenen, in het Engels white matter hyperintensities [WMH]). 
Cerebrovasculaire afwijkingen op MRI komen veel voor bij ouderen. Verder is er aangetoond dat de 
prevalentie van deze vasculaire afwijkingen hoger is bij patiënten met dementie, alhoewel de klinische 
implicaties niet geheel duidelijk zijn.
Dementie wordt gekarakteriseerd door een verkregen stoornis van het cognitief functioneren (met 
betrekking tot het denkvermogen) in ten minste twee domeinen, die interfereren met het normale 
dagelijkse leven. Het meest voorkomende type dementie is de ziekte van Alzheimer (in het Engels 
Alzheimer’s disease [AD]), gevolgd door vasculaire dementie (VaD; dementie veroorzaakt door schade aan 
de bloedvaten in de hersenen). De ervaring leert dat VaD moeilijk is te definiëren. Vroeger nam men aan 
dat large vessel disease de belangrijkste oorzaak was van VaD, maar het wordt steeds duidelijker dat ook 
juist small vessel disease een belangrijke rol speelt. De criteria van de ‘National Institute of Neurological 
Disorders and Stroke Association Internationale pour la Recherche et al’Enseignement en Neurosciences’ 
(NINDS-AIREN) zijn op dit moment de criteria die het meest gebruikt worden voor de definitie van VaD. 
Mogelijk door de strikte criteria en de moeilijkheden met de definitie is er relatief weinig onderzoek 
verricht in de groep VaD patiënten naar bijvoorbeeld risicofactoren en klinische verschijnselen. 
Het idee bestaat dat dementie zich vaak langzaam ontwikkelt en dat dit vooraf gegaan kan worden door 
cognitieve stoornissen die nog niet voldoen aan de criteria voor dementie. Dit stadia wordt ook wel 
mild cognitive impairment (MCI) genoemd. Omgekeerd bestaat het idee dat mensen die voldoen aan de 
criteria voor MCI, een verhoogd risico lopen op het krijgen van dementie, maar de invloed van vasculaire 
factoren is hierbij niet duidelijk. 
Het klinisch beeld van dementie bestaat per definitie voor een belangrijk deel uit cognitieve stoornissen, 
zoals een stoornis van het geheugen, maar ook stoornissen van bijvoorbeeld aandacht, oriëntatie 
of taal komen veel voor. Daarbij wordt het de laatste tijd steeds duidelijker dat ook andere klinische 
symptomen belangrijk zijn bij dementie, zoals lichamelijke afwijkingen die gevonden kunnen worden bij 
neurologisch onderzoek, of neuropsychiatrische symptomen, zoals depressieve symptomen of agressief 
gedrag. Er is echter nog weinig onderzoek verricht naar de mate van voorkomen van deze symptomen bij 
dementie, of om welke specifieke symptomen het gaat. 
Het doel van dit proefschrift was om verschillende cerebrovasculaire MRI maten te onderzoeken, zoals 
cerebrale bloed flow, small vessel en large vessel disease, in het klinische spectrum van normale  
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veroudering tot dementie en om te zoeken naar relaties tussen deze MRI afwijkingen en mogelijke 
risicofactoren voor het krijgen van deze afwijkingen. Tevens wilden we een beter beeld krijgen van het 
klinische beeld van dementie, met betrekking tot het voorkomen van neurologische afwijkingen bij 
lichamelijk onderzoek en neuropsychiatrische symptomen, waarbij ook de relatie met verschillende MRI 
maten werd onderzocht. 
Cerebrale bloed flow in ouderen
In de eerste studies onderzochten we de totale bloed flow naar de hersenen in een oudere populatie in 
IJsland. Met gebruik van 2D-phase contrast MR angiografie werd de bloed flow gemeten in de arteriae 
carotes en in de arteria basilaris en opgeteld om totale cerebrale bloed flow (tCBF) te verkrijgen. 
Overeenkomstig met de literatuur, vonden we dat het toenemen van de leeftijd geassocieerd was 
met een afname van tCBF (hoofdstuk 2.1). Verder bleek tCBF op oudere leeftijd af te hangen van 
verschillende cardiovasculaire factoren, zoals factoren gerelateerd aan hematologie, hemodynamica en 
metabole en cardiale ziekte. Enkele van deze omgekeerde associaties met tCBF konden zelfs gevonden 
worden met cardiovasculaire factoren die bepaald waren op middelbare leeftijd. Deze bevindingen 
benadrukken het belang om cardiovasculaire risicofactoren vroeg in het leven te herkennen. Naast 
cardiovasculaire factoren lijkt het duidelijk dat ook karakteristieken van de hersenen zelf de bloed 
flow kunnen beïnvloeden door een verandering in vraag en behoefte. Het is bekend dat tCBF afhangt 
van het totale hersenvolume, en met veroudering neemt het hersenvolume af, terwijl bijvoorbeeld 
ischemische vaatschade zich juist kan ontwikkelen. In de volgende studie hebben we ons daarom gericht 
op de relatie tussen longitudinale maten van hersenvolume, zoals volumes van grijze en witte stof en 
ischemische witte stof afwijkingen, en tCBF (hoofdstuk 2.2). We vonden relaties tussen de hoeveelheid 
atrofie (=afname van volume) van de grijze stof en van het globale hersenvolume per jaar, en een lagere 
tCBF en een lagere perfusie van de hersenen. Ook was de jaarlijkse progressie van ischemische witte stof 
afwijkingen omgekeerd gerelateerd aan de totale hersenperfusie, onafhankelijk van leeftijd, geslacht 
en vasculaire risicofactoren. Deze bevindingen suggereren dat schade aan hersenweefsel leidt tot een 
afname van de vraag naar bloed, wat een cirkel van afname van vraag en hersenschade doet vermoeden.
Vasculaire maten op MRI bij MCI en dementie
Volgend op veroudering in de algemene populatie zoals hierboven beschreven, waren we geïnteresseerd 
in cerebrovasculaire MRI veranderingen in ouderen met cognitieve problemen. Alhoewel eerdere 
studies reeds hebben laten zien dat zowel atrofie van de mediale temporaalkwab (MTA; de mediale 
temporaalkwab is een structuur aan de zijkant van het hoofd die een belangrijke rol speelt bij 
het functioneren van het geheugen) en globale hersenatrofie onafhankelijke voorspellers zijn van 
progressie naar dementie bij patiënten met MCI, is de impact van vasculaire ziekte op progressie naar 
dementie minder duidelijk. Wij onderzochten patiënten met MCI om de voorspellende waarden van 
cerebrovasculaire ziekte op MRI op progressie naar dementie te bepalen (hoofdstuk 3.1). MCI patiënten 
van onze polikliniek werden geincludeerd in de studie en gedurende 2 jaar gevolgd. De aanwezigheid van 
MTA en vasculaire ziekte (aanwezigheid van lacunes, microbloedingen, infarcten, ernst van ischemische 
witte stof afwijkingen) werd bepaald op de baseline MRI’s. We vonden dat in MCI patiënten, MTA en 
de maten voor cerebrovasculaire ziekte progressie naar verschillende type dementie voorspelden. MTA 
was een risicofactor voor progressie van MCI naar AD, terwijl de aanwezigheid van cerebrovasculaire 
afwijkingen onafhankelijk was geassocieerd met progressie van MCI naar een non-Alzheimer dementie, 
met name naar VaD. 
Er wordt aangenomen dat VaD de op een na meest voorkomende dementie is. Echter, er zijn 
nauwelijks grote studies in deze patiëntengroep beschreven, over bijvoorbeeld klinische maten of MRI 
karakteristieken. Om dit gat te vullen hebben wij de baseline karakteristieken van een grote populatie 
VaD patiënten (n=706) onderzocht die participeerden aan een multi-center klinische trial naar de effecten 
van rivastigmine in VaD (hoofdstuk 3.2). Op basis van de MRI werden patiënten geclassificeerd als 
large vessel VaD (vasculaire dementie op basis van schade aan de grote bloedvaten), small vessel VaD 
(vasculaire dementie op basis van schade aan de kleine bloedvaten), of een combinatie van beide. We 
lieten zien dat de diagnose VaD in driekwart van de patiënten gebaseerd was op small vessel disease, in  
vergelijking met ongeveer één vijfde van de patiënten die voldeden aan de criteria voor large vessel VaD 
en één op de tien die voldeden aan de criteria voor beide type VaD. Patiënten met small vessel disease 
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waren ouder en hadden minder onderwijs gevolgd, en ze lieten meer corticale atrofie en meer MTA 
zien op de MRI dan patiënten met large vessel disease. Daarentegen, patiënten met large vessel disease 
hadden vaker hypercholesterolemie en vaker cardiale risicofactoren in vergelijking met patiënten met 
small vessel disease, wat de heterogeniteit illustreert tussen small vessel en large vessel VaD. 
Neurologische symptomen bij dementie in relatie tot MRI maten
Vervolgens onderzochten we klinische verschijnselen in dementie (anders dan cognitie) en bepaalden 
we de relaties tussen deze klinische symptomen en verschillende MRI maten. Om te beginnen bepaalden 
we de aanwezigheid van extrapyramidale en unilaterale symptomen in patiënten die onze geheugen 
polikliniek bezochten, waaronder patiënten met AD, VaD, MCI en patiënten met subjectieve klachten 
(= patiënten die met klachten naar de geheugenpolikliniek komen, maar waarbij de onderzoeken 
niet afwijkend zijn) (hoofdstuk 4.1). Tevens werden op MRI van de hersenen de volumes bepaald van 
ischemische witte stof afwijkingen. We vonden extrapyramidale symptomen in 10% en unilaterale 
symptomen in 12% van de patiënten. Gecorrigeerd voor leeftijd en geslacht, werden er meer 
extrapyramidale symptomen gevonden in VaD in vergelijking met patiënten met subjectieve klachten. 
Unilaterale symptomen hadden een hogere prevalentie in alle groepen in vergelijking met patiënten met 
subjectieve klachten. Daarbij vonden we dat als unilaterale symptomen aanwezig waren, patiënten met 
subjectieve klachten en VaD ook meer ischemische witte stof afwijkingen hadden, terwijl er geen relatie 
was in AD en MCI. 
Vervolgens hebben we de aanwezigheid van neurologische afwijkingen bij lichamelijk onderzoek 
uitgebreider onderzocht in VaD (hoofdstuk 4.2). Hiervoor hebben we de aanwezigheid van een groot 
aantal symptomen onderzocht in een grote groep VaD patiënten en de prevalentie van symptomen 
vergeleken aan de hand van onderliggende cerebrovasculaire afwijkingen op MRI. Literatuur over dit 
interessante onderwerp is zeldzaam, terwijl volgens de huidige criteria voor VaD de aanwezigheid van 
neurologische afwijkingen vereist is. Wij vonden een mediaan aantal van 4.5 symptomen per patiënt, 
met asymmetrische peesreflexen als meest voorkomende bevinding. Maten van small vessel disease 
waren geassocieerd met een verhoogde prevalentie van de volgende symptomen: dysarthrie, dysfagie, 
parkinsonachtige loopstoornis, rigiditeit en hypokinesie en ook hemimotore dysfunctie. Daarentegen, 
in de aanwezigheid van een cerebraal infarct werden afasie, hemianopsie, hemimotore dysfunctie, 
hemisensorische dysfunctie, asymmetrie van de peesreflexen en een hemiplegische loopstoornis vaker 
gevonden.
Neuropsychiatrische symptomen bij de ziekte van Alzheimer en vasculaire dementie
In het laatste deel van dit proefschrift hebben we de prevalentie van neuropsychiatrische symptomen 
onderzocht, eerst in AD (hoofdstuk 5.1) en daarna in VaD (hoofdstuk 5.2). De prevalentie van 
neuropsychiatrische symptomen was in beide gevallen hoog, en zowel in AD als in VaD was apathie het 
symptoom wat het meeste voorkwam. In AD vonden we geen verschil in het voorkomen van symptomen 
in relatie tot het hebben van MTA of ischemische witte stof afwijkingen op MRI, wat suggereert dat de 
symptomen in AD afhankelijk zijn van andere factoren, zoals bijvoorbeeld genetische factoren. Aan de 
andere kant zou het ook zo kunnen zijn dat neuropsychiatrische symptomen gerelateerd zijn aan een 
specifieke verdeling/ specifieke locaties van atrofie of ischemische witte stof afwijkingen. Toekomstige 
studies zijn nodig om deze hypothese te bevestigen. In VaD vonden we dat patiënten met small vessel 
VaD en met large vessel VaD verschillende profielen van neuropsychiatrische symptomen lieten zien.  
Zo werd er vaker apathie gemeld in small vessel VaD en meer agitatie/agressie in large vessel VaD. 
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Conclusies
Gebaseerd op de studies uit dit proefschrift kunnen de volgende conclusies getrokken worden:
1.  De totale bloed flow naar de hersenen bij ouderen is afhankelijk van verschillende cardiovasculaire 
karakteristieken waarvan de waarde van hemoglobine en hematocrit, diastolische bloeddruk en 
aanwezigheid van cardiale ziekte het belangrijkste zijn. Daarbij kunnen de associaties met tCBF 
teruggevoerd worden tot cardiovasculaire karakteristieken op middelbare leeftijd.
2.  Longitudinale MRI maten, zoals atrofie van het globale hersenvolume en van de grijze stof,  
en progressie van ischemische witte stof afwijkingen per jaar voorspellen de totale bloed flow  
naar de hersenen bij ouderen.
3.  Bij patiënten met MCI voorspellen MTA en maten van cerebrovasculaire ziekte  progressie naar 
verschillende type dementie. MTA is een risicofactor voor progressie van MCI naar AD, terwijl de 
aanwezigheid van cerebrovasculaire afwijkingen geassocieerd is met progressie van MCI naar een 
non-Alzheimer dementie, met name VaD. 
4.  Onderliggende cerebrovasculaire afwijkingen bij VaD bestaan in de meerderheid uit small vessel 
disease en in ongeveer één vijfde uit large vessel disease. Er bestaat heterogeniteit tussen deze twee 
groepen met betrekking tot risicofactor profiel en atrofie scores op MRI, waarbij de atrofie ernstiger is 
bij patiënten met small vessel disease in vergelijking met large vessel disease. Daarentegen, patiënten 
met large vessel disease hebben meer cardiale risicofactoren in vergelijking met patiënten met small 
vessel disease. 
5.  Neurologische afwijkingen bij lichamelijk onderzoek worden vaak gevonden bij patiënten die 
een geheugenpolikliniek bezoeken, maar ze zijn maar matig gerelateerd aan het voorkomen van 
ischemische witte stof afwijkingen op MRI.
6.  Bij patiënten met VaD verschillen de neurologische afwijkingen bij lichamelijk onderzoek aan de 
hand van de cerebrovasculaire afwijkingen op MRI. Bij small vessel disease worden vaak meer subtiele 
symptomen gevonden, waaronder extrapyramidale symptomen, terwijl large vessel disease vaker 
gerelateerd is aan gelateraliseerde sensorische en motorische symptomen en afasie. 
7.  Neuropsychiatrische symptomen komen vaak voor bij AD, maar er is geen verschil in prevalentie van 
deze symptomen aan de hand van het voorkomen van MTA of ischemische witte stof afwijkingen op 
MRI.
8.  In VaD komen neuropsychiatrische symptomen veel voor. Small vessel VaD en large vessel VaD zijn 
gerelateerd aan een verschillend profiel van symptomen, met met name meer apathie in small vessel 
VaD en meer agitatie|agressie in large vessel VaD. 
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Dankwoord
Ooit heb ik bedacht dat ik in iedere geval 1 boek wilde schrijven in mijn leven. Dat het een proefschrift 
zou worden, wist ik niet. En ook dat ik onderzoek doen zo leuk zou vinden, had ik niet bedacht. Met 
name het samenwerken met zoveel verschillende mensen, allemaal gefoccussed op hetzelfde doel, vond 
ik boeiend. Nu is het zo dat ik voor dit onderzoek enigszins in een rollende trein ben gestapt; veel zaken 
liepen soepel omdat anderen reeds voorwerk hadden verricht Al deze mensen die het voortbewegen van 
de trein mogelijk hebben gemaakt en met mij in de trein hebben gezeten ben ik zeer dankbaar.
De passagiers
Allereerst wil ik graag alle patiënten en deelnemers aan de onderzoeken die beschreven zijn in dit 
proefschrift hartelijk bedanken. Zonder deelnemers en patiënten geen onderzoek. Dank gaat onder 
andere uit naar de patiënten van de geheugenpolikliniek VUMC die hun gegevens beschikbaar stellen 
voor onderzoek, my thanks go out to all participants of the VantagE studies in the different participating 
countries, og að lokum vil ég þakka allir sem tóku hlut (stundum mjög lengi) í Reykjavík rannsókn og siðan 
Reykjavík-AGES rannsókn.
De conducteurs
Prof.dr. Scheltens, beste Philip, de eerste keer dat ik je ontmoette, had ik als geneeskunde student 
een gesprek met een Engelse professor op jouw kamer, en je vertelde me bij het gedag zeggen dat ‘ik 
ook altijd welkom was bij het Alzheimercentrum’. Toen ik daar (nog steeds als student) vervolgens ook 
terecht kwam, voelde dit als een warm bad en wist ik dat hier onderzoek doen, was wat ik echt wilde. 
Bedankt dat je me die mogelijkheid ook daadwerkelijk hebt geboden. Met aan de ene kant jouw niet bij 
te houden energie en aan de andere kant de vrijheid die je geeft aan de medewerkers, zorg je voor een 
perfecte omstandigheid en is het zeer prettig en stimulerend om bij het Alzheimcentrum te werken.  
Prof.dr. Barkhof, beste Frederik, met jouw zorgvuldige manier van werken ben je een groot voorbeeld. 
Bedankt voor de radiologische kennis die ik van je heb mogen leren (schuif voor het beoordelen van 
lacunes soms je stoel even 3m naar achteren en bepaal of je er nog steeds van overtuigd bent dat het een 
is). Je bent in staat om je kritiek opbouwend uit te drukken, met duidelijke handvatten over het ‘hoe nu 
verder’. Dit maakt jouw kritische blik zeer waardevol. 
De machinist
Dr. van der Flier, beste Wiesje; wat een geluk heb ik gehad om onder jouw vleugels te komen werken. 
Ik voelde me bijzonder, soms als uitverkorene om enkele van jouw plannen waar te maken. Zonder 
twijfel ben jij de motor geweest achter mijn proefschrift, die mij voortdurend in de goede richting wist 
te krijgen. Altijd was je zeer betrokken en wist je te inspireren. Ik heb veel van je mogen leren en ik hoop 
dat ik dit in de toekomst ook nog kan blijven doen.
Reizen over de grens
Dr Launer, dear Lenore, thank you for the trust you gave me in the cerebral blood flow project. It was 
a great experience to work on data of such a large population based study as the AGES-Reykjavik study. 
Next to your extensive epidemiological knowledge, I admire your careful way of working and your talent 
to see with which little change the message of a manuscript can be so much clearer.  
I’d like to thank dr. Jack Guralnik, dr. Tamara Harris and the other members of the Laboratory of 
Epidemiology, Demography, and Biometry of the NIA/NIH in Bethesda for the opportunity to work at 
their lab and for the pleasant athmosphere during my stay.
Ég vil þakka Vilmundi Guðnasyni og Guðnyju Eiriksdóttur fyrir að hafa veitt mér tækifæri til að gera mælingar 
í Hjartavernd sem voru grundvöllur rannsóknarverkefnisins um blóðrennsli heilanns. Einig vil ég þakka öðru 
starfsfólki Hjartaverndar, sérstaklega Sigurði Sigurðssyni, Sigga sem var alltaf hress og hafði alltaf svör á 
reiðum höndum þegar ég kom með spurningar.
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Technische controle
Prof.dr. Heimans, beste Jan, bedankt voor de gelegenheid die je me biedt om tot neuroloog opgeleid te 
worden in het VUMC, en dank voor het deelnemen aan de promotiecommissie van dit proefschrift.
Dr. Biessels, beste Geert-Jan, jij bent de eerste geweest die me met veel enthousiasme liet zien hoe 
boeiend het onderzoeksveld binnen de neurologie is. Bedankt hiervoor. Het is mede hierdoor voor mij 
een extra eer dat je plaats hebt willen nemen in de promotiecommissie.
De overige leden van de promotiecommissie, dr. N. Prins en prof.dr. M. van Buchem, wil ik bedanken 
voor hun bereidheid in de promotiecommissie plaats te nemen en in het laatste geval ook voor de 
samenwerking.
Voorstations
Alida, bedankt voor je tomeloze geduld, wat was het fijn om jou als voorgangster te hebben. Niet alleen 
altijd bereid om mijn vragen te beantwoorden, met me mee te denken en scans mee te beoordelen, ook 
was je in staat om je interesse en het belang van onderzoek naar cerebral small vessel disease goed over 
te brengen. Hier zou ik ook graag Ilse willen noemen, bedankt voor je werk over, en voor de studies over 
vasculaire dementie. 
Behulpzame medepassagiers
Maja Binnewijzend, Hanneke de Waal en Tanja Su, jullie hebben als student veel vóór en met mij 
gewerkt. Bedankt voor jullie enthousiasme en inzet, het heeft in alle drie de gevallen tot een mooi paper 
geleid. Ik wens jullie veel succes en plezier met jullie toekomstige onderzoek.
Dr. Vrenken, beste Hugo, bedankt voor je geduld, je begeleiding en voor alles wat je me hebt geleerd over 
onderzoek doen met MRI scans, toen ik als groentje in de eerste fase nog zoveel te leren had. 
De andere co-auteurs van artikelen beschreven in dit proefschrift, waaronder dr. Faiza Admiraal,  
Roger Lane en dr. Yolande Pijnenburg. Ronald van Schijndel en Tabe Kooijstra voor hun 
computerkundige hulp en inzicht in de wondere wereld ‘achter’ de computer, die soms nodig is  
om MRI onderzoek mogelijk te maken.
Koffie/ thee en de rest
Mijn kamergenoten door de jaren heen: speciaal Esther en Nelleke, Laura, Ingeborg, Paulien, Lieke, 
Jeroen, Willem, Fransje en Maarten, dank!
Jasper en Wouter, bedankt voor de gezelligheid en alles wat jullie mij over de radiologie hebben geleerd. 
Ander mensen van het Alzheimercentrum: Jeske, Niek, Alie, Femke, Annelies, Maartje, Danielle, Evelien, 
Rolinka, Freek, Sietske, Marian, Ellemarije, Mike, Ernesto en de andere onderzoekers zoals Machteld en 
andere ‘MS’-, ‘parkinson’- en neuro-oncologie-onderzoekers.  
De Clinical Trial Unit en Hoda in het bijzonder.
Balie medewerkers, zoals de altijd geïnteresseerde Salah en de polizusters.
Andere medewerkers van het Alzheimercentrum die nog niet aan bod zijn gekomen maar die met hun 
inzet en houding bijdragen aan de prettige werksfeer.
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Kijkend uit het raam
Vrienden, waaronder Willemijn, Ilse, Jozefien, Klaartje, Sanne, Marloes en de Jongens (Tinus je bent een 
topper!); omdat het soms ook heel fijn is om even uit de trein te stappen.
Familie Staek en Spans voor de familie die ze zijn, en ook familie Pijlman/Geerdink die erbij is gekomen. 
Sérstakar þakkir til Atla, Bíbí og Láru sem veittu mér þá tilfinningu að vera heima úti í hinni viðu veröld.
Jón en Sten, als kind wilde ik graag een zusje, maar ik had me geen betere broers kunnen wensen 
en voel me trots als ik tussen jullie in sta. 
Josee en Sturla, met jullie positiviteit, eeuwige interesse in andere mensen en jullie eigenwijsheid 
zijn jullie nog altijd mijn grote voorbeeld.
Robbert; omdat jij weet wat de basis is, ik heb je lief. 
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